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Abstract 
There is extensive evidence demonstrating the protective effects of fish oils or omega-3 
polyunsaturated fatty acids (n-3 PUFAs) against cardiovascular diseases. It is widely 
accepted that the main n-3 PUFAs involved with these therapeutic effects are DHA and 
EPA. These PUFAs have been reported to reduce blood pressure by improving various 
vasodilation pathways. However, most of these studies focus on either DHA or EPA in a 
single artery. Therefore, this PhD project involved the comprehensive characterisation of 
the underlying vasodilation mechanisms of both n-3 PUFAs using conduit and resistance 
rat arteries. 
Wire myograph was used to examine acute vasodilation effects of n-3 PUFAs in pre-
constricted rat arteries, mostly via the use of pharmacological inhibitors. Stable cells that 
allowed inducible expression of TRPV4 was generated to assess changes in channel 
activity with n-3 PUFAs, using Fluo-4 AM based calcium imaging. n-3 PUFA mediated 
activation of KATP channels was also examined by using stable cells and whole cell patch 
clamp.    
The novel role of IKCa was observed in DHA-induced relaxation. Consistent with 
previous studies, BKCa was also involved in the relaxation effects of n-3 PUFAs. The 
presence of KATP and Kv7 component in n-3 PUFA-mediated vasodilation was also 
demonstrated for the first time. One of the most important highlights of my findings is 
the heterogeneity in the vasodilation mechanisms that was dependent upon both the type 
of n-3 PUFA and artery. These findings will be invaluable for future vascular studies that 
focus on investigating the prospect of using n-3 PUFA and novel fatty acid analogues as 
treatments that target specific vasodilation pathways, that are involved in providing 
therapeutic benefits against certain cardiovascular disorders.  
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1.1 Introduction 
The cardiovascular system is a complex network of organs that function together to 
deliver oxygen and nutrients to different parts of the body. The main components that are 
involved are the heart, blood and blood vessels. As the heart pumps blood into the arteries, 
pressure is exerted against the vessel wall. Blood pressure is affected by various factors 
such as the cardiac output (volume of blood ejected from the left ventricle per minute), 
blood viscosity and systemic vascular resistance (Betts et al. 2013). The vascular 
resistance can be calculated by using the Poiseuille’s equation of blood flow where 
(Pfitzner 1976); 
Resistance = 
8𝜂𝜆
𝜋𝑟4
 
η = Blood viscosity 
λ = Length of the blood vessel 
r = Radius of the blood vessel 
According to the equation, viscosity and length of the blood vessels are directly 
proportional to the resistance, however, these variables are fairly consistent throughout 
the body and do not undergo drastic changes. The radius of blood vessels on the other 
hand can be readily altered and as demonstrated by the above equation is raised to the 
power of 4, indicating that minute changes in the radius can significantly affect the 
arterial resistance. Based on the size, the arteries can be further subdivided into conduit 
and resistance arteries. Conduit arteries are the larger blood vessels such as aorta and are 
mainly involved in the distribution of blood throughout the body (London 1997). 
Resistance arteries are the smaller arteries (lumen diameter <300 μm) that are involved 
in blood pressure regulation (Davis et al. 1986; Schiffrin 1992). The greatest vascular 
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resistance and reduction in pressure occurs in resistance arteries and as demonstrated by 
Poiseuille’s equation, minute changes in their radius can significantly influence blood 
pressure (Pocock et al. 2013). Although the diameter of capillaries are the smallest in the 
circulatory system, the vascular resistance that they offer is relatively small due to their 
large total cross-sectional area which is 25 times greater than resistance arteries (Pocock 
et al. 2013). Majority of the blood is found in the larger veins which are also known as 
capacitance vessels. However, these vessels also offer little vascular resistance due to 
relatively thinner walls and higher compliance compared to arteries. Therefore, the 
venous pressure ranges from 2-20 mmHg whereas the average arterial pressure is about 
100 mmHg in humans (Pocock et al. 2013).  
Anatomical differences depending upon the size and the type of blood vessels are present 
throughout the body, however arteries and veins are mainly composed of three layers; 
tunica intima, tunica media and tunica externa (Fig 1.1) (Betts et al. 2013). Tunica intima 
forms the inner layer and is composed of endothelial cells (ECs) and internal elastic 
lamina. ECs can regulate the vascular tone via the production of various vasoconstrictors 
and vasodilators. Tunica media is mostly composed of smooth muscle cells (SMCs) 
which can directly alter the diameter of blood vessels, whereas the outer layer also known 
as tunica externa is composed of connective tissue. Most blood vessels involved in the 
systemic circulation, excluding cerebral arteries, are surrounded by an outer layer of 
perivascular adipose tissue (Brown et al. 2014). This adipose layer is involved in various 
physiological processes including regulation of the vascular tone (Lynch et al. 2013; 
Withers et al. 2014).  
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Fig 1.1 Anatomy of blood vessels. The three main layers of blood vessels are; tunica intima, 
tunica media and tunica externa. Capillaries are made up of single layer of endothelial cells. 
The endothelium is involved in the production of various vasodilators and vasoconstrictors 
that can regulate the vascular tone. Image taken from (Marieb 2014).   
The vascular tone is regulated by vasoconstriction and vasodilation which involves the 
narrowing and widening of the blood vessels, respectively. SMCs are non-striated 
spindle-shaped cells composed of actin and myosin filaments that are involved in 
constriction of the blood vessels. Unlike striated muscle cells, SMCs lack troponin and 
therefore require calmodulin to reversibly bind to Ca2+. Elevated levels of intracellular 
Ca2+ [Ca2+]i promotes formation of the calcium-calmodulin (CaM) complex, which 
subsequently activates myosin II light chain kinase (MLCK). Myosin regulatory light 
chain (20 kDa) is then phosphorylated at Ser19 by MLCK, facilitating binding with the 
actin filaments (Dabrowska et al. 1982; Allen and Walsh 1994). This results in 
subsequent activation of myosin adenosine triphosphatase (ATPase) initiating the cross 
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bridge cycle and contraction of the SMCs (Dabrowska et al. 1982; Allen and Walsh 
1994). Myosin light chain phosphatase (MLCP) present in SMCs can inhibit the effects 
of MLCK by dephosphorylating the myosin regulatory light chain (Jianhua Feng et al. 
1999). Therefore, the relative proportions of MLCK and MLCP can be crucial in 
determining the phosphorylation state of myosin light chain and the vascular tone.     
Certain agonist-mediated smooth muscle contractions can be biphasic, involving an 
initial rapid increase (Phasic) and subsequent steady sustenance (Tonic) of contractile 
tone. As shown in Fig 1.2, agonists such as phenylephrine can bind to alpha-1 adrenergic 
receptor, which is a G protein-coupled receptor (GPCR) present in SMCs, resulting in 
activation of phospholipase C (PLC) via Gαq protein. This subsequently results in the 
production of inositol 1,4,5-triphosphate (IP3) (Daykin et al. 1993) and 1,2-diacylglycerol 
(DAG) (Berridge 1987; Exton 1985). IP3 can bind to receptors present in the sarcoplasmic 
reticulum (SR) facilitating the transient release of [Ca2+]i that results in the phasic 
contraction of SMCs (Patel et al. 1999). DAG can further activate protein kinase C (PKC) 
which phosphorylates C-kinase potentiated protein phosphatase-1 inhibitor (CPI-17) (Eto 
et al. 1995; Li et al. 1998; Kitazawa et al. 1999). The phosphorylated CPI-17 then inhibits 
MLCP resulting in enhancement of smooth muscle contraction at a given [Ca2+]i, this 
phenomenon is also referred as calcium sensitisation and is involved in the tonic 
contraction of SMCs (Eto et al. 1995; Li et al. 1998; Kitazawa et al. 1999). Other GPCR 
agonists such as U46619, a thromboxane A2 (TXA2) mimetic, can bind to thromboxane 
A2 receptor (TP) resulting in activation of multiple G proteins such as Gα12/13 and Gαq 
(Moers et al. 2004) [for more information regarding other GPCRs that bind to Gα12/13, see 
review (Riobo and Manning 2005)]. Gα12/13 can elicit ras homolog gene family member 
A (RhoA) mediated activation of rho-associated protein kinase (ROCK) (Swärd et al. 
2003; Somlyo and Somlyo 2000). ROCK then inhibits MLCP by phosphorylating the 
  
6 
 
myosin targeting subunit present in MLCP (J Feng et al. 1999). This also results in 
calcium sensitisation and tonic contraction of SMCs. 
In 1902, a study demonstrated that resistance arteries were able to autoregulate blood 
flow by either contracting (myogenic tone) during elevation in intravascular pressure or 
relaxing when the pressure declined (Bayliss 1902). It has been reported that this 
mechanism of maintaining a constant blood flow with changes in arterial pressure is 
primarily elicited by vascular SMCs and is known as the myogenic response, as it does 
not necessarily require the presence of endothelium (Falcone et al. 1991) and nerve 
innervation (Bayliss 1902). The degree of myogenic response can vary depending upon 
the vascular bed, however most studies indicate that this response is the strongest in 
smaller resistance blood vessels such as coronary (Liao and Kuo 1997), mesenteric (Sun 
et al. 1992) and renal (Edwards 1983) arteries. Mechanistic studies have revealed that an 
increase in arterial pressure can elevate [Ca2+]i following opening of voltage-dependent 
calcium channels through membrane depolarization, subsequently generating the 
myogenic tone (Davis 2012). Furthermore, angiotensin II receptor type 1, a Gαq GPCR 
(Hong et al. 2016), has been reported to act as a membrane pressure sensor that 
depolarizes vascular SMCs resulting in myogenic constriction. There is also evidence of 
ROCK signalling in myogenic tone via activation of the purinergic GPCRs (Kauffenstein 
et al. 2016). 
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Fig 1.2 Pathways involved in GPCR-induced contraction of smooth muscle cells. Activation 
of GPCR by an agonist can result in dissociation of G proteins that affect the phosphorylation 
state of MLC. Gαq can enhance the production of [Ca2+]i that binds to CaM resulting in subsequent 
activation of MLCK. The dephosphorylation of MLC by MLCP is inhibited by CPI-17 and 
ROCK following activation of Gαq and Gα12/13 respectively. CaM = calmodulin, CPI-17 = C-
kinase potentiated protein phosphatase-1 inhibitor, DAG = 1,2-diacyglycerol, GPCR = G protein 
coupled receptors IP3 = inositol 1,4,5-triphosphate, MLC = myosin light chain, MLCK = MLC 
kinase, MLCP = MLC phosphatase, PKC = protein kinase C, PLC = phospholipase C, RhoA = 
ras homolog gene family, member A, ROCK = rho-associated protein kinase and SR = 
sarcoplasmic reticulum.    
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1.2 Pathways involved in vasodilation 
1.2.1 NO 
The inner endothelium layer (Fig 1.1) of blood vessels has an integral role in the 
regulation of vasomotor parameters. Various vasodilator pathways have been associated 
with the endothelium including nitric oxide (NO) signalling. In 1980, Furchgott first 
discovered that acetylcholine (ACh) mediated relaxation was inhibited in endothelium-
denuded rabbit aorta (Furchgott and Zawadzki 1980). Subsequent studies revealed that 
the mechanism involved activation of soluble guanylate cyclase (sGC) in SMCs 
(Furchgott et al. 1984) via an endothelium-derived relaxing factor (EDRF) which was 
later identified as NO (Ignarro et al. 1987). There is also extensive evidence 
demonstrating that endothelial NO is the predominant vasodilation mechanism in conduit 
arteries whereas resistance arterial tone is mostly under the influence of NO-independent 
pathways (Triggle and Ding 2011). The heterogeneity in the vasodilation mechanisms 
due to anatomical differences between blood vessels will be further discussed throughout 
section 1.2.   
1.2.1.i Mechanisms involved with NO-induced vasodilation 
In the endothelium, NO pathway can be activated by various GPCRs such as muscarinic 
3 receptors (M3) (Eglen and Whiting 1990), bradykinin 2 receptors (B2) (Agostoni and 
Cugno 2001), neurokinin 1 receptor (Andoh and Kuraishi 2003) and mechanical stimulus 
such as shear stress [for review see (Busse and Fleming 2003)]. Stimulation of this 
pathway increases [Ca2+]i levels, resulting in activation of endothelial NO synthase 
(eNOS) (Fig 1.3). eNOS is a homodimer and each monomer is composed of N-terminal 
oxygenase and a C-terminal reductase subunits with a CaM-binding domain in the middle 
(Wu et al. 2012). Elevation in [Ca2+]i levels facilitates formation of Ca
2+-CaM complex 
  
9 
 
which binds to eNOS resulting in the conversion of L-arginine into L-citrulline and NO 
(Marlettaz 1993). NO diffuses into SMCs where it activates sGC converting guanosine 
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) which enhances protein 
kinase G (PKG) activity (Moncada et al. 1991). PKG is a homodimer connected by a 
leucine zipper and is further subdivided into PKGI and PKGII encoded by two distinct 
genes, pkrg1 and pkrg2 respectively (Orstavik et al. 1997). PKGI is the isoform expressed 
in vascular SMCs (Tamura et al. 1996) and is involved in the activation of MLCP 
resulting in dephosphorylation of MLCK and inhibition of vasoconstriction (Wu et al. 
1996; Lee et al. 1997). PKGI has also been reported to induce vasodilation through 
mechanisms that can reduce the levels of [Ca2+]i. Direct stimulation of Ca
2+ activated 
potassium channels (KCa) by PKGI has been reported in porcine tracheal SMCs 
(Yamakage et al. 1996) and myometrial cells (Zhou et al. 1998), resulting in 
hyperpolarization and subsequent inhibition of voltage-gated Ca2+ channels. In addition, 
using patch clamp electrophysiology NO has also been reported to directly activate KCa 
channels in SMCs derived from rat mesenteric artery (Mistry and Garland 1998). PKGI 
has also been reported to inhibit PLC mediated IP3 production (Hirata et al. 1990; Pfeifer 
et al. 1995) and IP3 receptor activity via phosphorylation (Komalavilas and Lincoln 1996; 
Komalavilas and Lincoln 1994), leading to the reduction of the intracellular Ca2+ release. 
Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) is a pump involved in transporting 
cytoplasmic Ca2+ into SR (Cornwell et al. 1991). PKGI is involved in the upregulation of 
calcium sequestration by phosphorylating and therefore suppressing phospholamban, a 
protein involved in the inhibition of SERCA (Cornwell et al. 1991). As mentioned earlier, 
studies have indicated that endothelial NO is the predominant vasodilation mechanism in 
conduit arteries (Shimokawa et al. 1996; Waldron et al. 1999). This could be explained 
by the higher expression of eNOS that was reported in rat aorta compared to mesenteric 
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arteries (Shimokawa et al. 1996). Furthermore, it was also demonstrated that ACh-
mediated relaxation was completely abolished in aorta derived from eNOS knockout 
(KO) mice, whereas relaxation of mesenteric arteries from the same animal remained 
unaffected (Waldron et al. 1999). 
1.2.1.ii Role of NO-induced vasodilation in cardiovascular diseases 
Although there are other endothelium-dependent vasodilation pathways, vascular studies 
mostly refer endothelial dysfunction as an impairment of NO mechanism in the 
endothelium (Zhao et al. 2015). It is well documented that various risk factors for 
cardiovascular diseases (CVDs) such as aging and hypertension can promote endothelial 
dysfunction (Hadi et al. 2005; Sitia et al. 2010). Studies also indicate that diet can affect 
endothelial function by modifying the NO signalling pathway. For example; in a porcine 
study, high-fat diet was reported to impair cGMP production due to enhanced eNOS 
uncoupling resulting in the formation of inactive eNOS monomers, although protein 
expression of eNOS was unaffected by the diet (Musicki et al. 2008). In contrast, 
hyperglycaemia has been indicated to promote NO production in rats and humans (Adela 
et al. 2015). Dose-dependent elevation of both eNOS expression and NO levels were 
reported in human umbilical vein endothelial cells following treatment with glucose 
(Adela et al. 2015). Furthermore, plasma level of NO was also enhanced in both 
hyperglycaemic rats and patients with type 2 diabetes compared to the normal control 
groups (Adela et al. 2015). There is also evidence indicating that high-salt diet can elevate 
eNOS expression in thick ascending limb derived from rats, however, it did not result in 
the subsequent increase of NO production (Ortiz et al. 2003).  
Endothelial dysfunction can develop in both conduit and resistance arteries (Blackwell et 
al. 2004; Csiszar et al. 2007; Lesniewski et al. 2009). Although smaller resistance arteries 
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are predominantly involved in the regulation of peripheral resistance and mean blood 
pressure; the larger conduit arteries, especially aorta, also have an important role in 
providing the dampening effect against the pulsatile ventricular pressure (Marchais et al. 
1993). Furthermore, aortic stiffening can significantly attenuate vascular compliance 
resulting in the subsequent increase of systolic central blood pressure and cardiac 
afterload (Chen et al. 2017); ultimately promoting ventricular hypertrophy (Yucel et al. 
2015) and impairment of smaller peripheral arteries (Van Sloten et al. 2015). In 
comparison to elevated peripheral resistance, studies indicate that aortic stiffening has a 
greater role in the development of isolated systolic hypertension (Wallace et al. 2007; 
McEniery et al. 2009). The impairment of NO pathway has been associated with the 
elevation of central pressure, resulting in the subsequent enhancement of arterial stiffness 
in conduit arteries including aorta (Wilkinson et al. 2002; Wilkinson et al. 2004). This is 
consistent with studies indicating that the improvement of NO production can reduce 
arterial stiffness in aorta, resulting in the subsequent attenuation of central blood pressure 
(McEniery et al. 2004; Dhakam et al. 2006; Kampus et al. 2011). Arotinolol, a 
nonselective α/β-blocker, was also reported to induce eNOS phosphorylation and NO-
dependent vasodilation in aorta, resulting in the subsequent reduction of central blood 
pressure and aortic stiffness (Zhou et al. 2014). Although the peripheral resistance is 
predominantly regulated by resistance arteries, findings from these studies clearly 
demonstrate that vasodilation of conduit arteries via NO pathway can also elicit 
therapeutic effects. Therefore, to enable a complete understanding of the beneficial 
effects of vasodilators, it is crucial to investigate their mechanisms using both conduit 
and resistance arteries (Pocock et al. 2013).         
The absence of NO signalling in mice has been reported to facilitate the development of 
CVDs such as hypertension and atherosclerosis (Huang et al. 1995; Kuhlencordt et al. 
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2001). Similarly, human studies have also reported an impairment of NO pathway in 
hypertension. A study demonstrated that L-NG-monomethyl arginine citrate (L-NMMA), 
an eNOS inhibitor, mediated attenuation of forearm blood flow was not as profound in 
hypertensive patients compared to the control (Panza et al. 1990). There is also evidence 
indicating reduction in NO bioavailability due to increased oxidative stress in arterial 
hypertension (Hermann et al. 2006). Oxidative stress is characterized by an increased 
production of reactive oxygen species (ROS) and an impairment in the antioxidant 
defence systems (Rodrigo et al. 2011). Nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase is the main enzyme involved in the production of superoxide in blood 
vessels (Rodrigo et al. 2011). An increase in NADPH oxidase expression and subsequent 
enhancement in superoxide production has been associated with hypertension by 
numerous studies, using various hypertensive animal models such as angiotensin II-
induced hypertensive rats (Fukui et al. 1997; Mollnau et al. 2002), deoxycorticosterone 
acetate-salt hypertensive rat (Beswick et al. 2001) and SHR (Zalba et al. 2000; Wassmann 
et al. 2001; Hamilton et al. 2002; Wassmann et al. 2002). NADPH oxidase-derived 
superoxide can react with NO to form peroxynitirte, which oxidizes and uncouples eNOS, 
resulting in an additional increase in ROS and attenuation in NO production (Laursen et 
al. 2001; Kuzkaya et al. 2003). As a result, these mechanisms can further elevate 
oxidative stress in the vasculature and impair NO-induced vasodilation, subsequently 
contributing to the development of hypertension [for an in-depth review regarding the 
role of oxidative stress in hypertension see (Rodrigo et al. 2011)]. Oxidative stress has 
also been reported to promote vascular inflammation through activation of pro-
inflammatory transcription factors such as nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and activator protein 1 (AP1) (Sen and Packer 1996; Imhoff 
and Hansen 2009). This in turn results in the subsequent production of inflammatory 
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cytokines such as interleukin-17 (IL-17) and tumour necrosis factor-alpha (TNF-α), 
facilitating further activation of adhesion molecules that promote leukocyte adhesion in 
the vasculature (Libby et al. 2002; Park et al. 2014). These mechanisms can contribute to 
the formation of atherosclerotic lesions and ultimately, lead to thrombotic events 
associated with atherosclerosis.  
There is also evidence indicating that T cells are involved in hypertension; for example, 
a study demonstrated that loss of mature T cells in recombination activating gene 1 
(RAG-1) KO mice led to attenuation in angiotensin II-induced; elevation of blood 
pressure, superoxide production and inhibition of endothelium-dependent vascular 
relaxation (Guzik et al. 2007). Furthermore, this inhibition of angiotensin II mediated 
effects was completely reversed following adoptive transfer of T cells into RAG-1 KO 
mice (Guzik et al. 2007). It was also indicated that angiotensin II facilitated the activation 
of effector T cells and chemokines, therefore suggesting the role of T cell-dependent 
inflammation in hypertension (Guzik et al. 2007). Furthermore, pro-inflammatory 
cytokines such as IL-17 and TNF-α produced by T cells are involved in hypertension. An 
elevated production of IL-17 was observed in mice following administration of 
angiotensin II (Madhur et al. 2010). Although an initial increase in blood pressure was 
observed with angiotensin II, IL-17 KO mice failed to maintain this hypertensive state in 
contrast to wild type mice (Madhur et al. 2010). Additionally, marked reduction in 
angiotensin II-induced T cell infiltration and superoxide production was also observed in 
IL-17 KO mice (Madhur et al. 2010). Higher plasma levels of IL-17 were reported in 
diabetic patients with hypertension compared to the normotensive diabetic control group 
(Madhur et al. 2010). There is also evidence indicating that TNF-α can activate NADPH 
and enhance ROS production (De Keulenaer et al. 1998). Etanercept, a TNF-α antagonist, 
was found to inhibit angiotensin II-induced hypertension and superoxide production in 
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mice (Guzik et al. 2007). Furthermore, etanercept prevented hypertension in fructose-fed 
rats (Tran et al. 2009) and lowered blood pressure in a mouse model of systemic lupus 
erythematosus (Venegas-Pont et al. 2010). Thus, hypertension is a complex disorder that 
not only involves endothelial dysfunction characterized by the impairment of 
vasodilation pathways such as NO signalling, but also involves mechanisms that promote 
oxidative stress and inflammation.  
An increase in the plasma levels of asymmetric dimethylarginine (ADMA), an 
endogenous eNOS inhibitor, is also associated with endothelial dysfunction, 
hypercholesterolemia and atherosclerosis (Böger et al. 1998; Ignarro and Napoli 2005). 
It is not surprising that the impairment of NO signalling would have such detrimental 
effects since in addition to having a role in blood pressure regulation; NO is also involved 
in inhibiting adhesion of leukocytes, platelet aggregation and proliferation of SMCs in 
the vasculature, all of which attenuate the development of atherosclerotic plaques 
(Kuhlencordt et al. 2001). Therefore, treatment drugs that are involved in the modulation 
of NO pathway are still being used against CVDs. According to the national institute for 
health and care excellence (NICE) guidelines, glyceryl trinitrate (NO donor) is used 
generally for the treatment of angina whereas sodium nitroprusside (another NO donor) 
is used for hypertension related emergencies, heart failure and during surgery with 
anaesthesia for controlled hypotension (NICE 2019f). Phosphodiesterase-5 are enzymes 
involved in the breakdown of cGMP (Corbin and Francis 1999). Currently, inhibitors of 
these enzymes such as tadalafil and sildenafil are used for the treatment of pulmonary 
arterial hypertension (NICE 2019a).  
  
15 
 
 
Fig 1.3 Pathways involved in vasodilation. Various agonists such as ACh can activate M3 
receptors present in the endothelium, that subsequently triggers the complex signalling cascade 
resulting in the relaxation of vascular smooth muscle cells. ACh = acetylcholine, BK = 
bradykinin, BKCa = large conductance calcium activated potassium channels,  cAMP = cyclic 
adenosine monophosphate, cGMP = cyclic guanosine monophosphate, COX = cycloxygenase, 
CYP = cytochrome P450 epoxygenase, DAG = 1,2-diacyglycerol, EETs = epoxyeicosatrienoic 
acids, eNOS = endothelial nitric oxide synthase, GPCR = G protein coupled receptors, IKCa = 
intermediate conductance calcium activated potassium channels, IP = prostaglandin I2 receptor, 
IP3 = inositol 1,4,5-triphosphate, KATP = adenosine triphosphate-sensitive potassium channel, NO 
= nitric oxide, PGI2 = prostaglandin I2, PKC = protein kinase C, PLA2 = phospholipase A2, PLC 
= phospholipase C, sGC = soluble guanylate cyclase and TRPV4 =  transient receptor potential 
cation channel subfamily vanilloid member 4.    
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1.2.2 Metabolites of AA in relaxation  
1.2.2.i COX-derived metabolites of AA 
a) Structure and function of COX 
Arachidonic acid is an omega-6 (n-6) polyunsaturated fatty acid (PUFA) 
involved in the regulation of various physiological processes including 
vasodilation. There is evidence indicating that activation of GPCRs such as 
M3 receptors, can enhance the release of AA following activation of 
phospholipase A2 (PLA2) (Fig 1.3) (Wang et al. 2004). Depending upon the 
enzymes, metabolites of AA also known as eicosanoids which are derived 
from the oxidation of AA are further subdivided into series-2 prostaglandins 
(PGs), leukotrienes (LTs), hydroxyeicosatetraenoic acids (HETEs) and 
epoxyeicosatrienoic acids (EETs). Cycloxygenase (COX) is a homodimeric 
enzyme and each monomer is composed of a membrane binding domain, an 
epidermal growth factor (EGF) domain and a catalytic domain containing 
the COX and peroxidase active sites (Smith et al. 2000) (Fig 1.4). There are 
two isoforms of COX; COX-1 (71 kDa) and COX-2 (73 kDa), which are 
both involved in the initial metabolism of AA into PGG2, which occurs in 
the COX active site. Subsequently, PGG2 is converted into PGH2 in the 
peroxidase active site (Smith et al. 2000). COX-1 is constitutively expressed 
in various tissues and is coupled with synthases that are involved in the 
production of TXA2, PGF2 and PGD2 (Naraba et al. 1998). COX-2 lacks 
constitutive expression and as a result require inflammatory stimuli such as 
bacterial endotoxin and cytokines to induce its expression. Synthases that 
couple with COX-2 catalyse the production of PGI2 and PGE2 (Hata and 
Breyer 2004). These COX-derived eicosanoids have an important role in the 
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body as they are involved in the regulation of various physiological 
processes such as inflammation, nociception, renal function and 
cardiovascular homeostasis (Smyth et al. 2009).  
 
 
Fig 1.4 3D schematic representation of the COX monomer. Each monomer is composed of 
three domains; EGF, membrane binding and catalytic domain which involves the COX and 
peroxidase active site. The EGF-domain forms the N-terminus. The COX active site is involved 
in conversion of AA to PGG2 and the peroxidase site subsequently converts PGG2 to PGH2. COX 
= cycloxygenase and EGF = epidermal growth factor. Image obtained from (Garavito and DeWitt 
1999).     
b) Mechanisms involved with COX-induced vasodilation 
PGI2 initially known as “prostaglandin X”, was first discovered by John 
Vane along with Salvador Moncada during 1970s and this discovery was 
crucial in understanding the pharmacology of aspirin (Bunting et al. 1976; 
Dusting et al. 1977). PGI2 is converted from AA mainly via the action of 
COX-2 (Ricciotti et al. 2013) (Fig 1.3). It can elicit vasodilation by binding 
to prostaglandin I2 receptor (IP) which is a GPCR (Gαs) and promotes 
adenylate cyclase (AC)-mediated production of cyclic adenosine 
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monophosphate (cAMP), subsequently enhancing intracellular protein 
kinase A (PKA) activity (Majed and Khalil 2012). Depending upon the type 
of vascular cells, PKA can induce vasodilation through different 
mechanisms. For example, in ECs derived from human and bovine aorta, 
PKA has been shown to elevate expression of eNOS resulting in enhanced 
NO production following administration of PGI2 analog, beraprost (Niwano 
et al. 2003).  Depending upon the type of tissue, PGI2-activated PKA has 
been reported to elicit vasodilation through different mechanisms which 
include; (i). Enhanced calcium sequestration via SERCA, (ii). Inhibition of 
TP receptor activity in human aortic SMCs (Wikström et al. 2008), (iii). 
Activation of potassium channels such as KCa in rat cerebral artery (Dong et 
al. 1998) along with rat pulmonary artery (Dumas et al. 1997), adenosine 
triphosphate-sensitive potassium channels (KATP) in rat pulmonary artery 
(Dumas et al. 1997) and voltage-gated potassium channels (Kv) in rat 
cerebral artery (Dong et al. 1998) and (iv). Phosphorylation and subsequent 
inhibition of MLCK (Horman et al. 2008).  
c) Role of PGI2-induced vasodilation in cardiovascular diseases 
PGI2 is primarily involved in vasodilation and inhibits platelet activation 
whereas TXA2 (COX-1 derived) is a vasoconstrictor and has prothrombotic 
effects. Due to the opposite effects of these prostanoids in the vasculature, 
the balance between these metabolites is important in the maintenance of 
cardiovascular health. In IP receptor/ApoE (Apolipoprotein E) KO mice 
(animal model for studying atherogenesis), elevated atheroma formation and 
platelet activation were reported (Kobayashi et al. 2004). However, these 
effects were reversed in TP receptor/ApoE KO mice (Kobayashi et al. 2004). 
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Using ovariectomized female mice, another study demonstrated that 
estrogen-derived PGI2 was involved in the inhibition of atherogenesis (Egan 
et al. 2004). R212C polymorphism of the IP receptor that results in 
impairment of receptor signalling was also reported to enhance 
atherothrombosis and disease severity in cardiovascular patients (Arehart et 
al. 2008). The pathophysiological mechanisms involved in pulmonary 
hypertension (PH) are associated with an increase in TXA2 production, 
thrombosis, vasoconstriction and vascular remodelling (Mitchell et al. 2014). 
As a result, various studies have indicated a protective role of PGI2 in PH 
(Mitchell et al. 2014) and PGI2 analogues such as iloprost and epoprostenol 
are currently used in the clinical setting. Iloprost is used for the treatment of 
idiopathic PH (NICE 2019c) and epoprostenol is used for primary PH 
resistant to other treatments (NICE 2019b).    
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1.2.2.ii CYP-derived metabolites of AA  
a) Structure and function of CYP 
Cytochrome P450 (CYP) are haemoproteins made up of 400-500 amino acid 
residues with an iron-containing cofactor present in the active site 
(Manikandan and Nagini 2018). CYP is encoded by more than 17,000 genes 
throughout the biological kingdoms and currently about 57 CYP genes have 
been identified in humans (Pikuleva and Waterman 2013). Although there 
are 18 families of human CYP, predominant expression occurs within three 
families; CYP2, CYP3 and CYP4 (Nebert et al. 2013). AA can be converted 
into epoxyeicosatrienoic acids (EETs) and  hydroxyeicosatetraenoic acids 
(HETEs) by CYP epoxygenase and omega-hydroxylase respectively 
(Panigrahy et al. 2010). In SMCs, CYP omega-hydroxylase from the 4A and 
4F families are generally involved in inserting a hydroxyl group into the AA 
molecule, resulting in the formation of 20-HETE (Fig 1.5) (Roman 2002). 
CYP epoxygenases are predominantly expressed in vascular ECs and belong 
to 2C along with 2J family (Fig 1.5) (Node et al. 1999; Zeldin 2001). These 
epoxygenases are found in the endoplasmic reticulum and they metabolize 
AA by adding an epoxide group to one of the double bonds, resulting in the 
production of four regioisomers, which include; 5,6-EET, 8,9-EET, 11,12-
EET and 14,15-EET (Zeldin 2001). CYP2C is mainly involved in the 
production of EETs in ECs. 11,12-EET and 14,15-EET are the main 
metabolites produced, accounting for up to 70-80% of the total EETs. In the 
presence of soluble epoxide hydrolase (sEH), EETs can be converted into 
less active metabolites known as dihydroxyeicosatrienoic acids (DHETs) 
(Yu et al. 2000). 
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Fig 1.5 Metabolism of AA by CYP epoxygenase and omega-hydroxylase. AA is converted 
into 20-HETE by CYP4A and CYP4F omega-hydroxylase. CYP2C and CYP2J epoxygenase are 
involved in metabolism of AA into EETs which is further metabolised by sEH into DHETs. AA 
= arachidonic acid, CYP = cytochrome P450, DHETs = dihydroxyeicosatrienoic acids, EETs = 
epoxyeicosatrienoic acids HETE = hydroxyeicosatetraenoic acid and sEH = soluble epoxide 
hydrolase. 
b) Mechanisms involved with CYP mediated vasodilation 
20-HETE is a CYP omega-hydroxylase metabolite found in resistance 
arteries such as cerebral (Harder et al. 1994), mesenteric (Zhang et al. 2001) 
and renal arteries (Marji et al. 2002; Roman 2002). The biosynthesis of this 
metabolite is predominantly observed in SMCs whereas its endothelial 
production has only been reported in pulmonary arteries (Zhu et al. 2002). 
20-HETE is involved in eliciting vasoconstriction through activation of 
kinases such as mitogen-activated protein kinase (MAPK) (Muthalif et al. 
1998), PKC (Lange et al. 1997; Sun et al. 1999) and src-type tyrosine kinase 
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(Sun et al. 1999); subsequently leading to inhibition of KCa channels and 
augmentation of depolarization through opening of L-type calcium channels 
(Gebremedhin et al. 1998). 20-HETE can also induce vasoconstriction 
through activation of ROCK resulting in MLCP inhibition and calcium 
sensitisation (Randriamboavonjy et al. 2003). In contrast to 20-HETE, the 
four regioisomeric EETs are involved in relaxation of the blood vessels and 
were first identified as an endothelium-derived hyperpolarization factor 
(EDHF) in 1996 by Campbell et al (Campbell et al. 1996). Their findings 
indicated that EETs-mediated relaxation of bovine coronary arteries 
involved KCa opening. 11,12-EET and 14,15-EET are the most abundant 
regioisomers in ECs. The general mechanism of EETs-induced vasodilation 
involves an initial release of these eicosanoids from ECs, followed by 
subsequent binding to potassium channels present in the SMCs, resulting in 
hyperpolarization of the arteries. Majority of the literature reports that EETs 
are involved in activation of large conductance KCa (BKCa) in various 
vascular beds including bovine coronary arteries (Li et al. 2002; Campbell et 
al. 2006), human mammary arteries (Archer et al. 2003) and rat mesenteric 
artery (Dimitropoulou et al. 2007) (Fig 1.3). However, some studies also 
indicate that EETs can activate adenosine triphosphate-sensitive potassium 
channels (KATP) resulting in relaxation of rat mesenteric arteries (Ye et al. 
2005; Ye et al. 2006). Furthermore, in depth mechanistic investigation 
revealed that EETs can stimulate Gαs-dependent activation of PKA which 
can subsequently activate both KCa and KATP (Imig et al. 1999; Ye et al. 2005; 
Ye et al. 2006; Dimitropoulou et al. 2007). EETs have also been reported to 
indirectly facilitate BKCa opening via initial activation of transient receptor 
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potential cation channel subfamily vanilloid member 4 (TRPV4) (Ma et al. 
2015; Vriens et al. 2005; Watanabe et al. 2003).  
c) Role of EET-induced vasodilation in cardiovascular diseases 
The protective effects of EETs in the cardiovascular system have been 
demonstrated by various studies. For example, attenuation in EET 
production due to decreased CYP2C expression (Imig and Hammock 2009) 
and increased activity of sEH enzyme (Zhao et al. 2003; Zhao et al. 2004) 
has been associated with hypertension. Although CYP2C44 KO mice 
initially remained normotensive with normal levels of dietary salt, these mice 
developed hypertension after 4-5 weeks of high salt diet whereas only a small 
increase in systolic blood pressure was observed with the wild type control 
mice (Capdevila et al. 2014). In spontaneously hypertensive (Yu et al. 2000) 
and angiotensin II-induced (Imig et al. 2002) hypertensive rats, increased 
expression of sEH was reported. Furthermore, sEH inhibitors have also been 
reported to inhibit inflammation and atherosclerosis of the vasculature 
[reviewed in (Imig and Hammock 2009; Imig 2012)]. Recently, two phase I 
clinical trials investigated the effects of a novel sEH inhibitor, GSK2256294, 
in overweight smokers (Yang et al. 2017; Lazaar et al. 2016). Results from 
these studies demonstrated that the inhibitor was well-tolerated and the 
suppression of sEH was effectively maintained for 24 h (Lazaar et al. 2016). 
Furthermore, administration of this inhibitor was also reported to potentiate 
bradykinin mediated vasodilation (Yang et al. 2017). Thus, the protective 
effects of EETs are currently under investigation for their therapeutic 
benefits against CVDs (Imig 2016).   
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1.2.3 EDH 
It was during the late 1970s that Hirosi Kuriyama et al first reported ACh-induced 
hyperpolarization of SMCs in rabbit mesenteric artery (Kuriyama and Suzuki 1978) and 
guinea pig coronary artery (Kitamura and Kuriyama 1979); but surprisingly, 
vasoconstriction was also observed. A later study led by Bolton et al, also demonstrated 
a similar effect involving hyperpolarization and constriction of SMCs by carbachol (an 
ACh mimetic) in guinea pig mesenteric artery (Bolton et al. 1984). It was this study that 
first identified the role of endothelium in this hyperpolarization response and therefore, 
the authors concluded by indicating that a diffusible factor released from ECs was 
possibly involved (Bolton et al. 1984). Similar to the earlier study, Bolton et al also 
reported the dual constrictive and hyperpolarization effects of these agonists. It was 
indicated that this effect was observed due to the expression of M3 receptors in both 
SMCs and ECs of these arteries, highlighting variability in vascular expression of these 
receptors between different species (Bolton et al. 1984). “EDRF” which involved the NO 
pathway was also discovered by Furchgott et al (Furchgott and Zawadzki 1980) during 
that time and as a result, it was speculated that EDRF was potentially involved in the 
hyperpolarization response. These speculations were later addressed by a Chen et al study 
demonstrating that the ACh-induced hyperpolarization of endothelium-intact rat aorta 
and pulmonary artery was independent of NO and COX pathway (Chen et al. 1988). The 
hyperpolarization was associated with an increase in the efflux of 86Rb+ efflux (a marker 
for K+), indicating the role of potassium channels (Chen et al. 1988). This endothelial 
factor was identified to be distinct from the EDRF and therefore was named as the 
“endothelium derived hyperpolarization factor” (EDHF) (Taylor and Weston 1988). It 
was only after another 6 years that Waldron and Garland demonstrated that this EDHF 
response was completely inhibited through the combined application of both apamin, a 
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small conductance KCa (SKCa) blocker and charybdotoxin which was considered to be a 
selective BKCa blocker at that time (Edwards et al. 2010). Zymunt and Högestätt then 
reported that combination of apamin and iberotoxin (a more selective inhibitor of BKCa 
compared to charybdotoxin) could not abolish the EDHF response in rat hepatic artery 
(Zygmunt and Högestätt 1996). It was later recognized that this discrepancy was due to 
the additional inhibition of intermediate conductance KCa channel (IKCa) by 
charybdotoxin (Vázquez et al. 1990; Garcia et al. 1995). As it was originally speculated 
that an EDHF released from the endothelium was involved in subsequent activation of 
SKCa and IKCa, these channels were considered to be possibly expressed in SMCs. 
However, SKCa and IKCa were only detected in the endothelium (Edwards et al. 1998). 
Therefore, this hyperpolarization response is generated from the endothelium itself and 
it does not always involve a diffusible factor. Due to these findings, this pathway is 
currently more accurately referred as the “endothelium-dependent hyperpolarization” 
(EDH) response [extensively reviewed by (Feletou and Vanhoutte 2006; Edwards et al. 
2010)]. As described earlier the EDH response is mainly regulated by SKCa and IKCa, 
however other potassium channels present in the SMCs such as KATP, potassium voltage-
gated channel subfamily Q member (Kv7) and especially BKCa can also be subsequently 
activated following the release of endothelial factors, resulting in hyperpolarization and 
vasodilation. These channels will be further discussed in the later sections. 
1.2.3.i SKCa and IKCa 
a) Structure and distribution of SKCa and IKCa 
SKCa and IKCa are tetramers composed of four α-subunits and each subunit 
contains six transmembrane segments (S1-S6) with a pore forming loop 
between S5 and S6 (Fig  1.6) (Guéguinou et al. 2014). There are three 
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subtypes of SKCa; SK1 (KCa2.1), SK2 (KCa2.2) and SK3 (KCa2.3) 
(Guéguinou et al. 2014). Due to similarities in the structure and function, 
IKCa is also referred as SK4, however it has a higher conductance (20-90 pS) 
in comparison to SKCa (5-20 pS) (Clements et al. 2015). Both SKCa and IKCa 
have calmodulin constitutively bound to intracellular carboxyl terminus of 
each subunit allowing binding of [Ca2+]i (Xia et al. 1998; Fanger et al. 1999). 
These channels do not have a voltage-sensing region and therefore their 
activities are insensitive to changes in membrane potentials.  
SKCa, particularly SK3 (Marchenko and Sage 1996), and IKCa are expressed 
in vascular ECs (Félétou 2009) but not in SMCs, although IKCa expression 
has been reported in proliferating SMCs in culture and also following an 
injury (Neylon et al. 1999; Kohler et al. 2003; Tharp et al. 2006). There is 
evidence indicating that the differential expression of KCa channels can partly 
elicit heterogeneity in the functional phenotype of vascular SMCs; for 
example, BKCa channels are predominantly expressed in contractile SMCs 
whereas an increased expression of IKCa channels is associated with 
proliferative SMCs (Neylon et al. 1999; Kohler et al. 2003; Tharp et al. 
2006). SKCa are generally found in homocellular endothelial gap junctions 
and in caveolar microdomains with other receptors such as IP3 and cationic 
channels including TRPV4 (Fig 1.8) (Félétou 2009; Sonkusare et al. 2012). 
IKCa are mostly expressed in endothelial projections that are in direct contact 
with the membranes of SMCs via myo-endothelial gap junctions (MEGJ) 
(Félétou 2009). Similar to SKCa, studies also report TRPV4 and IP3 receptor-
dependent activation of IKCa (Fig 8) (Sonkusare et al. 2012). There is 
extensive evidence indicating the predominance of EDH vasodilation 
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mechanism in resistance arteries compared to conduit arteries. An increase 
in the expression of both KCa channels (Hilgers et al. 2006) and MEGJ with 
decreasing arterial size has been reported in rats (Sandow and Hill 2000). 
Furthermore, the thicker internal elastic lamina of conduit arteries, compared 
to resistance arteries, has been suggested to provide a greater barrier against 
electrotonic signalling, resulting in inhibition of EDH dispersal (Triggle and 
Ding 2011). It has also been indicated that microdomains found in 
endothelial projections that consists of IKCa, IP3 receptors, calcium-sensing 
receptors and MEGJ are predominantly involved in the regulation of 
resistance arterial tone [for review see (Triggle and Ding 2011)]. 
 
 
Fig 1.6 Structure of the endothelial KCa channels. (A) SKCa (KCa2.3) and IKCa (KCa3.1) are 
composed of six transmembrane segments (S1-6) with calmodulin attached to carboxyl terminus 
that confers calcium sensitivity. CaM = calmodulin, KCa = calcium activated potassium channel, 
KCa2.1-3 = small conductance KCa and KCa3.1 = intermediate conductance KCa. Image obtained 
from (Grgic et al. 2009). 
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b) Mechanisms involved with SKCa- and IKCa-induced vasodilation 
ACh and shear stress (involving TRPV4 channels) can activate endothelial 
KCa channels by increasing [Ca
2+]i levels resulting in the efflux of K
+
 and 
hyperpolarization of the ECs (Fig 1.3) (Félétou 2009). The hyperpolarization 
can further facilitate the influx of Ca2+ into ECs through non voltage-gated 
calcium channels such as TRP channels [for review see (Guéguinou et al. 
2014)], resulting in the activation of calcium-sensitive enzymes such as 
eNOS and PLA2 (Clark et al. 1991). This can subsequently enhance the 
production of vasodilators such as NO, PGI2 and EETs. Furthermore, electric 
transmission of EDH from ECs to SMCs via myoendothelial gap junctions 
has also been reported, especially in resistance arteries, leading to the 
subsequent hyperpolarization of SMCs (Feletou and Vanhoutte 2006). The 
main gap junction connexin (Cx) proteins that are expressed in the 
vasculature are Cx37, Cx40 and Cx43 (Lang et al. 2007). Evidence of their 
involvement in the EDH response has mostly been found in in vitro 
experiments using human subcutaneous resistance arteries (Lang et al. 
2007), rat cerebral and mesenteric arteries (Matchkov et al. 2006; Haddock 
et al. 2006). On the contrary, results from most in vivo experiments have 
failed to indicate the role of myoendothelial gap junctions in the EDH 
response [reviewed by (de Wit et al. 2008)]. This discrepancy may be partly 
explained by differences in the type of arteries that were studied, since in 
vitro experiments involved mesenteric artery whereas skeletal muscle 
arterioles were mostly used in vivo experiments (de Wit et al. 2008). 
Furthermore, multiple in vivo physiological factors such as mechanical 
stress, sympathetic innervation and signalling molecules present in the 
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blood, may also influence these gap junctions. The opening of endothelial 
KCa can also result in a modest increase of K
+ ions (1-15 mmol/L) in the 
intercellular space between ECs and SMCs (Haddy et al. 2006). This 
elevation of K+ ions can activate potassium voltage-gated channel subfamily 
J member 2 (Kir2.1) (Bradley et al. 1999) and sodium-potassium adenosine 
triphosphatase (Na+/K+-ATPase) (Prior et al. 1998), resulting in 
hyperpolarization of the neighbouring SMCs. However, these mechanisms 
are not ubiquitous to all arteries (Feletou and Vanhoutte 2006) and there is 
heterogeneity in the pathways involved depending upon the type of species 
and the vascular bed under investigation. 
c) Role of SKCa- and IKCa-induced vasodilation in cardiovascular diseases 
In transgenic mice using Tet-off inducible expression system, SKCa was 
reported to be involved with the hyperpolarization of SMCs and inhibition 
of SKCa expression through dietary doxycycline led to an increase in blood 
pressure (Taylor et al. 2003). In addition, it was also demonstrated that this 
effect on blood pressure was subsequently reversed following exclusion of 
doxycycline, further suggesting the role of SKCa in pressure regulation 
(Taylor et al. 2003). Loss of IKCa expression in mice also led to impairment 
in ACh-induced dilation of carotid artery and subsequent elevation of blood 
pressure (Si 2006). Numerous in vitro and in vivo studies involving the eNOS 
KO mice have demonstrated the compensatory role of EDH in different 
vascular beds such as femoral artery (Waldron et al. 1999), mesenteric artery 
(Waldron et al. 1999; Ding et al. 2000; Chen et al. 2012) and skeletal 
arterioles (Huang et al. 2000; Huang et al. 2001). In female eNOS/COX KO 
mice, the EDH-like response was found to act as a compensatory 
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vasodilation mechanism that prevented these animals from being 
hypertensive (Scotland et al. 2005). This was also reported in coronary 
arteries from rats with congestive heart failure (Ueda et al. 2005). Similarly, 
the compensatory role of EDH following hypercholesterolemia-induced 
inhibition of the NO pathway, has also been demonstrated in porcine brachial 
artery (Woodman et al. 2005), rabbit renal artery (Brandes et al. 1997; 
Taniguchi et al. 2005), renal arteries from SHR (Kagota et al. 1999), 
mesenteric artery from ApoE-deficient mice (Ding et al. 2009) and gracilis 
artery from dislipidaemic mice (Krummen et al. 2005). On the contrary, 
significant attenuation of EDH response was associated with severe 
hypercholesterolemia and aging in human gastroepiploic arteries (Urakami-
Harasawa et al. 1997). This indicates that the severity of physiological 
disorders may influence the compensatory role of the EDH pathway. 
Currently, there are no treatments that primarily focus in opening the 
endothelial KCa channels. This may be due to their role in other physiological 
processes that could introduce unwanted adverse effects; for example, IKCa 
is involved in the proliferation of ECs (Grgic et al. 2005), SMCs (Neylon et 
al. 1999), pancreatic cancer cell (Jager et al. 2004) and endometrial cancer 
cells (Wang et al. 2007). In addition, SKCa are also involved in neuronal 
excitability (Blank et al. 2004) and therefore, sustained activation of these 
channels in the body can have multiple effects which is yet to be investigated. 
These findings suggest that these channels might not be an ideal therapeutic 
target against CVDs. However, there is some evidence of an improvement 
in the EDH response with current treatment drugs such as losartan 
(angiotensin receptor antagonist) (Feletou and Vanhoutte 2004), cizalaprilat 
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(angiotensin-converting enzyme blocker) (Feletou and Vanhoutte 2004) and 
cilostazol (phosphodiesterase inhibitor) (Matsumoto et al. 2005), although 
these drugs primarily act via other vasodilation pathways. 
1.2.3.ii BKCa 
a) Structure and distribution of BKCa 
Endothelial factors such as EETs (Dimitropoulou et al. 2007) and NO 
(Félétou 2009) have been reported to activate BKCa resulting in 
hyperpolarization of the SMCs. BKCa (KCa1.1) is composed of four α- (Slo1 
α) and four accessory β-subunits with a conductance of ~100-300 pS (Fig 
1.7) (Lee and Cui 2010). The α subunit is encoded by a single gene 
(KCNMA1) and is made up of seven transmembrane segments (S0-S6) (Lee 
and Cui 2010). The S4 segment is composed of positively charged residues 
involved with voltage sensitivity and the S5-S6 segments form the channel 
pore with the selectivity filter for potassium ions (Lee and Cui 2010). The 
intracellular carboxyl-terminus of the α subunit contains a regulator of 
conductance for K+ (RCK) domain and Ca2+ bowl regions which confer 
sensitivity to Ca2+ (Lee and Cui 2010). The β-subunit (β1-4) is encoded by 
four genes (KCNMB1-4) and is made up of two transmembrane segments 
with intracellular amino- and carboxyl-terminals (Lee and Cui 2010). The β1 
subunit is predominantly expressed in the vascular SMCs and interacts with 
the amino-terminus along with S0 segment of the α subunit (Lee and Cui 
2010).  
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Fig 1.7 Structure of the BKCa channels. BKCa (KCa1.1) is made up of α subunits with seven 
transmembrane segments (S0-6) and β subunits with two transmembrane domains. α subunit 
contains a calcium binding region (Ca2+ bowl) in the C-terminus and voltage sensing S4 region.  
CaM = calmodulin, KCa = calcium activated potassium channel and KCa1.1 = large conductance 
KCa. Image obtained from (Grgic et al. 2009). 
b) Mechanisms involved with BKCa-induced vasodilation 
BKCa  channels can be modulated by both changes in membrane potential and 
[Ca2+]i. Depolarizing potential can activate these channels during low [Ca
2+]i 
conditions (McManus 1991) and increase in [Ca2+]i can shift the voltage 
dependence of these channels to a more negative and physiological 
membrane potentials facilitating channel opening (Fig 1.3) (McManus 
1991). Furthermore, depolarization of the membrane has also been reported 
to increase sensitivity of these channels to [Ca2+]i (McManus 1991). BKCa 
are predominantly expressed in vascular SMCs and are found in clusters of 
20-100 units (Félétou 2009). The clustered arrangement amplifies channel 
activation as localized Ca2+-release events (Ca2+ sparks) from the ryanodine 
receptors are able to generate large spontaneous transient outward currents 
(STOCs) (Bolton and Imaizumi 1996; Zhuge et al. 2002); subsequently 
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leading to hyperpolarization, reduction in [Ca2+]i and vasodilation. 
Electrophysiological techniques have been used to demonstrate that NO can 
directly activate BKCa in SMCs derived from rat mesenteric artery (Mistry 
and Garland 1998). Indirect activation of BKCa by NO through PKG 
mediated phosphorylation has also been reported in pulmonary artery 
(Archer et al. 1994). Another group of endothelial factors reported to activate 
BKCa are the EETs and has been demonstrated in various vascular beds 
including bovine coronary (Rosolowsky et al. 1990; Rosolowsky and 
Campbell 1993; Campbell et al. 1996), human mammary (Archer et al. 2003) 
and rat cerebral arteries (Earley et al. 2005). Most studies indicate an indirect 
activation of BKCa by EETs through mechanisms such as stimulation of Gαs 
protein-dependent activation of PKA which can subsequently facilitate 
opening of BKCa channels (Imig et al. 1999; Fukao et al. 2001; 
Dimitropoulou et al. 2007). Furthermore, EETs have also been reported to 
activate BKCa by upregulating the production of carbon monoxide in rat 
mesenteric arteries (Sacerdoti et al. 2006). Lastly, a study led by Earley et al 
demonstrated that EETs can facilitate BKCa channel opening by initially 
activating TRPV4-mediated release of Ca2+ sparks from the SR (see section 
2.6, ii) (Fig 1.3 and 1.9) (Earley et al. 2005).  
c) Role of BKCa-induced vasodilation in cardiovascular diseases 
An increase in oxidative stress has been associated with atherogenesis (Singh 
and Jialal 2006) and studies report that vasodilation pathways involving NO,  
KATP and Kv channels can be impaired by ROS (Liu and Gutterman 2002). 
However, BKCa channels were less sensitive to this ROS-mediated inhibition 
and were reported to act as a compensatory relaxation pathway in 
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atherosclerosis (Liu and Gutterman 2002). This was further confirmed by 
studies conducted using SHRs which demonstrated increased expression of 
α (Liu et al. 1998) and β1 (Chang et al. 2006) BKCa subunits in cerebral 
arteries and mesenteric arteries, respectively. In addition, elevated 
expression of β1 subunits in cerebral arteries were also found in aging rats 
which prevented the impairment of BKCa function (Nishimaru, Eghbali, 
Stefani, et al. 2004). In contrast, depending upon the type of arteries and 
animal models, reduced expression of the BKCa subunits has also been 
reported. The reduction in the expression of α subunit was demonstrated in 
pulmonary artery from rats with pulmonary hypertension (Bonnet et al. 
2003), superior mesenteric artery from N-nitro-L-arginine hypertensive rats 
(Bratz et al. 2005) and coronary artery from aging rats (Nishimaru, Eghbali, 
Lu, et al. 2004). Similarly, decreased expression of β1 subunit was also 
reported in cerebral arteries from SHR (Amberg and Santana 2003) and 
angiotensin II-induced hypertensive rats (Amberg et al. 2003). Currently, 
BKCa openers are not used for the treatment of CVDs since these drugs have 
mostly failed in clinical trials due to insufficient selectivity and potency 
(Nardi and Olesen 2008; Bentzen et al. 2014). However, a BKCa opener, 
andolast, is undergoing clinical investigation at the moment for the treatment 
of mild to moderate asthma (Malerba et al. 2015). A lot of the current 
medicinal treatments that elicit NO and PGI2 mediated vasodilation have also 
been reported to activate BKCa and these drugs include; sildenafil 
(phosphodiesterase inhibitor) (Werner et al. 2008), iloprost (PGI2 analog) 
(Clapp et al. 1998) and nitroglycerin (NO donor)  (Gruhn et al. 2002). 
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Therefore, there is still some potential for these channels to act as therapeutic 
targets with more selective and potent BKCa openers. 
1.2.3.iii TRPV4 
a) Structure and distribution of TRPV4 
It was initially thought that EETs hyperpolarized SMCs through direct 
activation of BKCa channels. However, currently there is extensive evidence 
indicating an indirect modulation of BKCa channels by these PUFAs (Imig et 
al. 1999; Fukao et al. 2001; Dimitropoulou et al. 2007) via various 
mechanisms including initial activation of TRPV4 channels (Earley et al. 
2005). TRPV4 is a non-selective cationic tetramer from the vanilloid sub 
group (Everaerts and Owsianik 2010). It contains six transmembrane 
segments (TM1-6) with intracellular amino- and carboxyl-terminus (Fig 1.8) 
(Everaerts and Owsianik 2010). The region between TM5-6 forms the pore 
of the channel (Everaerts and Owsianik 2010). The cytoplasmic N-terminus 
is composed of an ankyrin repeat domain which is involved in interaction 
between different ligands and proteins (Sullivan et al. 2015). The C-terminus 
also contains binding sites for calmodulin and cytoskeletal proteins 
(Takahashi et al. 2014). It has a conductance of 50-60 pS for inward current 
and 90-100 pS for outward currents (Everaerts and Owsianik 2010). TRPV4 
channels can be activated by various stimuli such as heat, mechanical stress, 
AA and EETs (Everaerts and Owsianik 2010). Endothelial expression of 
TRPV4 has been reported in both conduit and resistance arteries, examples 
include mouse aorta along with mesenteric artery, rat carotid artery and rat 
pulmonary artery (Filosa et al. 2013). TRPV4 expression in vascular SMCs 
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has also been reported in rat aorta, rat cerebral artery, rat pulmonary and 
mesenteric artery (Filosa et al. 2013).  
 
Fig 1.8 Structure of TRP channels. TRPV4 is a tetramer and each subunit is composed 
of six transmembrane segments with the N- and C-terminus located in the cytoplasm. 
TRPV4 is expressed in both endothelial and the smooth muscles cells of the vasculature. 
The region between TM5-6 forms the pore of the channel. TRPV4 = transient receptor 
potential cation channel subfamily vanilloid member 4. Image was obtained from 
(Blackshaw et al. 2010). 
b) Mechanisms involved with TRPV4-induced vasodilation 
The signalling pathway involving TRPV4 and BKCa channels in EET-
induced vasodilation was first reported in rat cerebral arteries (Fig 1.3 and 
1.9) (Earley et al. 2005). This study demonstrated that EETs initially 
activated TRPV4 channels resulting in the subsequent stimulation of the 
ryanodine receptors. The localized Ca2+ sparks released from these receptors 
then activated the neighbouring BKCa channels, generating STOCs which 
hyperpolarized and relaxed the pressurized arteries (Earley et al. 2005). 
Similarly, Sonkusare et al. also demonstrated regulation of endothelial SKCa 
and IKCa channels by TRPV4 in carbachol-induced relaxation of pressurized 
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mouse mesenteric arteries (Fig 1.3 and 1.9) (Sonkusare et al. 2012). 
However, this pathway did not involve the BKCa channels and the release of 
Ca2+ from intracellular stores (Sonkusare et al. 2012). TRPV4 was indicated 
to function cooperatively forming a cluster of four-channels resulting in an 
amplified influx of Ca2+ that directly activated the endothelial KCa channels 
(Sonkusare et al. 2012). In addition, IKCa was found to be primarily activated 
by the TRPV4 and SKCa activation required higher concentration of the 
TRPV4 agonist. A subsequent study led by the same group investigated the 
mechanisms involved with TRPV4 activation in carbachol-induced 
relaxation (Sonkusare et al. 2014). Carbachol activates the muscarinic M3 
GPCR present in the endothelium, resulting in subsequent production of 
PKC. This study revealed that PKC stimulates PKC-anchoring protein 
(AKAP150) which facilitates the opening of TRPV4 channels resulting in 
the subsequent activation of IKCa (Sonkusare et al. 2014). Furthermore, 
AKAP150 was also found to be localised in the myoendothelial projections, 
suggesting the presence of microdomains involving the TRPV4, IKCa and 
AKAP150 (Sonkusare et al. 2014). Consistent with the earlier findings 
another study also confirmed the interaction between SKCa and TRPV4 
channels in rat mesenteric arteries (Ma et al. 2013). Using 
coimmunoprecipitation and double immunolabeling, these channels were 
shown to be physically associated with each other and shared a functional 
interaction in ECs (Ma et al. 2013).  
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Fig 1.9 Mechanisms involved in the regulation of EDH response by TRP channels. 
TRP channels were found to directly activate endothelial SKCa and IKCa channels whereas 
BKCa channels were indirectly activated by TRP channels through the release of calcium 
sparks, resulting in the hyperpolarization of SMCs and relaxation of the arterial bed. ACh 
= acetylcholine, BK = bradykinin, BKCa = large calcium activated potassium channels, 
CaV = voltage-gated calcium channels, Cx = connexin, EC = endothelial cell, eNOS = 
endothelial nitric oxide synthase, IKCa = intermediate conductance calcium activated 
potassium channels, KIR = inward-rectifier potassium ion channel,  Na+/K+-ATPase = 
sodium-potassium adenosine triphosphatase, NO = nitric oxide, PE = phenylephrine, RyR 
= ryanodine receptor, SKCa = small conductance calcium activated potassium channels, SP 
= substance P, TRPC1 = transient receptor potential cation channel subfamily C member 
1, TRPV4 =  transient receptor potential cation channel subfamily vanilloid member 4 and 
VSMCs = vascular smooth muscle cells. Figure was obtained from (Félétou and Vanhoutte 
2009). 
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c) Role of TRPV4-induced vasodilation in cardiovascular diseases 
There is evidence indicating the role of TRPV4 in the regulation of vascular 
tone; for example, loss of TRPV4 expression in KO mice led to impairment 
of shear stress mediated vascular relaxation in carotid (Hartmannsgruber et 
al. 2007) and mesenteric arteries (Mendoza et al. 2010). Studies also indicate 
inhibition of ACh-mediated vasodilation both in vivo and in vitro using 
mesenteric arteries derived from TRPV4 KO mice (Zhang et al. 2009; 
Earley, Pauyo, et al. 2009). In human coronary arteries, TRPV4 was 
associated with flow mediated dilation and the mechanism involved the 
release of mitochondrial ROS (Bubolz et al. 2012). AA was also reported to 
activate endothelial TRPV4 that resulted in hyperpolarization and relaxation 
of human coronary arteries (Zheng et al. 2013). TRPV4 KO mice did not 
develop hypertension, however, administration of eNOS inhibitor led to 
significant increase in blood pressure in these KO mice compared to the wild 
type controls (Earley, Pauyo, et al. 2009). These findings indicate that there 
is therapeutic potential for TRPV4 modulation against CVDs, however it 
should be noted that these channels are also involved in other physiological 
processes such as nociception (Qu et al. 2016), pulmonary fibrogenesis 
(Rahaman et al. 2014) and epithelial permeability (Reiter et al. 2006). 
Therefore, in contrast to the beneficial effects of TRPV4 activation with 
CVDs, studies also report that antagonism of TRPV4 would be 
therapeutically advantageous for diseases that involve oedema, pain and 
bronchoconstriction (Grace et al. 2017). Perhaps targeting signalling 
mechanisms, that are more specific to a certain disorder or tissue of the body, 
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would be the safer approach for cardiovascular treatments that involve 
TRPV4 channels. 
1.2.4 Other potassium channels involved in vascular relaxation 
1.2.4.i KATP 
a) Structure and distribution of KATP 
In 1983, an ATP-sensitive potassium channel (KATP) was first reported in 
cardiac myocytes by Noma (Noma 1983). The study demonstrated that 
intracellular ATP inhibited these channels and therefore were distinct from 
the inward rectifier potassium channels (Kir) (Noma 1983). Six years after 
this discovery, a similar current was observed in rabbit mesenteric SMCs and 
was found to regulate vasodilation (Standen et al. 1989). KATP channel is a 
hetero-octameric complex composed of four sulfonylurea receptor (SUR) 
subunits and four pore-forming Kir6 subunits (Fig 1.10) (Shi et al. 2012). 
Kir6 subunits are further divided into Kir6.1, encoded by KCNJ8 and Kir6.2, 
encoded by KCNJ11 (Shi et al. 2012). SUR subunits are also subdivided into 
SUR1 encoded by ABCC8 and SUR2A along with SUR2B are encoded by 
ABCC9 (Shi et al. 2012). Kir6 is composed of two transmembrane regions 
(M1-M2), a pore-forming loop and both the N- and C-termini located in the 
cytoplasm (Shi et al. 2012). SUR subunits are part of the ATP-binding 
cassette family and are composed of seventeen transmembrane segments 
(Shi et al. 2012). These segments are divided into three transmembrane 
domains (TMD0, TMD1 and TMD2) (Shi et al. 2012). TMD1 and TMD2 
are connected by intracellular nucleotide binding fold (NBF1) containing 
Walker A and Walker B domains which are involved in nucleotide 
hydrolysis [for review see (Foster and Coetzee 2016)]. Another nucleotide 
  
41 
 
binding fold (NBF2) is present in the intracellular carboxyl-terminus and 
also contains Walker A along with Walker B domains (Foster and Coetzee 
2016). NBF1 and NBF2 are involved in the binding of MgATP and MgADP 
respectively (Foster and Coetzee 2016). Kir6.1 has been reported to be 
ubiquitously expressed whereas Kir6.2 are mostly expressed in pancreatic 
beta, cardiac and skeletal muscle cells (Foster and Coetzee 2016). SUR2A is 
highly expressed in cardiac and skeletal muscle cells (Foster and Coetzee 
2016). The expression of SUR2B has been detected in tissues such as heart, 
lung epithelium, astrocytes, vascular ECs and SMCs (Foster and Coetzee 
2016). Most studies report lower expression of SUR1 and SUR2A messenger 
ribonucleic acid (mRNA) compared to SUR2B in SMCs (Inagaki et al. 1995; 
Chutkow et al. 1996; Isomoto et al. 1996). Although the presence of Kir6.2 
mRNA was reported in SMCs, the protein expression of this subunit was not 
detected (Yoshida et al. 2004). In ECs derived from guinea pig cardiac 
capillaries and human coronary artery, the KATP complex was made up of 
Kir6.1, Kir6.2 and SUR2B subunits (Mederos y Schnitzler et al. 2000; 
Yoshida et al. 2004). Therefore, majority of the studies indicate that the 
vascular KATP channels, present in both ECs and SMCs, are mainly 
composed of Kir6.1 and SUR2B (Foster and Coetzee 2016). 
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Fig 1.10 Schematic representation of the structure of the KATP channels. KATP is composed 
of Kir6 and SUR subunits. Kir6 subunit is composed of two transmembrane helices linked by an 
extracellular pore-forming loop (P loop). SUR is composed of three transmembrane domains 
(TMD0-2) and two nucleotide binding folds (NBF1-2) located intracellularly. NBF1 and NBF2 
are involved in the binding of MgATP and MgADP respectively. Walker A and Walker B 
domains are involved in nucleotide hydrolysis. Kir6 = inwardly rectifier potassium channels and 
SUR = sulfonylurea receptor. Figure obtained from (Foster and Coetzee 2016). 
b) Mechanisms involved with KATP-induced vasodilation 
One of the main features of the KATP channels is the direct inhibition 
mediated by intracellular ATP (Foster and Coetzee 2016). Using the inside-
out patch clamp technique, about 100 µM of ATP was able to reduce KATP 
channel activity by half in cardiac myocytes (Foster and Coetzee 2016). As 
a result, these channels have a reduced activity at basal conditions in the 
vasculature since the intracellular concentration of ATP is at the millimolar 
range (1-11.7 mM) (Foster and Coetzee 2016). Studies also indicate that 
these channels are inhibited to a lesser extent by other nucleotides such as 
adenosine diphosphate (ADP) and GTP (Foster and Coetzee 2016). 
However, ADP in the presence of Mg2+ can activate KATP channels and 
therefore the intracellular ATP/ADP ratio determines the channel opening. 
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Most studies indicate that PKA is involved in KATP-induced vasodilation (Fig 
1.3). Vasoactive intestinal polypeptide (VIP) is a vasodilator that activates 
GPCRs (Gαs), VIP receptor 1 and 2, resulting in the subsequent production 
of PKA. VIP was reported to induce hyperpolarization and relaxation of rat 
mesenteric artery through a PKA-dependent pathway (Yang et al. 2008). 
PKA phosphorylates serine residues (Ser1351 and Ser1387) present in NBF2 
region of the SUR2B subunit resulting in channel activation (Shi et al. 2007). 
In contrast, exchange protein activated by cAMP (EPAC) which forms a 
complex with KATP channels is involved in the activation of Ca
2+-sensitive 
protein phosphatase 2B (PP-2B, calcineurin) and subsequent inhibition of 
KATP (Purves et al. 2009). A higher concentration of cAMP was required to 
activate EPAC compared to PKA. Therefore, it is currently suggested that 
the differential cAMP-mediated modulation of KATP is dependent upon the 
concentration of cAMP. CYP metabolites of AA, EETs, have also been 
reported to dilate rat mesenteric arteries through activation of KATP. 
However, the pathways were indicated to differ depending upon the type of 
EET regioisomers. Activation of KATP channels by 11,12-EET (Ye et al. 
2005) was dependent upon PKA activity whereas 14,15-EET (Ye et al. 2006) 
mediated activation required ADP-ribosylation of Gαs. NO has also been 
reported to activate KATP channels by upregulating the production of cGMP 
in rabbit mesenteric arteries (Murphy and Brayden 1995). However, sodium 
nitroprusside was unable to stimulate these channels in SMCs derived from 
pig coronary (Wellman et al. 1998) and rabbit mesenteric artery (Quayle et 
al. 1994). Hydrogen sulphide was also reported to activate KATP channels in 
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porcine cerebral arterioles (Liang et al. 2011) and rat aorta (Zhao and Wang 
2002) along with mesenteric arteries (Tang et al. 2005). 
c) Role of KATP-induced vasodilation in cardiovascular diseases 
Loss of Kir6.1 and SUR2 expression in the coronary artery was associated 
with coronary artery vasospasm, sudden cardiac death and hypertension [for 
review see (Nichols et al. 2013)]. The vasospasm was reported to decrease 
following treatment with nifedipine (Ca2+ channel blocker) in SUR2 KO 
mice (Nichols et al. 2013), indicating a protective role of KATP channels in 
vasospasms. Moreover, expression of a dominant negative Kir6.1 subunit in 
transgenic mice increased the coronary perfusion pressure which was 
attributed to the elevated levels of the vasoconstrictor, endothelin-1 (Nichols 
et al. 2013). In transgenic mice expressing gain of function mutants of Kir6.1 
in SMCs, attenuation of blood pressure was reported (Nichols et al. 2013). 
In SUR2 null mice, re-establishing the expression of SUR2 was associated 
with reduction in infarct size and increased recovery in cardiac function 
compared to the control mice (Stoller et al. 2010). However, compared to the 
animal models, loss of function mutations of Kir6.1 and SUR2 in humans 
were not involved in hypertension and coronary vasospasm (Nichols et al. 
2013). In contrast, genetic variation in the KCNJ8 (Kir6.1) was associated 
with several disorders involving the heart such as J wave syndromes along 
with ventricular and atrial fibrillation (Foster and Coetzee 2016). It is 
possible that this inconsistency in human studies might have occurred partly 
due to the expression of KATP channels in multiple tissues other than the 
vascular bed. Therefore, it is crucial to develop openers that selectively target 
the vascular KATP isoform. Due to lack of selectivity, the current KATP 
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openers are only used for the treatment of severe hypertension (Minoxidil 
with diuretic and beta-blocker) (NICE 2019d) and stable angina (Nicorandil, 
second line) (NICE 2019e). 
1.2.4.ii Kv7 
a) Structure and distribution of Kv7 
Potassium voltage-gated channel subfamily KQT (Kv7) are tetramers 
composed of four α subunits (Fig 1.11) (Fosmo and Skraastad 2017). Each 
subunit has six transmembrane segments (S1-S6) with the intracellular 
amino- and carboxyl-terminus. The voltage sensing domain is present 
between S1-S4 whereas S5-S6 regions form the pore of the channel (Fosmo 
and Skraastad 2017). The α subunits can be divided into five Kv7.1-7.5 
subtypes encoded by KCNQ1-5 genes respectively (Fosmo and Skraastad 
2017). Kv7 subunits can form both homomers and heteromers depending 
upon where they are expressed (Fosmo and Skraastad 2017). There are six 
positively charged arginine residues present in the S4 segment which is 
involved in closing and opening of the channel following changes in the 
membrane potential (Fosmo and Skraastad 2017). Kv7 subunits can also 
coassemble with auxiliary β subunits (KCNE1-5) that are involved in 
regulating the function and expression of Kv7 channels (Fosmo and 
Skraastad 2017). In cardiac muscle cells,  Kv7.1 subunits can assemble with 
KCNE1 to form the IKS channel involved with the repolarization of ventricles 
(Fosmo and Skraastad 2017). In the neuronal system, M-currents are 
associated with the regulation of action potentials and release of 
neurotransmitters (Fosmo and Skraastad 2017). These currents are generated 
by homomeric and heteromeric complexes formed with Kv7.2, Kv7.3 and 
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Kv7.5 subunits (Fosmo and Skraastad 2017). Studies using rat renal arteries 
(P. S. Chadha et al. 2012) and human visceral arteries (Fosmo and Skraastad 
2017) report that Kv7.1, Kv7.4 and Kv7.5 subunits were predominantly 
expressed in SMCs. Kv7.4 and Kv7.5 channels were reported to be mostly 
involved in the regulation of vascular tone (Fosmo and Skraastad 2017).  
 
Fig 1.11 Structure of the Kv7 channels. Kv7 channel is a tetrameric complex composed of α 
subunits containing six transmembrane regions (S1-6). S4 segment contains positively charged 
arginine residues involved in channel opening and closing following changes in the membrane 
potential. S5-S6 regions form the pore of the channel. Auxiliary KCNE1 subunits can also 
coassemble with Kv7 and regulate channel function. Figure obtained from (Foster and Coetzee 
2016). 
b) Mechanisms involved with Kv7-induced vasodilation 
In rat renal arteries, isoproterenol (β2 adrenoceptor agonist)-induced 
relaxation was mediated via the cAMP-dependent activation of Kv7.4 
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channels (P. S. Chadha et al. 2012). A recent electrophysiological study also 
demonstrated that isoproterenol elicited activation of the β2 adrenoceptor 
(GS) resulting in the cAMP-induced production of PKA that subsequently 
activated Kv7.4/Kv7.5 heteromers and Kv7.5 homomers (Mani et al. 2016). 
Furthermore, Kv7.5 was found to be more sensitive to PKA activation 
compared to the Kv7.4/Kv7.5 heteromers. In contrast to KATP channels, 
EPAC is involved in the activation of Kv7 (Stott et al. 2016). Using proximity 
ligation, Kv7.4 channels were reported to be localized with EPAC in rat renal 
and mesenteric artery (Stott et al. 2016). Moreover, there was heterogeneity 
in the pathway involved with isoproterenol-induced relaxation depending 
upon the type of vascular bed (Stott et al. 2016). In rat renal artery, 
relaxations were reduced via inhibition of EPAC and was not associated with 
PKA activity. On the contrary, relaxations were only sensitive to PKA 
activation in rat mesenteric artery. cGMP was also found to be involved in 
the relaxation of rat aorta and renal artery through activation of Kv7.4 
channels (Stott et al. 2015). Although there are no studies indicating the role 
of AA in the activation of Kv7 channels in the vasculature, 12-lipoxygenase 
metabolites of AA were involved in activation of M-currents in the 
sympathetic neurons of bullfrogs (Yu 1995). 
c) Role of Kv7-induced vasodilation in cardiovascular diseases 
In SHR, a decrease in expression of Kv7.4 subtype and attenuation of 
agonist-induced relaxation has been reported in aorta, coronary and 
mesenteric artery (Jepps et al. 2011). PKA-induced relaxation of rat renal 
arteries following application of β adrenergic agonist (Isoproterenol) was 
also inhibited in SHR (P. S. Chadha et al. 2012). This study also indicated 
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that decreased Kv7.4 activity was associated with hypertension (P. S. Chadha 
et al. 2012). cGMP-dependent vasodilation pathway involving the activation 
of Kv7 was also attenuated in aorta and renal artery derived from SHR (Stott 
et al. 2015). Small GTPase Ras-related protein 1 (Rap1b) is a GTP-binding 
protein involved in different cellular functions including regulation of 
vascular tone and can be activated by EPAC (Lakshmikanthan et al. 2014). 
Inactivation of Rap1b in mice was associated with hypertension 
(Lakshmikanthan et al. 2014). Since Kv7.4 channels are reported to be 
localized with EPAC (Stott et al. 2016), it can be speculated that inhibition 
of these channels is possibly involved. A Kv7 opener, flupirtine, was reported 
to elicit vasodilation in pulmonary arteries and reduce right ventricular 
pressure and hypertrophy in mouse models of pulmonary hypertension 
(Morecroft et al. 2009). Furthermore, flupirtine was also indicated to reduce 
pulmonary pressure and prevent pulmonary hypertension in rats (Sedivy et 
al. 2015). Currently, there are only two studies that have reported the effects 
of flupirtine in human blood pressure. Chronic treatment with flupirtine for 
52 weeks led to reduction in blood pressure (Herrmann et al. 1987), however 
an elevation in pressure was reported following a single dose administration 
after 2h (Hummel et al. 1991). These findings indicate that the therapeutic 
effects of Kv7 openers can depend upon the duration of the treatment and as 
a result, further studies need to be conducted to validate these findings using 
more selective Kv7 openers. 
  
  
49 
 
1.3 Role of n-3 PUFAs in vasodilation 
1.3.1 Arachidonic acid 
In the beginning of the 20th century, dietary fatty acids were only known as a great source 
of energy and were not considered as an essential nutrient (Spector and Kim 2015). It 
was only after three decades that a deficiency disease was initially reported in rats fed 
with fat-excluded diet resulting in the development of severe symptoms such as necrosis 
of the tail, hair loss, scaly skin, abrogation of growth, lesions in the urinary tract and 
kidney resulting in premature death (Burr and Burr 1929). Furthermore, it was later 
indicated that inclusion of linoleic acid (LA), an n-6 PUFA with 18 carbon chain and two 
double bonds, reversed these detrimental effects and therefore this established the role of 
fats as an essential nutrient (Burr and Burr 1930). Numerous studies were then conducted 
investigating the physiological effects of fatty acids and by 1940s, substantial amount of 
evidence demonstrated that LA could be endogenously converted into arachidonic acid 
(AA) (Nunn and Smedley-Maclean 1938; Holman and Burr 1948; Rieckenhoff et al. 
1949; Widmer and Holman 1950). AA is an omega-6 PUFA composed of 20-carbon 
chain and four cis-double bonds. AA can be physiologically acquired either through a 
dietary source or by enzymatic elongation and desaturation of precursor PUFAs as shown 
in figure 1.12. This enzymatic metabolism of LA into AA has been demonstrated in 
various tissues including vascular ECs and SMCs (Rosenthal and Whitehurst 1983; 
Garcia et al. 1990; Harmon et al. 2003). In 1964, there was another breakthrough 
discovery demonstrating further conversion of AA into  COX metabolites, prostaglandins 
(section 1.2.2.i) (Bergstroem et al. 1964; Van Dorp et al. 1964). Prostaglandins have a 
major role in maintaining homeostasis throughout the body as they are involved in 
various physiological processes including inflammation (Ricciotti and FitzGerald 2011). 
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Therefore, the insufficient production of prostaglandins due to a fat-deficient diet 
provided an explanation for the fatal symptoms that were previously reported in rats by 
Burr (Bergstroem et al. 1964; Van Dorp et al. 1964). PUFAs such as AA can be found in 
membrane phospholipids and are released as a free fatty acid into the cytosol following 
hydrolysis of the phospholipid ester bond by calcium-sensitive phospholipase A2 (PLA2) 
(Clark et al. 1991; Dennis 1994). As previously described (section 1.2.2.ii), AA can be 
metabolised by various enzymes including CYP, resulting in the production of different 
types of PUFA metabolites that have diverse functions throughout the body. Studies also 
indicate that AA itself can also elicit some of the responses mediated by its metabolites; 
for example, AA can directly activate BKCa channels involved in vasodilation, however, 
EETs (CYP metabolites of AA) were reported to be 1000 times more potent than AA 
(Lu, Katakam, et al. 2001; Martín et al. 2014). Due to the reported functional similarities 
between AA and its metabolites, it is important to consider that perhaps other types of 
fatty acids such as n-3 PUFAs could also elicit similar effects. In fact, both n-3 and n-6 
PUFAs have been reported to activate identical pathways involved in vasodilation and 
these studies will be further discussed in the following sections. 
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Fig 1.12 Enzymatic conversion of omega-3 and omega-6 PUFAs in the human body. LA and 
ALA act as precursors which undergo elongation and desaturation processes producing a range 
of PUFAs. A = adrenic acid, AA = arachidonic acid, ALA = alpha-linoleic acid, DGLA = dihomo-
gammalinolenic acid, DHA = docosahexaenoic acid, DPA = docosapentaenoic acid, EPA = 
eicosapentaenoic acid, FADS = fatty acid desaturase, GLA = gamma linolenic acid, LA = linoleic 
acid, LTs = leukotrienes, PGs = prostaglandins, RVs = resolvins, TXs = thromboxanes. Figure 
obtained from (Rzehak et al. 2010). 
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1.3.2 n-3 PUFAs 
According to World Health Organization, CVDs are number one cause of deaths 
worldwide (WHO 2017). Endothelial dysfunction, hypertension and dyslipidemia are 
some of the major risk factors for CVDs. Vascular endothelial dysfunction refers to the 
abnormality in the vasomotor pathways of the endothelium. This dysfunction results in 
impaired vasodilation and enhanced vasoconstriction (Sitia et al. 2010). Dyslipidemia is 
another disorder that involves an imbalance in the circulating lipids of the blood stream. 
It can result in lower levels of high density lipoprotein and higher levels of low density 
lipoprotein, promoting the formation of atherosclerosis. There is evidence indicating that 
atherogenesis mostly occurs in larger and medium-sized elastic and muscular arteries 
(Glagov et al. 1988). Furthermore, the interaction between endothelium and 
haemodynamic forces such as shear stress and circumferential tensile stress (stretch), was 
reported to influence the localization of atherorsclerotic lesions in various vascular beds 
(Glagov et al. 1988). Major arterial sites with bifurcations and branches were indicated 
to be more prone to plaque formations due to their increased susceptiblility of developing 
an impairment in unidirectional laminar flow, via reduction in shear stress and flow 
velocity [for a comprehensive review see (Glagov et al. 1988; Frangos et al. 1999)]. As 
a result, studies suggest that carotid bifurcation, coronary arteries, major branches of 
aortic arch and abdominal aorta have the highest risk of developing atherosclerosis 
(Glagov et al. 1988; Frangos et al. 1999).  
Omega-3 (n-3) PUFAs or in more popular term “Fish oils” have been identified as healthy 
fats and so far numerous studies have investigated the protective effects of these PUFAs 
in the cardiovascular health of different subpopulations (Miller et al. 2014; Aung et al. 
2018). Earliest records of the protective effects of n-3 PUFAs in the vasculature were 
found during the late 1970s, in studies involving Greenland Eskimo and Japanese people 
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(Bang et al. 1976; Hirai et al. 1980). The diets of these people were found to be low in 
carbohydrates whereas high in protein and omega-3 fatty acids, due to an increased intake 
of fish compared to the western population. These studies also reported lowering of 
plasma triglycerides and low-density lipoprotein levels. Following these novel findings, 
numerous human supplementary and dietary intervention studies were carried out to 
investigate the protective effects of n-3 PUFAs in CVDs. Reduction in plasma 
triglyceride levels present in very low-density lipoprotein were reported both in healthy 
volunteers and hypertriglyceridemic (elevated plasma triglyceride levels) patients (Harris 
et al. 1988). Triglycerides containing n-3 PUFAs had a reduced intestinal absorption rate 
resulting in lowered plasma levels. In addition, another study confirmed reduction in 
esterified eicosapentaenoic acid (EPA) absorption due to decreased rate of hydrolysis by 
the pancreatic lipase (Chen et al. 1987). An extensive review regarding n-3 PUFAs and 
lipoproteins can be found elsewhere (Harris 1997). However, depending upon the target 
subpopulations, there are also reports indicating an ineffectiveness of n-3 PUFAs in 
providing cardiovascular benefits. A recent study that involved meta-analysis of ten 
randomized clincial trials with a minimum of 500 participants with coronary heart disease 
(CHD), demonstrated that treatments with n-3 PUFAs (0.226-1.8 g/day) for an average 
duration of 4.4 years, did not cause any signifcant reduction in adverse events which 
include myocardial infraction, fatal coronary heart disease (CHD) and stroke (Aung et al. 
2018). It is possible that depending upon the dosage and type of CVD, the efficacy of n-
3 PUFAs in improving cardiovascular health may differ. For example, a meta-analysis 
study of randomized trials revealed that a higher dose (3.7 g/day) of n-3 PUFAs lowered 
both systolic and diastolic blood pressure especially in older and hypertensive patients 
(Geleijnse et al. 2002). Campbell et al also verified these findings, following meta-
analysis of 17 studies, by indicating that that n-3 PUFA supplementation led to significant 
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reduction of blood pressure in hypertensive patients but not in healthy volunteers 
(Campbell et al. 2013). Furthermore, a more recent meta-analysis study that evaluated 70 
randomized trials, reported that the decrease in blood pressure associated with n-3 PUFAs 
(≥1 g/day) was the most potent in unmedicated hypertensive participants (Miller et al. 
2014). Therefore, the discrepancy that has been reported between n-3 PUFA studies could 
be explained by the heterogeneity involved with the protective effects of n-3 PUFAs, that 
seems to depend upon the type of; target subpopulation (eg: normotensive vs 
hypertensive), CVDs (eg: CHD vs hypertension) and possibly the dosage of these 
PUFAs. Furthermore, genetic variations in the vasodilation pathways between different 
subpopulations should also be considered when comparing these studies. As mentioned 
earlier (section 1.2.2.ii), CYP2C and CYP2J are the main epoxygenases that are 
expressed in the ECs and are involved in the production of EETs, which are known to 
elicit vasodilation (Zeldin 2001). Similar to the n-3 PUFAs, conflicting findings have 
been reported by studies investigating the role of CYP polymorphisms in various CVDs 
[reviewed by (Zordoky and El-Kadi 2010)]. Besides the expected differences in diet, 
ethnicity and family history between different subpopulations (Arun Kumar et al. 2011); 
the reported inconsistency could also be perhaps explained by the propensity of specific 
CYP polymorphisms to affect certain CVDs. For example; in African American 
population, CYP2J polymorphism was reported to lower the risk of coronary artery 
disease (Lee et al. 2007), however this polymorphism was not involved with hypertension 
(Dreisbach et al. 2005). CYP2C polymorphism on the other hand was not associated with 
both coronary artery disease (Lee et al. 2007) and hypertension (Dreisbach et al. 2005) 
in African Americans. There is extensive evidence indicating that both n-3 PUFAs and 
its CYP metabolites can elicit vasodilation by directly activating BKCa channels 
(discussed in section 1.3.3.iii) (Ye et al. 2002; Hercule et al. 2007; Wang et al. 2011; 
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Toshinori Hoshi, Wissuwa, et al. 2013; Nagaraj et al. 2016). As discussed earlier in 
section 1.2.3.ii.c, the expression profile of BKCa has been reported to alter depeding upon 
the type of CVD. An increase in β1 BKCa subunit expression was reported in SHR (Liu 
et al. 1998) whereas reduction in the expression of α subunit of BKCa was demonstrated 
in rats with pulmonary hypertension (Bonnet et al. 2003). Therefore, depending upon the 
disorder of the subpopulation, it seems that the therapeutic effectiveness of n-3 PUFA 
supplementation may differ due to changes in the expression and the functional activity 
of the vasodilation pathways.  
n-3 PUFAs are essential fats which comprise of alpha-linoleic acid (ALA, C18:3), EPA 
(C20:5), docosapentaenoic acid (DPA, C22:5) and docosahexaenoic acid (DHA, C22:6). 
Figure 1.12 illustrates the endogenous enzymatic pathway involving fatty acid desaturase 
enzymes, which orchestrate elongation and desaturation reactions that convert ALA into 
eicosanoids, DPA, EPA and DHA. EPA and DHA are considered as essential fatty acids 
since the enzymatic conversion of ALA into EPA and DHA in the human body is very 
inefficient, and only about 0.2 to 8% of EPA and 0 to 4% of DHA are produced (Burdge 
et al. 2002; Mozaffarian and Wu 2011). As a result, optimum levels of EPA and DHA 
are only achieved through diet and supplementation.   
Similar to AA, n-3 PUFAs are also released from the membrane phospholipids via the 
activity of PLA2 and can compete with AA for similar enzymes (Bogatcheva et al. 2005). 
As a result, EPA also produces various eicosanoids including series-3 PG, series-5 LTs 
and epoxyeicosatetraenoic acids (EPETEs) (Thomson et al. 2012). DHA is also converted 
into metabolites such as epoxydocosapentaenoic acids (EDPs) and hydroxy-DHA 
(HDHA) (Arnold, Konkel, et al. 2010). Figure 1.13 summarises the metabolism of these 
fatty acids and the enzymes involved.   
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Fig 1.13 Enzymes involved in the metabolism of AA, DHA and EPA. Dietary intake of DHA 
and EPA results in incorporation of these fatty acids into the cell membrane. Following its release 
from membrane phospholipids, it can compete with enzymes that metabolise AA. AA, 
Arachidonic acid; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid; 
EETs, epoxyeicosatrienoic acids; EDPs, epoxydocosapentaenoic acids; EPETEs, 
epoxyeicosatetraenoic acid; EPA, eicosapentaenoic acid; HDHA, hydroxy-docosahexaenoic 
acid; HETEs, hydroxyeicosatetraenoic acids; LOX, lipoxygenase and LTs, leukotrienes. 
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1.3.3 n-3 PUFAs and vasodilation 
As discussed earlier, although n-3 PUFAs were not involved in improving the 
cardiovascular health of participants with CHD (Aung et al. 2018), various meta-analysis 
studies have reported that these PUFAs are involved in the reduction of blood pressure 
in patients suffering from hypertension (Geleijnse et al. 2002; Campbell et al. 2013; 
Miller et al. 2014). Likewise, improvements in vasodilation response of arteries have also 
been reported as a common effect of n-3 PUFAs supplementation (Mori 2014). This 
section of the introduction will discuss both the endothelium-dependent and -independent 
mechanisms that have been associated with n-3 PUFAs in various vascular beds.    
1.3.3.i Effects of n-3 PUFAs in NO production 
n-3 PUFAs have been shown to improve endothelial dysfunction and reduce progression 
of CVDs. Many studies indicate that n-3 PUFAs enhance endothelial NO levels; for 
example, EPA was reported to induce calcium-independent increases in endothelial NO, 
resulting in relaxation of bovine coronary arteries (Omura et al. 2001). Similarly, DHA 
enhanced interleukin-1β-mediated NO production in SMCs derived from rat aorta 
(Hirafuji et al. 2002). An increase in eNOS mRNA and protein levels in isolated aortic 
tissues are possible mechanisms of n-3 PUFA-induced NO production (López et al. 
2004). In SHR, dietary supplementation with DHA and EPA for two months reduced 
plasma levels of ADMA, an endogenous eNOS inhibitor (Raimondi et al. 2005). Rats fed 
with high-fructose diet exhibited endothelial dysfunction that was prevented by 
upregulation of eNOS expression, following dietary inclusion of n-3 PUFAs (Nyby et al. 
2005). Likewise in nephrectomized rats and ApoE KO mice, an elevated aortic expression 
of eNOS and NO production was reported following inclusion of n-3 PUFA-rich diet 
(Casós et al. 2010; Zanetti et al. 2017). Clinical studies have also validated these findings; 
for example, chronic treatment of EPA in patients with coronary artery disease led to 
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improvements of both NO-dependent and -independent vasodilation (Tagawa et al. 
1999). Furthermore, acute treatment (4 h) with n-3 PUFAs prevented high fat meal-
induced impairment of flow mediated dilation, a measure of NO-dependent relaxation, in 
the brachial artery of healthy volunteers (Fahs et al. 2010). Most of the animal studies 
indicated that n-3 PUFA-induced elevation of NO production in the aortic vasculature 
(Table 1.1), resulting in the reversal of endothelial dysfunction. Although large conduit 
arteries are not involved in the regulation of mean arterial blood pressure, NO-mediated 
vascular relaxation of aorta has been reported to reduce arterial stiffness and central blood 
pressure, as discussed previously in section 1.2.1.i (Kampus et al. 2011; Zhou et al. 2014). 
Furthermore, it is possible that n-3 PUFAs might also enhance NO production in other 
vessels, therefore, highlighting the necessity of investigating this pathway in conduit and 
resistance arteries.      
1.3.3.ii Effects of n-3 PUFAs in KATP-induced vasodilation 
There is also evidence indicating the involvement of KATP channels with n-3 PUFA-
induced vasodilation. For example, in rat aorta pre-constricted with noradrenaline and 
high concentration of potassium (80 mM), EPA-induced relaxation was sensitive to 
blockade of COX and KATP channels (Engler et al. 2000). The author suggested that COX 
metabolites of EPA were possibly involved in KATP activation. Furthermore, there is some 
evidence indicating that n-3 PUFA supplementation (28 days) can alter prostanoid 
production in humans (Chin et al. 1993). n-3 PUFAs were found to attenuate 
noradrenaline- and angiotensin II-induced vasoconstriction of human forearm resistance 
vessels which was sensitive to COX inhibition. 
A recent study also reported that DHA might be involved in the activation of KATP 
channels in rat aorta (Sato et al. 2014). In contrast to the earlier study, this relaxation 
persisted following inhibition of COX and endothelium removal, perhaps indicating a 
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direct role of DHA in KATP activation. However, CYP metabolite of DHA, 16, 17-EDP, 
was also involved in KATP-dependent relaxation of rat aorta (Sato et al. 2014). Another 
interesting observation in this study was the presence of remaining residual relaxation 
following CYP inhibition and the additional blockade of KATP channels (Sato et al. 2014). 
Therefore, it is essential to conduct further investigations to fully elucidate these 
unknown mechanisms involved with n-3 PUFA-mediated relaxation. 
1.3.3.iii Effects of n-3 PUFAs in KCa-induced vasodilation 
The EDH response involves activation of KCa channels which hyperpolarize vascular 
SMCs resulting in vasodilation. AA and its metabolites have been reported to regulate 
the EDH response via KCa channels. Currently there is no evidence indicating the role of 
SKCa and IKCa in n-3 PUFA-mediated vasodilation. However, there is one study that has 
investigated the modulation of IKCa by DHA (Kacik et al. 2014). Their findings 
demonstrated that PUFAs including DHA, AA and EETs were involved in the inhibition 
of human IKCa channels expressed in human embryonic kidney (HEK) cells (Kacik et al. 
2014). Therefore, further studies are required to investigate whether this inhibition is also 
observed in intact arteries and if EPA has a similar effect. 
As discussed earlier, AA-derived EETs can activate BKCa channels present in vascular 
SMCs mainly derived from resistance arteries confirming their role as EDH factors 
(72,73). CYP epoxygenase metabolites of DHA, EDPs, have also been reported to 
activate BKCa channels resulting in hyperpolarization of vascular SMCs derived from 
porcine coronary arteries (Ye et al. 2002). Similarly, DHA mediated a concentration-
dependent increase in BKCa channel currents in SMCs derived from rat coronary artery 
(Lai et al. 2009). In isolated rat coronary arterial tissues, the blockade of BKCa channels 
completely abolished DHA-induced vasodilation (Wang et al. 2011). The underlying 
mechanism involved the release of calcium from sarcoplasmic reticulum mediated by 16, 
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17-EDPs in rat coronary arteries, resulting in subsequent activation of BKCa channels. 
This was further confirmed in a recent study involving patients with idiopathic pulmonary 
arterial hypertension and BKCa KO mice (Nagaraj et al. 2016). DHA was reported to 
enhance BKCa currents in pulmonary arterial SMCs derived from these patients. In BKCa 
KO mice, DHA-induced relaxation in pulmonary artery was significantly attenuated 
compared to the control mice (Nagaraj et al. 2016).   
CYP enzymes can oxygenate EPA into 17(R), 18(S)-epoxyeicosatetraenoic acids (17R, 
18S-EPETEs) which were reported to activate BKCa channels in rat cerebral arteries 
(Hercule et al. 2007). Supporting this, 17R, 18S-EPETEs were unable to activate BKCa 
channels in SMCs extracted from the cerebral arteries of KO mice lacking the BKCa alpha 
subunit (BK α-/-). Consistently, 17R, 18S-EPETEs mediated a concentration-dependent 
relaxation in mesenteric arteries derived from wild type mice which was significantly 
impaired in BK α-/- arteries. Therefore, the authors from this study suggested a direct 
interaction between 17R, 18S-EPETEs and the alpha subunit of BKCa channels, since this 
phenomenon was not dependent upon the intracellular levels of calcium and sarcoplasmic 
reticulum-induced calcium events.                 
Lipoxygenase metabolites of n-3 PUFAs, especially DHA, are also implicated in the 
regulation of BKCa channels. 15- and 5-lipoxygenase metabolite of DHA, 17S-Hydroxy 
DHA (17S-HDHA), was reported to activate BKCa channels (Li et al. 2011). Whole cell 
patch clamp with SMCs extracted from bovine coronary arteries revealed that 17S-
HDHA treatment enhanced outward potassium currents. Application of 17S-HDHA into 
the extracellular side of inside-out patches of these SMCs, led to the enhancement of 
BKCa currents suggesting a direct activation of the BKCa channel (Li et al. 2011). 
Furthermore, 17S-HDHA was also reported to cause relaxation in bovine coronary 
arteries which was significantly inhibited through lipoxygenase blockade and 
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endothelium removal (Li et al. 2011). A residual relaxation was also observed following 
blockade of BKCa channels indicating that other mechanisms are also involved.  
Both n-3 PUFAs, especially DHA, have also been associated with direct activation of 
BKCa channels (Toshinori Hoshi, Wissuwa, et al. 2013). An increase in BKCa channel 
currents following the application of DHA was demonstrated in mice aortic SMCs and 
cell-free patches derived from HEK cells (Toshinori Hoshi, Wissuwa, et al. 2013). This 
effect persisted when DHA was applied to both extracellular and intracellular sides of the 
patches. These cell-free patches lacked intracellular signalling proteins and therefore a 
direct binding of DHA to BKCa channels was mentioned as a possible explanation for the 
channel activation. EPA was also found to activate BKCa but less potently compared to 
DHA. In contrast to earlier studies, inhibiting CYP had no effect in DHA-induced 
activation of BKCa channels in HEK cells. Intravenous administration of DHA into wild 
type mice led to a transient drop in arterial blood pressure which was absent in BKCa KO 
mice (BK α-/-) (Toshinori Hoshi, Wissuwa, et al. 2013). This was also confirmed by a 
recent study that investigated the effects of DHA in mice with hypoxia-induced 
hypertension (Nagaraj et al. 2016). Injection of DHA into the central vein of the mice led 
to reduction in pulmonary pressure and returned the right ventricular systolic pressure to 
normal levels (Nagaraj et al. 2016). This finding is important as clinical studies have also 
indicated blood pressure lowering effects of n-3 PUFAs and therefore activation of BKCa 
channels could be one of the mechanisms involved (Mori 2014). In agreement with this 
suggestion, a study involving human coronary arteries demonstrated an increase in 
outward potassium currents in DHA-treated SMCs (Wu et al. 2007). DHA was also 
shown to inhibit phasic constrictions in these arteries. Although the potassium channels 
involved were not characterized, BKCa channels could be possibly associated with these 
outward currents based on the studies reviewed earlier.  
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1.3.3.iv Justification for the study 
The findings discussed in this section; firstly validates the role of n-3 PUFAs in 
improving vasodilation through hyperpolarization of arteries and most studies indicate 
that BKCa channels are involved, secondly they demonstrate the complexity and 
variability in the mechanisms of n-3 PUFAs and its metabolites in eliciting vasodilation, 
and thirdly they highlight the need for an investigation of the vasorelaxant mechanisms 
that still remain unexplained. For example, the role of other KCa channels and as yet 
unidentified endothelium-independent mechanisms demonstrated by the presence of 
residual relaxation in some studies. Therefore, this study aimed at fully characterizing the 
vasodilation mechanisms of both n-3 PUFAs, DHA and EPA, in conduit (aorta) and 
resistance arteries (mesenteric).    
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Table 1.1 Summary of the major findings from vascular studies investigating the role of n-
3 PUFAs and its metabolites in the regulation of vasodilation. Majority of the studies indicate 
activation of BKCa channels by n-3 PUFAs and its metabolites. ADMA = asymmetric 
dimethylarginine, BKCa = large conductance KCa, COX = cyclooxygenase, CYP = cytochrome 
P450, DHA = docosahexaenoic acid, ECs = endothelial cells, EDPs = epoxydocosapentaenoic 
acids, EETs = epoxyeicosatrienoic acids, eNOS = endothelial nitric oxide synthase, EPETEs = 
epoxyeicosatetraenoic acid, EPA = eicosapentaenoic acid, HDHA = hydroxy-docosahexaenoic 
acid, HETEs = hydroxyeicosatetraenoic acids, IKCa = intermediate conductance KCa, KCa = 
calcium activated potassium channels, NO = nitric oxide and SMCs = smooth muscle cells. 
Species Type of 
Artery 
Cell Constrictor Type of 
n-3 
PUFA 
Concentration 
of n-3 PUFA 
Effect Ref. 
 
Bovine 
Coronary ECs U46619 EPA 30-60 µM Improved NO 
production 
(Omura et 
al. 2001) 
Coronary SMCs U46619 17S-
HDHA 
0.1-1 µM Direct 
activation of 
BKCa channels 
(Li et al. 
2011) 
 
 
 
 
Mouse 
Aorta ECs - EPA & 
DHA 
- Enhanced 
eNOS levels 
(Casós et 
al. 2010) 
Aorta SMCs - DHA 3 µM Activation of 
BKCa channels 
(Toshinori 
Hoshi, 
Wissuwa, 
et al. 
2013) 
Cerebral SMCs U46619 17R, 18S- 
EPETEs 
100 nM α subunit 
dependent 
BKCa 
activation 
(Hercule 
et al. 
2007) 
Mesenteric SMCs U46619 17R, 18S- 
EPETEs 
100 nM α subunit 
dependent 
BKCa 
activation 
(Hercule 
et al. 
2007) 
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Pulmonary - U46619 DHA 0.3-100 µM Activation of 
BKCa channels 
(Nagaraj 
et al. 
2016) 
Porcine Coronary SMCs - 13, 14-
EDPs 
EC50 (2.2 ± 0.6 
pM) 
Activation of 
BKCa channels 
(Ye et al. 
2002) 
 
 
 
 
 
 
 
Rats 
- - - EPA & 
DHA 
1 g/kg/day Reduced 
ADMA levels 
(Raimondi 
et al. 
2005) 
Aorta ECs - EPA & 
DHA 
50g/kg Enhancement 
of eNOS 
levels 
(López et 
al. 2004) 
Aorta - Phenylephrine DHA & 
EPA 
200mg/g (DHA) & 
300mg/g (EPA)  
Enhancement 
of eNOS 
levels 
(Zanetti et 
al. 2017) 
Aorta SMCs High KCl & 
Noradrenaline 
COX 
metabolites 
of EPA 
3-100 µM Activation of 
KATP channels 
(Engler et 
al. 2000) 
Aorta SMCs - DHA 3-30 µM Enhanced IL-
1β induced 
NO 
production 
(Hirafuji 
et al. 
2002) 
Aorta SMCs U46619 16, 17-
EDPs 
1 µM Activation of 
KATP channels 
(Sato et 
al. 2014) 
Cerebral SMCs U46619 17R, 18S- 
EPETEs 
100 nM Activation of 
BKCa channels 
(Hercule 
et al. 
2007) 
Coronary SMCs - DHA EC50 (37.53±1.65 
µM) 
Activation of 
BKCa channels 
(Lai et al. 
2009) 
Coronary SMCs Endothelin-1 16, 17-
EDPs 
EC50 (19.7 ± 2.8 
nM) 
Calcium 
sparks 
mediated 
BKCa 
activation 
(Wang et 
al. 2011) 
 
 
 
Human 
Coronary VSMCs PGF2α, 
Ouabain & 
High KCl 
DHA 1-30 µM Enhanced 
outward 
potassium 
currents 
(Wu et al. 
2007) 
- HEK - DHA EC50 value of 
500nM 
Activation of 
BKCa channels 
(Toshinori 
Hoshi, 
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Wissuwa, 
et al. 
2013) 
- HEK - DHA 10 µM Inhibition of 
IKCa channels 
(Kacik et 
al. 2014) 
Pulmonary SMCs - DHA 10 µM Activation of 
BKCa channels 
(Nagaraj 
et al. 
2016) 
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Table 1.2 Summary of the major findings from studies investigating potassium channels in 
human arteries. Through the use of molecular biology, electrophysiology and myograph, 
functional potassium channels have been reported to regulate vascular tone, especially in 
resistance arteries. BKCa = large conductance KCa, IKCa = intermediate conductance KCa, KATP = 
adenosine triphosphate-sensitive potassium channel, KCa = calcium activated potassium channels, 
Kv7 = potassium voltage-gated channel subfamily Q member, mRNA = messenger ribonucleic 
acid, PCR = polymerase chain reaction, qPCR = quantitative PCR, Ref. = reference, RT-PCR = 
reverse transcription-PCR and SKCa = small conductance.  
Type of 
ion 
channel 
Type of blood 
vessel 
Techniques used Summary of key findings  Ref. 
 
 
 
 
 
SKCa and 
IKCa 
Coronary artery Organ bath video-
microscopy, PCR, 
western blot and whole 
cell patch-clamp 
Confirmation of both SKCa 
and IKCa channel currents, 
expressions and their role in 
vasodilation 
(Feng et al. 
2008; Takai 
et al. 2013) 
Myometrial and 
omental artery 
Wire myograph Involvement of both channels 
in vasodilation 
(Gillham et 
al. 2007) 
Skeletal muscle 
arterioles 
Organ bath video-
microscopy and 
western blot 
Confirmation of both SKCa 
and IKCa expression and its 
role in vasodilation 
(Liu et al. 
2008) 
Mesenteric artery Immunohistochemistry 
and pressure myograph 
Only IKCa channels were 
expressed and involved in 
vasodilation  
(Chadha et 
al. 2011) 
 
 
 
 
 
 
BKCa 
Adipose artery Immunofluorescence, 
inside-out patch-clamp, 
pressure myograph and 
western blot 
Confirmation of BKCa 
channel currents, expression 
and its role in vasodilation 
(Nieves-
Cintrón et al. 
2017) 
Aorta Hybridization probe 
and sanger sequencing 
Confirmation of BKCa 
nucleotide sequence  
(McCobb et 
al. 1995) 
Coronary artery Immunocytochemistry, 
patch-clamp, western 
blot 
Confirmation of BKCa 
channel currents and 
expression 
(Tanaka et 
al. 1997; 
Marijic et al. 
2001) 
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Mesenteric artery Whole cell patch-
clamp, real time RT-
PCR and western blot 
Confirmation of BKCa 
channel currents and 
expression 
(Yang et al. 
2013) 
 
 
 
KATP 
Coronary artery Immunoprecipitation, 
RT-PCR and western 
blot 
Confirmation of Kir6.1 and 
SUR2 expression  
(Yoshida et 
al. 2004) 
Meningeal artery RT-PCR and qPCR Detection of Kir6.1 and 
SUR2B mRNA transcripts 
(Ploug et al. 
2008) 
Pulmonary artery RT-PCR and patch-
clamp 
Confirmation of KATP channel 
currents and detection of 
Kir6.1 and SUR2B mRNA  
(Cui et al. 
2002) 
 
 
 
Kv7 
Adipose artery Immunohistochemistry, 
qPCR,  whole cell 
patch-clamp, and wire 
myograph 
Confirmatiion of Kv7.1 & 
Kv7.3-5 expression, channel 
currents and their role in 
vasodilation  
(Ng et al. 
2011) 
Mesenteric artery qPCR,  and wire 
myograph 
Confirmatiion of Kv7.1 & 
Kv7.3-5 mRNA and their role 
in vasodilation 
(Ng et al. 
2011) 
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1.4 Aims of this project 
Numerous studies have demonstrated the benefits of fish oil intake and as a result it is 
currently one of the most used dietary supplements in the market. The complex 
mechanisms of fish oil-induced vasodilation can range from enhancement in NO 
production to regulation of BKCa channels (Table 1.1). However, most of these studies 
are limited to a certain type of vascular bed and n-3 PUFA. Furthermore, a significant 
amount of residual relaxation was reported indicating the presence of other unknown 
vasodilation mechanisms. Due to findings from previous studies indicating the role of 
BKCa channels, we hypothesised that other vascular potassium channels were possibly 
involved in n-3 PUFA-induced vasodilation. Therefore, my project was initially focused 
on fully characterizing the vasodilation pathways of both DHA and EPA using rat aorta 
(a conduit artery) and rat mesenteric artery (a resistance artery). These previously 
unidentified pathways were then investigated to determine whether a direct activation by 
n-3 PUFA was involved. The ultimate goal of this project is to facilitate the development 
of novel PUFA analogues that can target specific vasodilation pathways involved in 
providing therapeutic benefits against cardiovascular disorders. Although the use of 
animal models can bring some uncertainty in the transferability of the acquired data to a 
clinical setting, there is tremendous evidence demonstrating that the investigated 
pathways are also involved in the human vasculature. Through the use of different 
techniques in the field of molecular biology, electrophysiology and myograph, multiple 
studies with human arteries have demonstrated both the expression and the functional 
vasoactive role of the potassium channels that were investigated in this project (findings 
summarized in table 1.2).  
Due to the presence of numerous vasodilation pathways that are dependent upon vascular 
endothelium and/or SMCs, this project was divided into three parts to effectively 
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characterize the mechanisms involved with n-3 PUFA-mediated vascular relaxation. The 
first part of the study involved the use of pharmacological inhibitors and wire myograph 
to: 
i. Investigate the role of endothelium in n-3 PUFA-induced relaxation using rat 
arteries. 
ii. Elucidate the endothelium-dependent vasodilation mechanisms of n-3 PUFAs in 
rat arteries.  
Using patch clamp and myograph techniques, multiple studies have demonstrated the role 
of BKCa in both DHA and EPA mediated vasodilation (Hercule et al. 2007; Wang et al. 
2011). Studies also indicate the role of BKCa in EET-induced vascular relaxation and most 
of these findings report an indirect stimulation of BKCa (Imig et al. 1999; Fukao et al. 
2001; Dimitropoulou et al. 2007). One of these pathways includes the TRPV4 channel, 
which is also involved in the activation of SKCa and IKCa. Therefore, the second part of 
this study examined whether TRPV4 was directly modulated by n-3 PUFAs and my main 
aims were to; 
i. Generate a stable cell line that allowed inducible expression of TRPV4. 
ii. Determine whether the inducible expression system was functional. 
iii. Verify whether n-3 PUFAs modulate TRPV4 channels expressed in the stable cell 
line. 
It is evident that depending upon the type of vascular bed, n-3 PUFAs and their 
metabolites can act through diverse mechanisms (Table 1.1). It is also evident that these 
mechanisms are not always endothelium-dependent. A lot of the studies indicate the role 
of hyperpolarization, mostly through BKCa, in n-3 PUFA-mediated relaxation. Therefore, 
in the final part of my study, my aims were to: 
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i. Investigate the role of hyperpolarization-induced by potassium channels and 
characterize the channels involved in the relaxation mediated by n-3 PUFAs using 
wire myograph. 
ii. Generate a stable cell line expressing the target potassium channel and verify its 
expression. 
iii. Assess if the target potassium channel is directly modulated by n-3 PUFAs using 
whole cell patch clamp. 
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Chapter 2 
 
Materials and Methods 
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2.1 Materials 
2.1.1 Animal 
Male Wistar Kyoto rats (WKY, 8-12 weeks, 200-300 g) were obtained from Harlan 
(Envigo) and were kept in a room inside the Bioresource Unit at the University of 
Reading with a 12h:12h dark:light cycle at 21°C with the humidity of 50±10% and ad 
libitum access to food and water. 
2.1.2 Cell lines 
Table 2.1 List of cell lines. *DMEM = Dulbecco’s modified eagle’s medium, FBS = foetal 
bovine serum and HEK = human embryonic kidney cells. 
Cell line Source Medium 
HEK* Flp-In T-REx-293 Invitrogen DMEM*, FBS* (10% v/v), 5 
μg/ml of blasticidin, 100 μg/ml 
of zeocin 
HEK Flp-In T-REx-293 
pcDNA5/FRT/TO (HEKVO) 
See chapter 2, 2.3 DMEM, FBS (10% v/v), 200 
μg/ml of hygromycin, 5 μg/ml 
of blasticidin 
HEK Flp-In T-REx-293 
pcDNA5/FRT/TO+TRPV4- HA 
(HEKTRPV4) 
See chapter 2, 2.3 DMEM, FBS (10% v/v), 200 
μg/ml of hygromycin, 5 μg/ml 
of blasticidin 
HEK Flp-In-293 Invitrogen DMEM, FBS (10% v/v) 
HEK Flp-In-293 pcDNA5/FRT 
(HEKVC) 
See chapter 2, 2.4 DMEM, FBS (10% v/v), 200 
μg/ml of hygromycin, 
HEK Flp-In-293 
pcDNA5/FRT+SUR2B 
(HEKSUR2B) 
See chapter 2, 2.4 DMEM, FBS (10% v/v), 200 
μg/ml of hygromycin, 
LentiX 293T Clontech DMEM, FBS (10% v/v) 
HEK Flp-In-293 
pcDNA5/FRT+ 
pLenti6.3/FRT/MCS (HEKVC1) 
See chapter 2, 2.4 DMEM, FBS (10% v/v), 200 
μg/ml of hygromycin, 10 μg/ml 
of blasticidin 
HEK Flp-In-293 
pcDNA5/FRT+SUR2B+ 
pLenti6.3/FRT/MCS+Kir6.1 
(HEKKATP) 
See chapter 2, 2.4 DMEM, FBS (10% v/v), 200 
μg/ml of hygromycin, 10 μg/ml 
of blasticidin 
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2.1.3 Pharmacological agents 
Table 2.2 List of pharmacological agents. *DDW = distilled deionised water and DMSO = 
dimethyl sulfoxide. Ref = reference for studies that investigated the potency of the 
pharmacological agents. 
Chemical Bath 
concentration 
EC50/IC50 Diluent Mechanism 
of action 
Supplier Cat. No. Ref. 
Acetylcholine 1 nM - 3 µM 35 nM DDW* M3 receptor 
agonist 
Sigma A6625 (Cheng et al. 
2002) 
Apamin 50 nM 8 nM DDW SKCa 
blocker 
Sigma A9459 (Kohler et al. 
2003) 
Clotrimazole 1 µM 5 µM DMSO CYP 
inhibitor 
Sigma C6019 (Oyekan et al. 
1991; Lischke 
et al. 1995) 
DHA 10 nM - 30 
µM 
0.9-3.8 
µM 
Ethanol Multiple Sigma D8768 -  
EPA 10 nM - 30 
µM 
2.5-5.1 
µM 
Ethanol Multiple Sigma E2011 -  
Glibenclamide 1 µM 86 nM DMSO KATP 
blocker 
Sigma G0639 (Russ et al. 
1997) 
GSK1016790A 3 nM 10 nM DMSO TRPV4 
activator 
Sigma G0798 (Willette et 
al. 2008) 
HC-067047 1 µM 133 nM DMSO TRPV4 
antagonist 
Sigma SML0143 (Everaerts et 
al. 2010) 
Indometacin 10 µM 0.25 µM DMSO COX 
inhibitor 
Sigma I7378 (Kassab et al. 
2017) 
L-NAME 300 µM 3.1 µM DDW NOS 
inhibitor 
Sigma N5751 (Rees et al. 
1990) 
NONOate 1 nM – 3 µM 0.1 µM DMSO NO donor Sigma Sigma (Hrabie et al. 
1993) 
TRAM-34 1 µM 20 nM DMSO IKCa blocker Sigma T6700 (Wulff et al. 
2000) 
Paxilline 1 µM 17 nM DMSO BKCa 
inhibitor 
Sigma P2928 (Sanchez and 
McManus 
1996) 
PNU37883A 300 nM - 3 
µM 
1 µM DMSO KATP 
blocker 
Tocris 2095 (Wellman et 
al. 1999) 
RN-1734 10-30 µM 3.2 µM DMSO TRPV4 
blocker 
Sigma R0658 (Vincent et al. 
2009) 
U46619 5-100 nM 35 nM DMSO TP receptor 
agonist 
abcam ab144540 (Abramovitz 
et al. 2000) 
XE991 1-30 µM 0.63 µM DDW Kv7 
inhibitor 
Tocris 2000 (Schroeder et 
al. 2000; 
Søgaard et al. 
2001) 
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2.1.4 Antibodies 
Table 2.3 List of primary and secondary antibodies. Antibody stocks were diluted in glycerol 
(50%, v/v) and stored at - 20 ℃. The extra dilution due to the glycerol was taken into 
consideration when diluting the antibodies. *HA = human influenza hemagglutinin, ICC = 
immunocytochemistry, IgG = immunoglobulin G, HRP = horseradish peroxidase, Kir6.1 = 
inward-rectifier potassium channel 6.1, SUR2B = sulfonylurea receptor 2B and WB = western 
blot. 
Type Antibody Host Dilution Supplier Cat No. 
WB* ICC* 
P
ri
m
a
ry
 
β-actin Mouse 1/10,000 - Sigma A5441 
HA* Mouse 1/5000 1/500 Bioscience 901514 
Kir6.1* Rabbit 1/1000 1/200 Sigma P0874 
SUR2B* Mouse 1/1000 1/200 Novus 
Biologicals 
MABN511 
S
ec
o
n
d
a
ry
 
Goat anti-
mouse-IgG*-
AlexaFluor488 
Donkey - 1/1000 Invitrogen A-21202 
Mouse-IgG-
HRP* 
Goat 1/10,000 - Stratech 43C-
CB1569-
FIT 
Rabbit-IgG-
HRP 
Goat 1/10,000 - Stratech 111-035-
144-JIR 
Rabbit-IgG-
Rhodamine 
Red-X 
Donkey - 1/1000 Stratech 711-295-
152-JIR 
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2.1.5 Plasmid DNA 
Table 2.4 List of plasmid DNA involved in creating stable cell lines expressing TRPV4 and 
KATP channels along with their respective controls (containing just the plasmid vector 
without the insert). Plasmids were stored at - 20℃. pLenti6.3/FRT/MCS (Roux et al. 2017), 
pcDNA5/FRT+HA and pcDNA5/FRT/TO+TRPV4 were kindly provided as gifts by Dr Graeme 
Cottrell (Hopkins building, University of Reading). pcDNA3+SUR2B and pcDNA3.1/Zeocin+ 
Kir6.1 were kindly sent as gifts by professor Andrew Tinker (William Harvey Heart Centre, 
Queen Mary University of London). 
Ion channel Plasmid Selectable 
Marker 
Source 
T
R
P
V
4
 
pOG44 - Invitrogen 
pcDNA5/FRT/TO Hygromycin Invitrogen 
pcDNA5/FRT+HA Hygromycin Dr Graeme 
Cottrell 
pcDNA5/FRT/TO+TRPV4 Hygromycin Dr Graeme 
Cottrell 
pcDNA5/FRT/TO+TRPV4-HA Hygromycin See chapter 4, 2.2 
K
A
T
P
 
pcDNA5/FRT Hygromycin Invitrogen 
pcDNA3+SUR2B Neomycin Andrew Tinker 
pcDNA5/FRT+SUR2B Hygromycin See chapter 5, 2.3 
pLenti6.3/FRT/MCS Blasticidin Dr Graeme 
Cottrell 
pcDNA3.1/Zeocin+ Kir6.1 Zeocin Andrew Tinker 
pLenti6.3/FRT/MCS+ Kir6.1 Blasticidin See chapter 5, 2.4 
 
2.1.6 Competent bacterial cells 
Mach1 and Stbl3 cells were purchased from Invitrogen. These cells were made competent 
using the protocol described by Inoue et al. (Inoue et al. 1990) and stored at – 80 ℃. 
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2.2 Wire Myograph 
2.2.1 Dissection of rat aorta and mesenteric artery 
Normal male WKY rats (250-300 g) were used for these experiments as studies have 
reported impairment of various vasodilation pathways in disease models; for example, 
reduction in the expression of BKCa channels and eNOS in SHR (Chou et al. 1998; 
Amberg and Santana 2003). Due to these findings, it is possible that additional unreported 
vasodilation pathways may also be impaired in disease models. Since my project was 
focussed on characterizing the mechanisms involved in n-3 PUFA-induced relaxation 
using a pharmacological approach, the presence of functional vasodilation pathways in 
the extracted arteries was essential as it allowed assessment of any significant 
modifications in n-3 PUFA-induced vasodilation before and after pharmacological 
treatment(s), using the same arterial segment. Therefore, due to this approach, healthy 
rats were used as the preferred mammalian model for the characterization of the 
relaxation response of n-3 PUFAs.  
WKY rats were killed in accordance with the schedule one of the Animals (Scientific 
Procedures) Act 1986 and thus waived by the University of Reading Animal Welfare and 
Ethical Review Board. This procedure involved an inhaled overdose of isoflurane by the 
animal followed by an immediate cervical dislocation to ensure death. The fur and skin 
were then removed from either the abdominal (mesenteric artery) and/or thoracic area 
(aorta) depending on the type of arteries required for the experiment. For aorta, an 
incision was made along the upper section of the abdomen allowing removal of the rib 
cage and providing access to the inner organs. This was followed by the careful removal 
of the inner organs and oesophagus found on top of the thoracic aorta. The aorta was 
gently removed and immediately placed in ice-cold isotonic Krebs solution (Table 2.5). 
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For mesenteric artery, the intestines were carefully removed and immediately kept in ice-
cold Krebs. 
Table 2.5 Composition of Krebs buffer. Components were dissolved in DDW. 
Chemical Final concentration (mM) 
CaCl2 (1 M solution) 2.5 
Glucose 11 
KCl 3.6 
KH2PO4 1.2 
MgSO4.7H2O 1.2 
NaCl 118 
NaHCO3 24 
 
 
2.2.2 Selection of mounting supports and measurement of tension 
Mulvany-Halpern wire myograph (Danish MyoTechnology, 620M) was used to examine 
arterial tension following application of different vasoactive compounds (Mulvany and 
Halpern 1976; Mulvany and Halpern 1977). Each myograph chamber was composed of 
two mounting supports each connected to a force transducer and a micrometer. These 
supports were initially adjusted depending upon the type of artery under investigation. 
For aorta, 200 µm pins were used as the mounting supports whereas for the mesenteric 
artery, myograph jaws were attached that enable the use of gold-plated tungsten wire 
(diameter: 25 µm). Measurement of tension was conducted using isometric force 
transducer connected to PowerLab (ML846; AD Instruments) and a computer with 
Labchart 7 software (AD Instruments). The force transducer was then calibrated using 
the step-wise force calibration procedure accessed from the myograph interface, whilst 
the signals were recorded using LabChart. The recorded signals were then converted from 
volts to millinewtons for each channel using the units conversion feature of LabChart. 
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2.2.3 Mounting of vessels  
The tissue was then pinned in a dissection dish coated with silicone elastomer (Sylgard, 
World Precision Instruments) for removal of any surrounding connective and 
perivascular adipose tissue using fine forceps and micro surgical scissors under the 
microscope (Olympus SZX10, OLYMPUS). It was imperative that the blood vessels 
were not excessively stretched to avoid any damage to the inner walls. 
2.2.3.i Aorta 
The chambers were initially filled with fresh Krebs solution (5 ml) and the support pins 
were brought closer using the micrometer to facilitate the mounting. Approximately 2 
mm segments of aorta were cut and carefully mounted onto the 200 µm pins. A small 
amount of tension (~1 mN) was applied to the vessels to prevent any detachment from 
the pins and vessels were washed (3x) with Krebs solutions. The vessels were then 
bubbled with 95% O2/5% CO2 throughout the experiment and then subjected to zero 
tension followed by equilibration at 37ºC for 20 min. 
2.2.3.ii Mesenteric artery 
Following removal of the vein and adipose tissue surrounding the third order mesenteric 
arteries, a partial cut was made at a 45º angle on top of the vessel near the proximal end. 
The tungsten wire (length: ~2.2 cm) was then cannulated and the vessel was excised 
towards the distal end ensuring that approximately 2 mm of the arterial segment was 
obtained; once the vessel rested on the middle of the wire, the proximal end of the vessel 
was then carefully excised. The mounting jaws were then moved apart using the 
micrometer and the cannulated tissue was then transferred into the chamber filled with 
fresh Krebs solution. The wire was then secured (clockwise) to one of the mounting jaws 
using the screws on top. The jaws were then brought closer such that there was just 
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enough space to fit the wire. Another piece of wire (length: 2.2 cm) was then carefully 
cannulated into the vessel and fastened in the clockwise direction to the other mounting 
jaw. The jaws were then moved apart ensuring that there was minimal to no tension on 
the vessel. This allowed the wires to be aligned in parallel to each other and the screws 
were further tightened. Tissue was washed (3x) with Krebs solutions and bubbled with 
95% O2/5% CO2 throughout the experiment. It was then subjected to zero tension 
followed by equilibration at 37ºC for 20 min. 
2.2.4 Normalisation 
The DMT normalization module in Labchart 7 was then used to pre-stretch the arteries 
to an internal circumference (IC100) that mimics the physiological transmural pressure of 
100 mm Hg or 13.3 kPa in rats (Hansen and Bohr 1975; Mulvany and Halpern 1977; 
Danish Myo Technology 2017). Due to the length/tension relationship, arterial segments 
can be stretched to an internal circumference which allows the optimum interaction 
between actin and myosin filaments, generating the maximum response to vasoactive 
agents (Mulvany and Halpern 1977). Therefore, this procedure is important in not only 
standardizing experimental conditions but also in enhancing vascular reactivity 
(McPherson 1992). To achieve this, recording was initially started in Labchart and the 
channel of interest was selected, opening the DMT normalization window. The tissue 
endpoint values for the length of the arterial segment were then added (a1 = 0 and a2 = 
~2 mm). The appropriate values for the wire diameter and micrometer reading were also 
added to the normalization window which allowed recording of the first data point. Small 
stepwise increase in tension was applied to the tissue using the micrometer to collect 
additional data points. A graph with the resting wall tension vs internal circumference 
was then plotted by Labchart 7 using the measured force and micrometer settings applied. 
The position of the micrometer required to achieve IC100 was then predicted using the 
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length/tension relationship that can be mathematically expressed with La Place’s 
equation ; 
Effective pressure = 
2.𝜋.𝑊𝑎𝑙𝑙 𝑡𝑒𝑛𝑠𝑖𝑜𝑛
𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑐𝑖𝑟𝑐𝑢𝑚𝑓𝑒𝑟𝑒𝑛𝑐𝑒
  
The predicted setting was then applied which subsequently stretched the tissues to a 
standardized tension within the range of 7-13 mN (aorta) and ~3 mN (mesenteric artery). 
The tissue was then allowed to stabilize for 20 min.  
2.2.5 Experimental protocol 
Before starting any experiments, arteries were initially tested for functional endothelium 
by preconstricting the arteries with TXA2 receptor (TP) agonist, U46619 (5-100 nM) 
followed by exposure to acetylcholine (ACh, 1 µM) to elicit arterial relaxation. Arteries 
demonstrating >90% of the maximum relaxation were used for subsequent myograph 
experiments. U44619 was preferred over other vasoconstrictors such as phenylephrine, 
as it elicited a robust sustained contraction of the arterial segment. Furthermore, an 
increased production of TXA2 has also been reported in patients with pulmonary 
hypertension indicating its role in cardiovascular disorders (Christman et al. 1992), which 
further justified the use of U46619 in my experiments. U46619 (5-100 nM) was added to 
elicit a stable sub-maximal tone (~ 50-80% of maximum) to ensure that there was enough 
stimulation to achieve a stable sustained tone and at the same time to limit any 
physiological antagonism that could attenuate the relaxation effects of n-3 PUFAs. 
Cumulative addition with increasing concentrations of n-3 PUFA (10 nM - 30 µM) was 
used to investigate vascular relaxation. In most experiments, control concentration 
response curves to n-3 PUFAs were initially obtained which ensured that each 
experimental group had an internal control to compare various treatments. Although 
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randomisation of experimental group may be reduced by this approach, it lowers 
sampling error/variance as the tissue is its own control.  
2.2.5.i Removal of endothelium from the arteries 
To assess the role of endothelium in n-3 PUFA mediated relaxation, some experiments 
involved removal of the endothelium. A control response curve was initially obtained by 
preconstricting the artery with U46619 and relaxing it with n-3 PUFA. Using the same 
tissue, the inner arterial layer was gently rubbed with either a stainless-steel wire 
(diameter: 250 µm) (aorta) or gold-plated tungsten wire (diameter: 25 µm) (mesenteric 
artery). Due to the nature of this procedure, there was a risk of damaging and impairing 
the viability of the arterial segments; as a result, vessels had to demonstrate ≥90% of the 
original contractile tone to be selected for further experiments. Functional removal of 
endothelium was demonstrated in arteries with <10% relaxation to ACh (1 µM). The 
tissue was then constricted with U46619 to reach a stable sub-maximal tone followed by 
relaxation using n-3 PUFA 
2.2.5.ii Pre-treatment of the arteries with pharmacological agents and high KCl 
Krebs: 
The role of various vasodilation pathways in n-3 PUFA mediated relaxation of rat arteries 
were assessed using pharmacological agents (see table 2.2) and high KCl Krebs (30 mM, 
for inhibition of hyperpolarization mediated by potassium channels). The final potassium 
ion concentration of 30 mM was achieved via alligation, which involved the use of high 
KCl Krebs and normal Krebs. High KCl Krebs was prepared by replacing NaCl (118 
mM) with KCl resulting in an overall potassium ion concentration of 122.8 mM [taking 
into account the additional presence of KCl (3.6 mM) and KH2PO4 (1.2 mM) in the 
buffer]. Appropriate volumes of high KCl Krebs (1.07 ml) and normal Krebs (3.93 ml) 
were then calculated using the following matrix setup and equations. 
  
82 
 
122.8 mM (a)  25.2 (c – b) 
 30 mM (c)  
4.8 mM (b)  92.8 (a – c) 
 
                        a = potassium concentration of high KCl Krebs 
                         b = potassium concentration of normal Krebs 
               c = final desired concentration of potassium in the organ bath 
                                     Total parts of potassium ions = 25.2 + 92.8 = 118 
Therefore, the volume of high KCl Krebs required to achieve a final potassium concertation of 
30 mM in an overall volume of 5 ml = 5 𝑥 
25.2
118
 = 1.07 ml.  
 
Arterial segments preconstricted with U46619 were relaxed using n-3 PUFA to initially 
obtain a control response curve. Pharmacological agents were then incubated with the 
same arterial tissue for 20 min. The pre-treatment concentration for each agent was 
determined by its IC50 value, generally a starting concentration of 10x IC50 was used 
(Table 2.2). However, for some of the drugs due to problems with selectivity and its effect 
on the maintenance of contractile tone, the pre-treatment concentration had to be reduced. 
Arteries were then constricted with U46619 to a similar level of tone (~50-80% of 
maximum) as was achieved in the control experiment by adjusting the concentration of 
U46619, if necessary, followed by relaxation with n-3 PUFA. Multiple incremental pre-
treatments were conducted using the same arterial segment as it allowed the same 
experiments to be ran in parallel using multiple wire myograph channels. This approach 
further validated the reproducibility of findings from each experimental group. 
2.2.5.iii Pre-treatment of the mesenteric artery with DHA: 
The effect of DHA on endothelium-dependent (ACh) and -independent (NONOate) 
vasodilation pathways were assessed using rat mesenteric artery. Control response curves 
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were initially obtained by relaxing the U44619 pre-constricted artery with either ACh (1 
nM–3 µM) or NONOate (1 nM–3 µM). DHA (300 nM) was then incubated with the same 
arterial tissue for 1 hour. The tissue was then constricted with U46619 to a similar level 
of tone, as observed in the control experiment, and cumulatively relaxed with either 
NONOate or ACh.  
2.2.6 Data analysis and statistical procedures 
Results from the myograph experiments were expressed as mean±SEM of n experiments, 
where n refers to the number of biological repeats each acquired from a different rat. Data 
was processed using Microsoft excel (Office 365) and graphically presented using 
GraphPad Prism 5 (v5.0, GraphPad Software). Relaxation was expressed as percentage 
reduction of U46619-induced stable tone. Statistical analysis of the curves was carried 
out using two-way analysis of variance (ANOVA) and Bonferroni post-hoc test in 
GraphPad Prism 5. P-value of < 0.05 was considered as being statistically significant. 
Potency (EC50) and maximal relaxation (Emax) values were obtained for each 
experimental group using standard variable slope least squares fit based on the hill 
equation in GraphPad Prism 5. However, the maximal response was not always 
adequately defined as the highest concentration of n-3 PUFAs that could be achieved 
without solubility or vehicle effects was 30 µM, as a result, curve estimation was prone 
to error. To assess if there was an overall difference in either potency (EC50) or maximum 
response (Emax) between DHA and EPA, pooled control curve data from both aorta and 
mesenteric artery were obtained and analysed using two-tailed t-test. P value of < 0.05 
indicated a significant difference from DHA in the artery studied.   
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2.3 Generation and maintenance of HEK Flp-In T-REX-293 cells 
expressing TRPV4 
2.3.1 Molecular cloning 
2.3.1.i Generation of a 3’ end DNA segment of TRPV4 without the stop codon 
using PCR 
To enable the expression of the HA epitope tag which was added at the end of the TRPV4 
gene, it was crucial to remove the stop codon present in the TRPV4 DNA sequence. I 
used polymerase chain reaction (PCR) to generate a DNA segment at the 3’ end of the 
TRPV4 sequence without the stop codon using the forward and reverse primers shown in 
table 2.6. The PCR reaction mix was prepared according to table 2.7 The mix was then 
transferred into a MJ Mini thermal cycler (Bio-Rad) and the following settings were then 
used for the PCR reaction: 
Steps Temperature Time  
1 98 ℃ 3 min  
2 98 ℃ 30 s  
3 55 ℃ 30 s 25 cycles, steps 2-4 
4 72 ℃ 30 s  
5 72 ℃ 10 min  
 
The first step of the PCR reaction is initialization which involves heat (98 ℃) activation 
of the DNA polymerase (New England Biolabs 2019). DNA is then denatured into two 
single strands by breaking the hydrogen bonds in the second step (Gibbs 1990; New 
England Biolabs 2019). The temperature of the reaction was then lowered to 55 ℃ to 
allow annealing of the primers to the denatured DNA strands. The temperature was then 
increased to 72 ℃ which enhances activity of DNA polymerase to synthesise new 
complementary DNA strands from the primer bound region. The PCR steps (2-4) were 
then repeated for 25 cycles to amplify the production of the DNA fragments. The final 
step of the PCR reaction allowed full elongation of any remaining denatured DNA 
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strands. The DNA obtained from the PCR reaction was then separated by gel 
electrophoresis and purified as described in section 2.3.1.iv and 2.3.1.v. 
Table 2.6 Forward and reverse primer used to generate the 3’ end DNA segment of TRPV4. 
Primers were obtained from Sigma and stored at -20 ℃. 
Gene Primers Product size 
(base pair) 
TRPV4 Forward 5’-TCATCCTCACCTTTGTGCTG-3’ 506 bp 
Reverse 5’-GAGCGGGGCGTCATCAGT-3’ 
 
 
Table 2.7 Composition of PCR mix. PCR reagents were obtained from New England Biolabs 
(NEB). *dNTPs = deoxyribonucleotide triphosphate. 
Components Final 
Concentration 
Volume (µl) 
DDW - 31.5 
5x reaction buffer (Q5) 1x 10 
DNA template 20 ng 2 
5 mM dNTPs* 200 µM 2 
Forward primer (Table 2.6) 20 pM 2 
Reverse primer (Table 2.6) 20 pM 2 
DNA polymerase (Q5) 0.02 U/µl 0.5 
 
2.3.1.ii Sanger sequencing 
The obtained DNA was analysed using sanger sequencing which is a method that 
involves the use of dideoxynucleotides, which are nucleotides without the 3' hydroxyl 
group that involved in 5'-to-3' DNA synthesis (Sanger et al. 1977; L. M. Smith et al. 1985; 
Smith et al. 1986). Each dideoxynucleotide is uniquely labelled with a different 
fluorescent marker. Similar to the PCR reaction; nucleotides, primers and DNA 
polymerase are used in sanger sequencing to synthesise complementary DNA from the 
target sequence, however the addition of a dideoxynucleotide terminates this elongation 
process. This allows formation of DNA fragments of every possible length which are 
subsequently separated using capillary gel electrophoresis and the sequences of 
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nucleotides is determined by generating a chromatogram, via the detection of 
fluorescence emitted by dideoxynucleotides following laser-excitation. Therefore, this 
technique was an important tool in verifying whether the recombinant DNA contained 
the correct sequence of nucleotides. 20 µl aliquot of the sample DNA (100 ng/µl) was 
sent to “Source BioScience” for sequencing. The required information about the DNA 
including the forward and reverse primers were also provided. The chromatogram data 
was then analysed using SnapGene Viewer (version 4.1.9). 
2.3.1.iii Restriction digest 
Table 2.8 Composition of the mix for digestion by RE(s). For multiple digestion, the volume 
of different RE was altered such that it ensured the same level of activity for each enzyme. To 
prevent star activity the total volume of RE was kept at a maximum of 1µl in 20 µl (5% glycerol). 
*BSA = bovine serum albumin and RE = restriction enzyme. 
Components Final amount Volume (µl) 
DDW - Until 20 
10x buffer [depending 
upon RE*(s) used] 
1x 2 
10x BSA* (1 mg/ml) 0.1 mg/ml 2 
RE(s) Varied 1 (Total) 
DNA 1 µg for insert and 
200 ng for vector 
Varied 
 
The full cDNA sequence of the plasmids were obtained and analysed using UniProt (an 
online resource for DNA sequence) (Anon 2018) and ExPASy translate (an online 
bioinformatics resource tool that allows the detection of the open reading frame) 
(ExPASy 2018). Restriction enzyme (RE) sites were identified using NEBcutter V2.0 
(online resource tool for identifying RE sites) (New England BioLabs 2018). The optimal 
RE sites were selected by ensuring that: the sites flanked the insert in the correct 
  
87 
 
orientation, the size of the fragments was significantly different, RE shared similar buffer 
and incubation temperatures. The restriction digest mix (Table 2.8) was incubated 
overnight at 37 ℃. The following REs were used to obtain the required DNA fragments 
for the plasmid, pcDNA5/FRT/TO+TRPV4-HA (Table 2.4): 
a) TRPV4 fragment = Bam HI and Kpn I 
b) 3’ end DNA segment of TRPV4 = Kpn I 
c) HA fragment = Eco RV and Xho I 
d) pcDNA5/FRT/TO fragment = Xho I and Bam HI 
2.3.1.iv Separation (DNA electrophoresis) 
1% agarose gel was made using 0.5 g of agarose and 50 ml of 1x Tris-acetate-
ethylenediaminetetraacetic acid (TAE) buffer (Table 2.9). 
Table 2.9 Composition of 50x TAE buffer dissolved in DDW. The 50x TAE was further diluted 
in DDW to make 1x solution.   
Components Final concentration 
Tris/HCl 2 M 
Glacial acetic acid 2 M 
EDTA (0.5 M pH 8) 50 mM 
 
This solution was microwaved for 1-2 min and swirled in 30 s intervals until the agarose 
completely dissolved. Subsequently, the solution was allowed to cool down for 3-5 min 
and 2 µl of the gel DNA stain, SYBR Safe (Invitrogen), was then added to the mix. 
Following levelling of the gel tray, the solution was poured and the appropriate comb was 
then clamped into the tray. The solution was left to solidify for 30 min. Whilst waiting 
the digested DNA was prepared by mixing it with the loading buffer (Table 2.10). 
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Table 2.10 Composition of 10x DNA loading buffer dissolved in DDW.   
Components Final amount 
Xylene cyanol FF 0.25% (w/v) 
Bromophenol blue 0.25% (w/v) 
Glycerol 50% (v/v) 
DDW 50% 
 
The comb was then gently removed and placed into the electrophoresis unit filled with 
TAE buffer, ensuring that the gel was completely submerged. The DNA samples and the 
DNA ladder (NEB) were then loaded into the appropriate wells. The gel was ran at 80 V 
for approximately 1 h. The bands were then compared and analysed using the reference 
DNA ladder. Images of the DNA fragments were then captured using U:Genius 3 
(Syngene) gel imaging system and U:Genius imaging software (version 3.0.7.0, 
Syngene). 
2.3.1.v Gel extraction 
DNA bands of interest were excised from the gel using a clean razor blade. Gel pieces 
were weighed and DNA was extracted using a QIAquick gel extraction kit according to 
the manufacturer’s guidelines (QIAGEN 2015). Briefly, gel pieces were solubilized by 
adding it to buffer QG and heating it in a waterbath (50°C) for 10 mins. Buffer QG 
contains guanidine thiocyanate which is a chaotropic salt that facilitates the binding of 
DNA to the silica membrane present in the spin column (Shi et al. 2015). Isopropanol (1 
gel volume) was then added and the mix was transferred into QIAquick spin column 
followed by centrifugation for 1 min at 17,000 g. Isopropanol and ethanol is used to 
precipitate the DNA from solution and further enhance binding to the column (Green and 
Sambrook 2017). The supernatant was then discarded and the column was centrifuged 
with buffer QG and subsequently with buffer PE for 1 min at 17,000 g. Buffer PE contains 
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ethanol which facilitates the removal of any excess salt (Green and Sambrook 2016). 
DNA was then eluted into a clean microcentrifuge tube using DDW. 
2.3.1.vi Ligation of DNA fragments 
Ligation experiments were conducted using 1:3 (plasmid:insert) ratio by volume as 
shown in table 2.11. The reaction was ran in parallel with a negative control containing 
the digested vector without the DNA insert at 14 ℃ for 4 h. 
Table 2.11 Composition of the DNA ligation mix. For each ligation reaction, a negative control 
was ran in parallel. Ligation reagents were obtained from NEB. 
Components Final amount Volume (µl) 
DDW - Until 5 
10x T4 DNA ligase buffer 1x 0.5 
DNA (Plasmid:insert) Ratio by volume of 1:3 Varied 
T4 DNA ligase 1.5 Weiss U/µl 0.25 
 
2.3.1.vii Bacterial transformation 
Bacterial agar (1.5%, w/v) was added to 250 ml of bacterial growth medium super optimal 
broth (SOB) (Table 2.12) and the solution was sterilized using autoclaving. Using aseptic 
techniques sterile solutions of MgCl2 (Final conc. 10 mM) and ampicillin (Final conc. 
100 µg/ml) were then added to the agar solution next to a flame. The solution was then 
gently swirled and poured into bacterial plates (~12 plates). The plates were left to set for 
30 min. Any moisture inside the plates was removed by incubating them at 37 ℃ for an 
hour, this was facilitated by placing the plates upside down with the lids partially opened. 
Plates were sealed with parafilm and stored at 4 ℃ until further use. 
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Table 2.12 Composition of SOB buffer dissolved in DDW. Buffer was sterilized through 
autoclaving. 
Components Final concentration 
Tryptone 2% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 8.56 mM 
KCl 2.5 mM 
 
The water bath was initially set to 42 ℃ and the frozen stock of competent Mach1 
(section 2.1.6) bacterial cells were placed in ice to allow thawing (~30 min). To reduce 
the sheer stress of pipetting, P200 pipette tips were cut to leave a wider bore. Competent 
cells (50 µl) were pipetted in a pre-chilled microcentrifuge tube. The ligation mixes (5 
µl) were then gently added to the cells followed by gentle flicking of the tubes. The mix 
was left in ice for 30 min. Cells were then heat shocked by placing them in the water bath 
for 30 s and were immediately placed in ice for 5 min. Using aseptic condition that 
required working near a flame, 950 µl of SOB with catabolite repression (SOC) (Table 
2.13) was added to the cells. Cells were then incubated at 37 ℃ for 1 h with shaking (250 
RPM). 
Table 2.13 Composition of SOC buffer dissolved in DDW. Buffer was sterilized through 
autoclaving. 
Components Final concentration 
Tryptone 2% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 8.56 mM 
KCl 2.5 mM 
Glucose 20 mM 
 
The transformed cells were then centrifuged at 3000 g for 3 min. The cell spreader was 
then sterilized by submerging it in ethanol and quickly passing it to through the flame. 
The spreader was then allowed to cool down. The excess supernatant was discarded by 
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tipping the tube. Cell pellet was resuspended in the remaining supernatant and pipetted 
onto the agar plate. Cells were then gently spread and the plates were incubated upside 
down at 37°C overnight. Plates were analysed the following morning and were sealed 
using parafilm and stored at 4°C until required.  
2.3.1.viii Colony PCR 
Table 2.14 Composition of colony PCR mix. 
Components Final Concentration Volume (µl) 
DDW - 13.55 
10x Taq buffer (Qiagen) 1x 2 
Bacterial colony - 2 
5mM dNTPs (NEB) 0.1 µM 0.4 
TRPV4 forward primer (Table 2.6) 0.5 µM 1 
BGH reverse primer  (Sigma) 0.5 µM 1 
Taq polymerase (Qiagen) 1.25x10-3 U/µl 0.05 
 
The single colonies were initially labelled with a number at the bottom of the plate and 
picked by gently touching it with a P10 tip for screening using colony PCR. Each bacterial 
colony was then resuspended with DDW (10 µl) in a microfuge tube. A mix for colony 
PCR was prepared as described in table 2.14. 2 µl of the single colony was added to a 
PCR tube containing the colony PCR mix (18 µl).     
The samples were then transferred into a MJ Mini thermal cycler (Bio-Rad) and the 
following settings were then used for the PCR reaction: 
Steps Temperature Time  
1 94 ℃ 10 min  
2 94 ℃ 30 s  
3 55 ℃ 30 s 35 cycles, steps 2-4 
4 72 ℃ 30 s  
5 72 ℃ 1 min  
6 10 ℃ Forever  
 
As described earlier, sagner sequencing (3.1.ii)  and gel electrophoresis (3.1.iv) were then 
used to analyse each sample. Using aseptic conditions, the remaining 8 µl of each positive 
clone was then inoculated in a sterile tube containing 5 ml of sterile SOB with MgCl2 
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(Final conc. 10 mM) and ampicillin (Final conc. 100 µg/ml), and grown overnight (37 
℃, 250 RPM). 
2.3.1.ix Bacterial glycerol stocks 
1 ml of the overnight culture was transferred into a cryovial labelled with the name of the 
DNA, bacterial species, antibiotic resistance and date. 250ul of glycerol was then added 
and gently mixed. The stocks were stored at -80°C. 
2.3.1.x Small scale plasmid preparation 
Using the remaining bacterial culture, the DNA was extracted and purified with QIAprep 
Spin Miniprep Kit (Qiagen) according to the manufacturer’s guidelines (QIAGEN 
2012b). Briefly, the culture was centrifuged at 3500 g for 10 min and the supernatant was 
discarded. The bacterial pellet was initially resuspended in buffer P1 (250 µl) which 
contains ethylenediaminetetraacetic acid (EDTA) and ribonuclease A that are involved 
in the inhibition of deoxyribonuclease activity and degradation of RNA, respectively 
(Zhou et al. 1997). Buffer P2 (250 µl) was then added to elicit alkaline lysis which 
involves solubilization of the cell membrane and denaturation of DNA, via the action of 
sodium dodecyl sulfate (SDS) and sodium hydroxide respectively (Zhou et al. 1997). 
Subsequently, buffer N3 (350 µl) which contains potassium acetate was then added to 
neutralize the alkaline pH, facilitating renaturation of the single stranded  DNA and 
precipitation of contaminants such as genomic DNA and cellular proteins (Zhou et al. 
1997). The mix was then centrifuged for 10 min at 17,000 g and the supernatant was 
transferred into a QIAprep spin column followed by centrifugation for 1 min. The spin 
column was then washed with buffer PB (500 µl) and subsequently with buffer PE (750 
µl) through centrifugation for 1 min/wash. These buffers contain isopropanol and ethanol 
which are used to precipitate the DNA from solution and enhance binding to the silica 
column (Green and Sambrook 2017). The residual ethanol was then removed by 
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centrifuging the column in an empty tube for 1 min. The column was then placed in a 
clean microcentrifuge tube and the DNA was eluted using sterile DDW. The purified 
DNA was then screened using restriction digest (3.1.iii) and DNA electrophoresis (3.1.iv) 
as described earlier. 
2.3.1.xi Large scale plasmid preparation 
250 ml culture was inoculated from the glycerol stock (3.1.ix) and transferred into 250 
ml of sterile SOB with MgCl2 (Final conc. 10 mM) and ampicillin (Final conc. 100 
µg/ml). The culture was incubated overnight with shaking at 37 ℃, 250 RPM. DNA was 
then purified from the culture with EndoFree Plasmid Maxi Kit (Qiagen) according to the 
manufacturer’s guidelines (QIAGEN 2012a).   
Briefly, the culture was centrifuged at 5000 g for 20 min and the bacterial pellet was 
resuspended initially in buffer P1 (10 ml) followed by buffer P2 (10 ml with 5 min 
incubation) and subsequently in buffer P3 (10 ml). The mix was then centrifuged for 5 
min at 5000 g and the supernatant was filtered using a QIAfilter cartridge. The 
supernatant was then incubated on ice with buffer ER (2.5 ml) for 30 min. Following 
equilibration of Qiagen-tip 500 with buffer QBT (10 ml), the supernatant was then added 
to the Qiagen-tip and purified using gravity flow. Buffer QBT contains the detergent 
triton-x-100 for further permeabilization of the cell membrane and sodium chloride along 
with isoprapanol facilitates the precipitation and binding of the DNA to the silica column 
(Green and Sambrook 2017). The Qiagen-tip was then washed (2x) with buffer QC (30 
ml) and subsequently the DNA was then eluted using buffer QN (15 ml). Isopropanol 
(10.5 ml) was subsequently added to the eluted DNA. Both buffer QC and QN contain 
contain sodium chloride and isopropanol. The mix was centrifuged for 1 h at 4 ℃ and 
5000 g. The pellet was then washed with endotoxin-free 70% ethanol (5 ml) followed by 
centrifugation at 5000 g for 10 min. The pellet was air-dried and resuspended in DDW 
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followed by centrifugation at 17,000 g for 1 min. The supernatant was then transferred 
into a clean tube and the DNA was analysed using the techniques described in 3.1.iii and 
3.1.iv. 
2.3.2 Cell culture 
2.3.2.i Revival of frozen mammalian cells 
Following removal of the frozen cells from liquid nitrogen, the cryovial was cleaned with 
70% ethanol and inside a microbiological safety cabinet, the lid of the vial was partially 
loosened and retightened to release any pressure. The vial was immediately placed into a 
water bath (37 ℃) and allowed to thaw completely before the cells were added to sterile 
tube containing 9 ml of the appropriate warm culture medium (see table 2.1) and 
centrifuged at 100 g for 5 min. Cells were resuspended in 10 ml of medium and 
transferred into a labelled sterile T75 flask.  
2.3.2.ii Culturing protocol 
Cells were cultured in Dulbecco's Modified Eagle’s medium (Sigma) at 37 ℃ in a 
humidified 95% (v:v) air/5% (v:v) CO2. Every 2-3 days, the older medium was removed 
and disinfected. Fresh medium (10 ml) was then immediately added to the T75 flask. 
Flasks were then transferred into an incubator. Once the cells were approximately 90% 
confluent, the medium was removed and cells were washed with PBS without Ca2+ and 
Mg2+ (5 ml). Trypsin-EDTA (5 ml) was then added to the flask to detach the cells. The 
cells were incubated at 37 ℃ for 5 min. Cells were then resuspended in medium (5 ml) 
to neutralize trypsin. This mix was then transferred into a sterile tube and centrifuged at 
100 g for 5 min. The pellet was resuspended in medium (10 ml) and cells were split at 
1:5 ratio. The flask was then labelled with the new passage number and date prior to 
incubation. Cells were cultured for a maximum of 35 passages. 
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2.3.2.iii Cryopreservation of cells 
Cells were counted and then resuspended in 90% FBS+10% DMSO at 1.2 x 106 cells/ml 
following passaging of the cells. 1 ml aliquots were then transferred into cryovials 
labelled with the passage number, date, culture medium used and the detailed description 
of cells. To ensure controlled freezing, the vials were then transferred into an isopropanol 
freezing container (Fisher scientific) and incubated overnight at -80 ℃. The vials were 
then stored in liquid nitrogen the following day and all the details regarding its location 
were recorded.  
2.3.3 Stable transfection using PEI 
Human embryonic kidney cells (HEK) Flp-In T-REx-293 were used to create stable cell 
lines expressing the TRPV4 channels. The Flp-In T-REx system allowed tetracycline-
inducible expression of TRPV4. These cells contained Flp recombination target (FRT) 
sites which allowed integration of the expression vector, pcDNA5/FRT/TO (Invitrogen), 
into its genome as shown in Fig 2.1 (ThermoFisher 2010) (O’Gorman et al. 1991). The 
methods used to create this stable cell line are further explained below. 
Cells were initially plated at approximately 1.5 x 106 cells per 35 mm well in antibiotic-
free DMEM medium (10% FBS, v/v) resulting in 90% confluency the following day. 
Cells were divided into two groups which included a control group that was transfected 
with just the empty plasmid vector, pcDNA5/FRT/TO, (HEKVO) and another group 
transfected with the vector containing the gene of interest or the insert, 
pcDNA5/FRT/TO+TRPV4-HA (HEKTRPV4). The following day, medium was replaced 
with 1.5 ml of fresh antibiotic-free medium (10% FBS, v/v), 2 h prior to transfection. 
Whilst waiting, the transfection mix was prepared at 3:1 ratio of PEI (9 µg/well) and 
pOG44+DNA (3 µg/well). Polyethylenimine (PEI) is a cationic polymer that can form 
positively charged complexes with DNA and can subsequently bind to the anionic 
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structures of the cell surface, ultimately resulting in DNA internalization via endocytosis 
(Boussif et al. 1995). pOG44 is a vector that contains the gene for FLP recombinase 
which mediates integration of the plasmid into the cell genome using the FRT sites (Fig 
2.1) (Buchholz et al. 1996; ThermoFisher 2012). The pOG44/DNA was prepared in 9:1 
ratio (2.7 µg of pOG44:0.3 µg of either pcDNA5/FRT/TO or pcDNA5/FRT/TO+TRPV4-
HA). pOG44 and DNA were initially added to 200 µl of DMEM medium (without 
antibiotics and FBS)/well followed by a 5 min incubation at room temperature. PEI was 
then added and the mix was allowed to incubate for 20 min at room temperature. The 
transfection mix (200 µl) was then slowly added in drops to each well. Cells were 
subsequently incubated for 2-3 days and transferred into 5x 10 cm dishes for each 3x 
wells from a 6 well plate. Cells were then selected using medium containing the 
appropriate antibiotics (Table 2.1) which was replaced every 2-3 days for 2-3 weeks. 
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Fig 2.1  Flp-In System (A) The host mammalian cells were stably transfected with pFRT/lacZeo 
confering resistance to zeocin. (B) These cells were then cotransfected with pOG44 and the 
expression vector (pcDNA5/FRT) with the gene of interest (GOI). (C) The expression vector is 
integrated into the genome of the host cell due to homologous recombination between the FRT 
sites catalyzed by Flp recombinase expressed from pOG44. This allows expression of the GOI 
and changes antibiotic resistance of the cells from zeocin to hygromycin. Image taken from 
(ThermoFisher 2010).  
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2.3.4 Isolation of single mammalian cell colonies 
Following selection of the transfected cells in antibiotics, some single cell colonies were 
identified under the microscope after 2-3 weeks. The colonies were labelled underneath 
the dish and prepared to be picked once enough cells were observed per colony, provided 
they were well separated from other colonies. A cloning cylinder was created by 
chopping the top part (accounting for 1/3 of the tube) of a sterile 500 µl tube and removing 
the lid. The top rim of the cloning cylinder was then coated with sterile vacuum grease. 
The 10 cm dish was then gently tilted freeing the cell colony from the medium, which 
allowed the formation of a tight seal around the cells once the cloning cylinder was placed 
on top of it. 80 µl of trypsin was then added to the cylinder and cells were incubated at 
37 ℃ until complete detachment. Cells were then resuspended with 80 µl of the 
appropriate medium (Table 2.1) and transferred to a 24 well plate containing an additional 
340 µl of medium per well. Clones were transferred to larger culture plates and flasks 
once they were confluent. After the cells reach confluency in a T25 flask, half of the cells 
were frozen down (section 2.3.2.iii) immediately whereas the other half remained in 
culture. Cells were later screened using immunocytochemistry (section 2.5) and western 
blotting (section 2.6) to detect expression of the protein of interest. Following 
confirmation of the expression, more stocks of cells were frozen down and the cells were 
expanded for experimentation. 
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2.4 Generation and maintenance of HEK Flp-In cells expressing KATP 
The KATP channel is a hetero-octameric complex composed of four SUR subunits and 
four Kir6 subunits (Shi et al. 2012). The predominant subunits that form the vascular 
KATP isoform are SUR2B and Kir6.1 (Foster and Coetzee 2016). Using molecular cloning 
the recombinant plasmids for each subunit were initially constructed. Due to the size of 
the plasmids, a two-step process was used to transfer each plasmid into HEK cells to 
generate the stable cell line. The first step involved lipofectamine mediated stable 
transfection of the SUR2B subunit into HEK cells (HEKSUR2B) and the second step 
involved lentiviral transduction of the Kir6.1 subunit into HEKSUR2B. The detailed 
protocol is described in the following sections.      
2.4.1 Molecular cloning 
2.4.1.i Construction of the recombinant plasmids 
RE digests were performed using the protocol detailed in section 2.3.1.iii. The following 
REs were used to obtain the DNA fragments (Table 2.4) for the plasmids, 
pcDNA5/FRT+SUR2B and pLenti6.3/FRT/MCS+ Kir6.1; 
a) pcDNA5/FRT and SUR2B fragments = Mfe I and Xho I 
b) pLenti6.3/FRT/MCS and Kir6.1fragment = Bam HI and Psp OMI 
The DNA fragments were separated using gel electrophoresis (section 2.3.1.iv) and 
purified using the QIAquick gel extraction kit (section 2.3.1.v). DNA fragments were 
then ligated using the protocol detailed in section 2.3.1.vi. 
2.4.1.ii Bacterial transformation 
Bacterial transformation was performed using the protocol described in section 2.3.1.vii, 
however for experiments with plasmids: pLenti6.3/FRT/MCS and 
pLenti6.3/FRT/MCS+Kir6.1, the incubation temperature was set to 28 ℃ resulting in a 
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3-4 h increase in incubation duration. Due to the presence of 5’ and 3’ long terminal 
repeats (LTR) in the lentiviral vector, bacterial cells can utilize these sites to delete the 
GOI through homologous recombination (Sharan et al. 2009; Im et al. 2014). Proteins 
that suppress these recombination events are more active at lower temperature, hence 
these experiments were carried out at 28 ℃ (Personal communication, Dr Graeme S. 
Cottrell). Furthermore, smaller single colonies of bacteria were preferred to be picked as 
it was believed that the bigger colonies were likely to have the smaller DNA sequence 
(without GOI), containing only the ampicillin resistance gene between the two LTR 
regions which facilitated cell growth. Initial transformation was done using Mach1 cells 
followed by plasmid purification using QIAprep Spin Miniprep Kit (section 2.3.1.x). The 
plasmid was then screened with restriction digest (section 2.3.1.iii) and gel 
electrophoresis (section 2.3.1.iv). The purified plasmid was then transformed into Stbl3 
(section 2.1.6) competent cells which are designed to suppress recombination events 
between LTRs (Al-Allaf et al. 2013). Cells were then spread onto agar plates as described 
in section 2.3.1.vii. 
2.4.1.iii Plasmid preparation 
Bacterial glycerol stocks were stored at -80 ℃ as described in section 2.3.1.ix. Both small 
and large scale plasmid preparation were conducted using the protocols described in 
section 2.3.1.x and 2.3.1.xi respectively, however Stbl3 cells containing either 
pLenti6.3/FRT/MCS or pLenti6.3/FRT/MCS+Kir6.1 were initially inoculated (28 ℃) in 
5 ml of SOB overnight and further inoculated (28 ℃) in another 250 ml of SOB for 24 h 
to maximize cell growth. 
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2.4.2 Cell culture 
Cell culture was performed using the protocol described in section 3.2, provided that any 
materials that came in contact with the virally transduced cells were initially disinfected 
before discarding. 
2.4.3 Stable transfection using lipofectamine 
HEK Flp-In-293 cells were used to stably transfect SUR2B subunits. Similar to Flp-In T-
REx cells, these cells were also composed of FRT sites which allowed integration of the 
expression vector, pcDNA5/FRT (Fisher scientific), into the genome of the cells 
(O’Gorman et al. 1991) (ThermoFisher 2018). Cells were plated using the same protocol 
as described in section 2.3.3 with antibiotic-free medium. The following day the older 
medium was aspirated and 1.5 ml of fresh antibiotic-free medium (10% FBS, v/v) was 
added 2 h prior to transfection. pOG44+DNA (3 µg/well) and lipofectamine (8 µl/well) 
were incubated into two different tubes containing Opti-MEM (250 µl/tube) for 5 min at 
room temperature. Lipofectamine is a cationic liposome that is extensively used for the 
transfection of recombinant DNA. The positively charged head group of the liposome 
condenses the nucleic acid and facilitates interactions with the anionic cell membrane 
resulting in the cellular uptake of the target DNA (Dalby et al. 2004). The pOG44/DNA 
mix was prepared in 9:1 ratio (2.7 µg of pOG44:0.3 µg of DNA). The diluted 
pOG44/DNA was added to the lipofectamine and were incubated for 20 min at room 
temperature. This transfection mix was then added to each well in a 6 well plate and the 
plate was carefully rocked to allow the mix to evenly spread across the well. Following 
2-3 days of incubation, cells were trypsinized and transferred to 5x 10 cm dishes for each 
3 wells from a 6 well plate. Cells were initially incubated in antibiotics-free medium 
(10% FBS, v/v) for 6-8 hours and then selected using medium containing the appropriate 
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antibiotics which was replaced every 2-3 days (Table 2.1). Single colonies of the cells 
were then picked and screened as described in section 2.3.4. 
2.4.4 Lentiviral production 
Lentivirus is a subtype of retrovirus and is extensively used as a viral vector for gene 
delivery due to its high transduction efficiency. Lenti-X 293T cells are subclones of HEK 
293 that are transformed with the adenovirus type 5 DNA and allows high-titer lentiviral 
production (Pear et al. 1993). These cells were transfected using the following viral 
plasmids which include; (i) pLenti6.3/FRT/MCS, the lentiviral transfer plasmid which 
contained the GOI (Kir6.1) flanked by two LTRs and a modified 3’ LTR with the deletion 
of U3 region which enabled self-inactivation of the virus following transduction 
(Thermofisher 2010), (ii) pMDG.1, VSV-G, envelope plasmid which contained the gene 
for the G protein of the vesicular stomatitis virus (VSV-G) envelope, (iii) pRSV.rev, 
HIV- 1 Rev, this plasmid contained the gene for Rev transactivating protein and (iv) 
pMDLg/p.RRE, packaging plasmid which contained genes for viral structural proteins, 
enzymes and rev response element (RRE) [for detailed review regarding lentiviral 
production see (Merten et al. 2016)].  
Lenti-X 293T cells were initially seeded at about 1.7 x 106 cells/dish in 4x 10 cm dishes. 
Briefly, following detachment of cells (10 ml) from a T75 flask, 8 ml of cells were diluted 
in 32 ml of antibiotic-free medium and 8 ml of this mix was added to each dish. After the 
cells were fully confluent, cells were trypsinized and diluted using 80 ml of antibiotic-
free medium. The pooled cells were transferred (8ml/dish) to 10x 10 cm dishes coated 
with poly-D-lysine (Final conc.: 40µg/ml) and incubated overnight. Medium was then 
replaced with 8 ml of antibiotic free medium containing 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) and FBS (10% v/v) for each dish 2 h prior to 
transfection.  
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Table 2.15 Composition of the transfection mix per 10 cm dish for lentiviral production. 
(Roux et al. 2017)  
Plasmids Conc. 
DNA of interest 9 µg 
pMDG.1, VSV-G (envelope) 4.5 µg 
pRSV.rev, HIV- 1 Rev 2.25 µg 
pMDLg/p.RRE (packaging) 4.5 µg 
Total Conc. 20.25 µg 
 
Two transfection mixes were prepared according to table 2.15 for pLenti6.3/FRT/MCS 
(control) and pLenti6.3/FRT/MCS+Kir6.1. The plasmids were incubated in optimem 
(2ml/dish) for 5 min at room temperature. Based on the 3:1 ratio of PEI:DNA, 60.75 µg 
of PEI was then added to each mix and allowed to incubate for 20 min at room 
temperature. 2 ml of this mix was then gently pipetted to each dish and cells were 
incubated overnight. The medium was then replaced with antibiotic free medium 
containing HEPES and FBS (10% v/v). Lentivirus was then purified using ViraBind 
lentivirus purification kit (Cell Biolabs) according to the manufacturer’s guidelines 
(CELL BIOLABS 2017).  
Briefly, after 36-48 hours of incubation to facilitate the viral production, the medium was 
collected and centrifuged for 5 min at 1700 g. The supernatant was then filtered through 
a 0.45 µm syringe filter. The purification filter was then pre-washed with the provided 
washing buffer and then used for purifying the viral supernatant using gravity flow. The 
filter was then washed again and the virus was eluted using the elution buffer. 100 µl 
aliquots of the virus were stored at -80 ℃ following addition of glycerol (10%). These 
steps were then repeated to get another batch of the purified virus using the same 
purification filter.  
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2.4.5 Viral transduction 
Stable HEK Flp-In-293 cell lines that were initially transfected with pcDNA5/FRT and 
pcDNA5/FRT+SUR2B were seeded at 1.5 x 106 cells/well in a 6 well plate with overnight 
incubation. The following day, HEK Flp-In-293 pcDNA5/FRT (control) cells (HEKVC) 
were virally transduced with pLenti6.3/FRT/MCS (control) whereas HEK Flp-In-293 
pcDNA5/FRT+SUR2B cells were virally transduced with pLenti6.3/FRT/MCS+Kir6.1 
(HEKKATP). Two different volumes of lentivirus were added to each well, which 
comprised of 5 µg/µl of polybrene with either 250 µl of lentivirus + 250 µl of antibiotic-
free medium or just 500 µl of lentivirus. Cells were then rocked for 30 min at 4 ℃. 1.5 
ml of antibiotic-free medium was then added to each well and cells were incubated for 
72 h. Cells were then trypsinized and transferred to 2x 10 cm dishes/well containing 
medium with the appropriate antibiotic (Table 2.1) for selection. 
2.4.6 Dilution cloning 
In contrast to cationic polymer-based transfection, it was impossible to isolate 
monoclonal cells directly from the dishes following antibiotic selection due to high 
efficiency of lentiviral transduction, resulting in an increased survival and close 
proximity of the cell colonies. As a result, dilution cloning was implemented to obtain 
single cell colonies. Cells were initially pooled from each dish following trypsinization 
and using serial dilution approximately 50-100 cells were added to 10 cm dishes. Half of 
the remaining cells were then cryopreserved whereas the other half remained in culture. 
After about 2 weeks, single cell colonies were identified, picked and screened using the 
methods described in section 2.3.4.    
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2.5 Immunocytochemistry 
2.5.1 Preparation of cells, materials and solutions 
Glass coverslips (13 mm) were initially placed in 12 well plate and coated with poly-D-
lysine (Final conc.: 40µg/ml) for 20 min which facilitated the attachment of cells. The 
coverslips were then washed with PBS (Phosphate buffered saline) (3x) and 2.5 x 105 
cells were added to each well. For HEK Flp-In T-REx-293 pCDNA5/FRT/TO and 
pCDNA5/FRT/TO+TRPV4-HA cells, tetracycline (0.1 ug/ml) was added for overnight 
incubation to induce protein expression.  
The following buffers were prepared before starting the experiment: 
2.5.1.i PBS with Ca2+ and Mg2+ (20 ml) 
Table 2.16 Composition of 10x PBS. 
Components Final concentration 
NaCl 1.36 M 
KCl 27 mM 
Na2HPO4 101 mM 
KH2PO4 18 mM 
 
10x PBS, CaCl2 (90 mM) and MgCl2 (49 mM) stock solutions were initially prepared.  
Table 2.17 Composition of PBS with Ca2+ and Mg2+ dissolved in DDW. 
Components Final concentration Volume (ml) 
10x PBS 1x 2 
DDW - 17.6 
MgCl2 0.49 mM 0.2 
CaCl2 0.90 mM 0.2 
 
2.5.1.ii 4% paraformaldehyde (PFA) solution (100 ml) 
A beaker containing 70 ml of DDW was initially microwaved for ~30s and 10 ml of 10x 
PBS was added. A stir bar was used to mix the solution inside a fume cupboard and 4 g 
of PFA was added to the solution. pH was increased using 10 M NaOH stock solution 
which was slowly added in drops until PFA completely dissolved. The solution was then 
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allowed to cool to room temperature and HCl was slowly added to get to pH 7.4. DDW 
was then added to make a final volume of 100 ml. Finally, the solution was filtered using 
0.2 µm filter. 
2.5.1.iii 5x blocking buffer (20 ml) 
Table 2.18 Composition of blocking buffer. 2 ml aliquots of the buffer were stored at -20 ℃. 
Buffer was thawed and diluted to 1x with DDW before use.  
Components Final concentration 
10x PBS 5x 
Normal Horse Serum 10% (w/v) 
Saponin 0.5% (w/v) 
DDW - 
 
2.5.2 Experimental protocol 
Cells were initially washed (3x) with PBS (Ca2+ and Mg2+), care was taken not to directly 
pipette onto the cells to prevent cell detachment. Cells were then incubated with either 
4% PFA (Anti-HA) or methanol (Anti-Kir6.1 and -SUR2B) for 20 min at 4°C. PFA and 
methanol are used as fixatives in order to preserve cell morphology and prevent 
degradation of the samples. Cells were again washed (3x) with blocking buffer for 5 
min/wash on the shaker. Coverslips were then transferred to a glass plate covered with 
parafilm. 50 µl of primary antibody with the appropriate concentration (section 2.1.4, 
Table 2.3) was gently pipetted to each coverslip. The glass plate was then transferred into 
a tray with a wet paper towel soaked with DDW at the bottom and the tray was covered 
with a lid to prevent the coverslips from drying. Cells were then incubated overnight at 
4°C. Coverslips were transferred back to the 12 well plate and washed (3x) with blocking 
buffer (500 µl/well). Whilst waiting for the wash, the appropriate concentration and 
volume of secondary antibody (section 2.1.4, Table 2.3) was prepared. Care was taken to 
limit direct exposure of the antibody to light, as this can result in photobleaching. The 
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coverslips were then transferred to the glass plate covered with parafilm. The secondary 
antibody (50 µl) was then gently pipetted onto the coverslip and the plate was transferred 
into the tray containing wet paper towel. Aluminium foil was used to cover the tray to 
prevent exposure to light and cells were incubated for 2 h at room temperature. 
Following incubation, coverslips were again transferred back to the 12 well plate and 
washed (3x) with blocking buffer whilst rocking for 5 min/wash. To prevent exposure to 
light the well plate was covered with tin foil. The coverslips were then washed with PBS 
(3x). Microscope slides were then labelled and a small drop of mounting medium 
(Vectashield with DAPI, Vector Laboratories) was added to the slide for each coverslip. 
Coverslips were then gently mounted face down and excess mounting medium was 
carefully squeezed out using a paper towel. The edge of the coverslips was then sealed 
with nail polish and was allowed to dry before imaging. 
2.5.3 Visualization of the cells using an epifluorescent microscope 
Cells were visualized with Axioimager.A1 microscope (Zeiss) and images were acquired 
using Axiovision 4.6.3 imaging software (Zeiss) with either x20 (Zeiss EC Plan-Neofluar 
20X/0.50) or x40 objective lens (Zeiss EC Plan-Neofluar 40X/0.75). The exposure mode 
was selected as “Fixed” which allowed comparison of the same fluorophore between 
different samples using the same level of exposure. Therefore, the cells transfected with 
the target protein DNA were initially used to measure and set the exposure, as these cells 
had the higher fluorescence compared to the control cells. Images were then processed 
using Axiovision4. 
2.5.4 Visualization of the cells using a confocal microscope 
Cells were prepared as described in section 2.5.2 and then visualized using A1-R confocal 
with resonant scanner microscope (Nikon) and x100 objective lens (Apo TIRF 100x/1.49 
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∞/0.13-0.20). Images were then processed with NIS Elements AR 4.51.00 (Nikon). Cells 
were located by selecting the Galvano scan mode in the graphical user interface panel. 
The zoom was set to 2 units and the image saturation was adjusted by changing the gain 
settings using a wavelength different from the fluorophore. After setting the focal plane 
at the centre of the cell, symmetric mode was then selected in the ND acquisition panel 
to obtain at least five optical sections with 0.5 µm intervals from bottom to top. Images 
were then processed using NIS Elements AR. 
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2.6 Western blot 
2.6.1 Cell lysis 
Table 2.19 Composition of lysis buffer (LB). pH was adjusted to 7.4 using HCl and 10 ml 
aliquots were stored at -20 ℃. 1 tablet of protease inhibitor (Fisher scientific) was added per 10 
ml of LB before use. 
Component Final concentration 
Tris base 50 mM 
Sodium Fluoride 10 mM 
Sodium Pyrophosphate 10 mM 
Triton –X-100 0.1% 
 
Western blotting was used to assess the protein expression of the different ion channels 
in the stable HEK cells following transfection and/or transduction. The experiments were 
conducted at 4 ℃ to prevent protein degradation. Cells were placed on ice and washed 
(3x) with PBS. 150µL of lysis buffer (LB) (Table 2.19) was added to each well in a 6 
well plate. Cells were then rocked at 4 ℃ for 30 min. Lysed cells were then scraped from 
the wells and pipetted into a microfuge tube. Cells were then centrifuged for 10 min at 
12,000 g, 4 ℃. The supernatant was then transferred to a new microfuge tube and kept 
in ice. 
2.6.2 Quantification of protein concentration 
Bicinchoninic acid (BCA) protein assay kit (Fisher scientific) was used to measure the 
protein concentration of our lysate samples. This method utilizes the biuret reaction 
which involves temperature-dependent reduction of Cu+2 to Cu+ ions mediated by the 
peptide bonds present in protein molecules (P. K. Smith et al. 1985). BCA then chelates 
Cu+ ions resulting in the formation of a purple-coloured complex that absorbs light at 540 
nm. BSA (1 mg/ml) was used as the protein standard and diluted to different 
concentrations ranging from 0, 0.2, 0.4, 0.6, 0.8 and 1 ug/well to an overall volume of 10 
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µl per well in duplicates in a 96 well plate. 2 µl of each lysate sample was added in 
triplicates to each well with 8 µl of DDW. BCA (Reagent A) and CuSO4 (Reagent B) 
were mixed in a 50:1 ratio (5 ml of BCA was added to 100 µl CuSO4 which was enough 
for 24 wells). 200 µl of BCA:CuSO4 mix was added to each well and the plate was 
incubated at 37 ℃ for 30 min. The absorbance for each well was then measured using 
Emax plate reader (Molecular Devices) at 540 nm and SoftMax Pro v5 software. 
Absorbance values were then averaged and subtracted with the value obtained from the 
blank standard in Microsoft excel. These values vs its concentration in mg/ml were then 
used to plot a standard curve in GraphPad Prism 5. The protein concentration for the 
lysate samples were then determined through interpolation of the curve. The samples 
were aliquoted at 30 µg of total protein and stored at -20°C until required. 
2.6.3 Preparation of SDS-PAGE gel and protein lysates 
2.6.3.i Assembling the gel apparatus 
The front and back (1.5 mm spacers) glass plates were initially washed with DDW 
followed by acetone. These plates were then carefully inserted into the casting frame with 
the shorter plate at the front. To prevent any leakage, the frame was then placed on top 
of a flat surface which allowed the plates to slide down allowing the bottom edges of both 
plates to become completely parallel. The rubber strips were then placed at the bottom of 
the casting stand and the frame was tightly secured. DDW was poured in between the 
glass plates to confirm if there was any leakage. The plates were then drained and dried 
using paper towel. 
2.6.3.ii Separating gel preparation 
Polyacrylamide gels are extensively used for the separation and analysis of proteins 
samples. Tetramethylenediamine (TEMED) is used to catalyse free radical formation 
from ammonium persulfate which subsequently reacts with acrylamide monomers to 
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initiate the polymerisation chain reaction (Shi and Jackowski 1998). SDS is a detergent 
that can solubilise cell membranes and is also added to the gel to ensure that the protein 
molecules are linearized and have a uniform negative charge throughout electrophoresis 
(Peters 1991). About 7.5 ml of the separating gel (Table 2.20) was gently pipetted into 
the glass plates and subsequently 200 µl of water-saturated butanol was pipetted across 
the surface of the separating gel. This butanol mix was prepared by mixing equal volumes 
of DDW and butanol which produced two different layers, the top butanol layer was then 
used. The gel was left to polymerise for 30 min. 
Table 2.20 Composition of 8% separating gel. 2.5 µl of TEMED was added in a fume cupboard. 
*APS = ammonium persulfate.  
Component Volume per 10 ml 
(8%) 
DDW 6.3 ml 
1.5 M Tris/HCl pH 8.8 2.5 ml 
40% Acrylamide 2.0 ml 
10% APS* (w/v) 100µl 
10% SDS (w/v) 100 µl 
 
2.6.3.iii Stacking gel preparation 
Table 2.21 Composition of 3% stacking gel. 2.5 µl of TEMED was added in a fume cupboard.  
Component Volume per 5 ml (3%) 
DDW 3.275 ml 
0.5 M Tris/HCl pH 6.8 1.25 ml 
40% Acrylamide 0.375 ml 
10% APS (w/v) 50µl 
10% SDS (w/v) 50 µl 
 
The stacking gel (Table 2.21) was then prepared whilst waiting for the separating gel to 
set. Upon completion of the gel polymerisation, butanol was washed away using DDW 
and filter paper was used to gently dry the plates without touching the gel. The stacking 
gel was then added until it filled the plates and the comb (1.5 mm) was gently inserted 
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into the plate ensuring that no air bubbles were present. The gel was then left to 
polymerise for 30 min. 
2.6.3.iv Reduction and denaturation of the protein lysates 
Table 2.22 Composition of 5x SDS loading buffer. Buffer was filtered using 0.45 μm syringe 
filter and aliquots of 500µl were stored at -20°C.  
Component Final concentration 
0.5 M Tris/HCl pH 6.8 250 mM 
Glycerol 50% (v/v) 
SDS 10% (w/v) 
Bromophenol blue - 
 
Whilst waiting for the gel to polymerise, 5x SDS loading buffer (Table 2.22) was initially 
warmed at 37 ℃ and vortexed until the residues completely dissolved. β-mercaptoethanol 
was then added to the loading buffer in a fume hood to a final concentration of 2.5% 
(v/v). β-mercaptoethanol is a reducing agent that cleaves disulphide bonds and denatures 
protein molecules (Peters 1991). Bromophenol blue dye was added to track the migration 
of the protein sample whereas glycerol was added to increase the density of the buffer 
which allowed the sample to settle at the bottom of the well. An appropriate volume of 
5x loading buffer (Final conc. 1x) was added to the lysate samples and the samples were 
briefly heated at 90 ℃. The lysates were then placed in ice allowing it to reach room 
temperature followed by centrifugation for 1 min at 10,000 g. 
2.6.4 Gel electrophoresis 
The electrophoresis works on the principle that glycine can acquire neutral, positive or 
negative charge states, depending on the pH (Peters 1991). Glycine becomes neutrally 
charged as it enters the stacking gel (pH 6.8) resulting in slower electrophoretic migration 
(Peters 1991). In contrast, chloride ions from Tris-HCl migrate at a higher speed and 
therefore protein molecules with intermediate electrophoretic mobility become 
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concentrated between glycine and chloride ions. This stacks the protein molecules into 
tight bands before it enters the running gel (pH 8.8). Due to the increase in pH, glycine 
then becomes negatively charged in the running gel and migrates at a faster speed, leaving 
the protein molecules behind to allow separation based on their size. The gel cassette was 
transferred into the electrode assembly and clamped with another gel or blank cassette on 
the opposite side. The assembly was then placed into the tank and the combs were 
carefully removed. Running buffer (Table 2.23) was then used to initially flush the wells 
to remove any unpolymerized acrylamide and then used to fill the tank. Subsequently, 
lysate samples and molecular weight markers were carefully pipetted into the appropriate 
wells. The lid was then secured on top of the tank and the gel was ran at constant current, 
20 mA (0.02 A) per gel for about 3 h until the dye front ran to the bottom. 
Table 2.23 Composition of 10x running buffer. DDW was added to dissolve the salts by stirring 
and HCl was used to adjust the pH to 8.3. For 1 litre of 1x running buffer, 10 ml of 10% SDS 
(w/v) was added to 100 ml of 10x running buffer and the buffer was further diluted with DDW 
(890 ml). 
Component Final concentration 
Tris base 250 mM 
Glycine 1.9 M 
 
2.6.5 Transfer to membrane 
Table 2.24 Composition of 20x transfer buffer. DDW was added to dissolve the salts by stirring 
and HCl was used to adjust the pH to 8.3. For 1 litre of final 1x transfer buffer, 200 ml of 100% 
methanol was added to 50 ml of 20x transfer buffer and the buffer was further diluted with DDW 
(750 ml). 
Component Final concentration 
Tris base 960 mM 
Glycine 781 mM 
SDS 26 mM 
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Transfer buffer (Table 2.24) was initially kept in 4 ℃ and about 20 min prior to 
completion of gel electrophoresis, a 9 x 7.5 cm segment of polyvinylidene fluoride 
(PVDF) membrane (Immobilon-P, Merck Millipore) was immersed in 100% methanol 
for 15 s. The membrane was then transferred to DDW for 2 min and subsequently 
equilibrated by immersing it in transfer buffer for 10 min on a rocker. 2 thick filter papers 
and 2 fibre pads were soaked in transfer buffer. Following the completion of the 
electrophoresis, the gel cassette was removed and the glass plates were separated using 
the gel releaser by gently opening each corner of the plates. Gel was then removed from 
the plate and equilibrated in transfer buffer for 10 min. In a tray containing transfer buffer, 
the transfer cassette was initially placed with the clear side at the bottom. 1 fibre pad was 
placed on top of the cassette followed by a filter paper and the PVDF membrane was 
added on top. The gel was then placed and a wet filter paper was added onto the gel 
followed by a wet fibre pad. Using a roller any air bubbles between the PVDF membrane 
and the gel was removed. The cassette was carefully closed and placed into the mini-trans 
blot cell (Bio-Rad). A magnetic stirring bar was placed at the bottom and the tank was 
filled with transfer buffer. The cooling unit filled with dry-ice was transferred into the 
tank and the mini-trans blot cell was placed on top of a magnetic stirrer. The transfer was 
carried out at 1 A per cell for 1 h at constant current and the dry ice was replaced every 
20 min. Following completion, the membrane was carefully immersed in PBS for 5 min 
on a rocker. PBS was then replaced with PBST/M (TWEEN 20, 0.1% and non-fat milk 
powder, 5%) and the membrane was further incubated for 1 h on a rocker. Due to the 
high affinity of the membrane for proteins, TWEEN 20 was used to prevent non-specific 
binding of the antibodies and the milk was used to block the free unbound sites of the 
membrane.  
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Depending on the size of the membrane (determined by the amount of protein samples 
used), appropriate concentration of primary antibody (Table 2.3) diluted in PBST/M was 
added to the membrane. Membrane was incubated overnight using a rocker at 4 ℃. The 
following day, the membrane was washed with PBST for 5 min (6x) on a rocker and was 
incubated with an appropriate concentration of secondary antibody for 1 h at room 
temperature. Lastly, membrane was washed with PBST (6x) for 5 min whilst rocking. 
2.6.6 Imaging of the membrane 
A mix containing 2 ml of each of the enhanced chemiluminescence detection buffers 
(Clarity Western ECL Substrate, Bio-Rad) were prepared into a vial. The PBST was 
drained from the membrane by gently touching its edge on a paper tower and was 
transferred onto a tray. The detection buffer was then pipetted onto the membrane and 
was incubated for 1 min at room temperature. Tin foil was used to cover the tray to 
prevent any extra exposure to light. Membranes were then imaged by transferring into 
ImageQuant LAS 4000 mini (GE Healthcare Life Sciences) and using ImageQuantTM 
LAS 4000 mini software (version 1.2, GE Healthcare Life Sciences). An image of the 
protein ladder was initially taken followed by the membrane which was exposed at 
increasing intervals until the optimum image was obtained without overexposure. Finally, 
images were then labelled and saved as TIFF files.   
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2.7 Measurement of changes in [Ca2+]i using Fluo-4 AM 
HEKVO and HEKTRPV4 cells were seeded (1 x 10
6 cells/well) onto a 6 well plate with 
coverslips (22x22 mm) coated with poly-D-lysine (Final conc.: 40 µg/ml). After 24 h, 
tetracycline (0.1 µg/ml, 16 h) was added to each well containing HEKTRPV4 cells. Cells 
were then washed with 3x PBS (with 1.3 mM CaCl2) and were loaded in the dark with 
Fluo-4 acetoxymethyl (AM) ester (4 μM, 20 min, 37 °C) using the loading buffer (Table 
2.25). Fluo-4 AM is a fluorescent dye that can bind to free [Ca2+]i ions which results in 
an increase in its fluorescent intensity and is therefore commonly used for calcium assays 
(Gee et al. 2000). For some experiments, inhibitors of TRPV4 were also added with the 
Fluo-4. Cells were then washed 3x with the loading buffer. Furthermore, some 
experiments involved the initial pre-treatment of the cells with either DHA or EPA (30 
μM, 1 h). The coverslips were then broken into smaller fragments using a diamond tipped 
scribe and the fragments were transferred into a 24 well plate containing the loading 
buffer. 
Table 2.25 Composition of loading buffer. *HBBS = Hank's Buffered Salt Solution 
Component Final concentration 
HEPES (Ca2+/Mg2+ free) pH 7.4 20 mM 
10x HBBS* 1x 
BSA-protease free (10%, v/v) 0.1% (v/v) 
CaCl2 (1 M) 1.3 mM 
DDW - 
 
Fluorescence was then measured (1.2 s intervals) at 488 nm excitation and 506 nm 
emission wavelengths using a Nikon Eclipse TE2000-5 inverted microscope with 40x 
objectives (Nikon Plan Fluor 40x/1.30 ∞/0.17 WD 0.2). Baseline fluorescence was 
initially measured for 30 s before the drug [n-3 PUFA (30 µM) or GSK1016790A (3 nM, 
GSK)] was applied and the responses were measured for an additional 370 s prior to the 
application of ionomycin (10 µM). WinFluor V3.9.1 (University of Strathclyde Glasgow) 
  
117 
 
was then used to obtain and export the images into TIFF files. Subsequently, ImageJ 
(1.51j8, National Institutes of Health) was used to analyse the imported images by 
initially selecting the cells as regions of interest (ROI) using the selection tool. The ROI 
manager was then opened to add each ROIs and multi measure their fluorescence 
intensity (mean grey value). Traces were then generated using Microsoft excel (Office 
365) as shown in Fig 2.2 and Fig 2.3. The values for the mean baseline fluorescence along 
with the maximum fluorescence induced by the drug (n-3 PUFA or GSK) and ionomycin 
were then obtained using the traces. Data was then processed using the following 
equations:  
 𝑎 =
b 
c
  and  𝑑 =
e 
c
 
b (HEKTRPV4+Tet cells) = maximum fluorescence induced by GSK – mean      
                                        baseline  fluorescence 
c = maximum fluorescence induced by ionomycin – mean baseline fluorescence 
e = maximum fluorescence induced by GSK (following treatments) or n-PUFA              
      – mean baseline fluorescence 
Values were then expressed as % response,  
Therefore,       
d 
a
 ×  100  
 
Fluorescence response for the representative traces were expressed as a % of the 
maximum response mediated by ionomycin. Results for the bar graph were expressed as 
mean % response (
d 
a
 ×  100)±SEM of n experiments, where n refers to each experiment 
carried out on a different day and data was graphically presented using GraphPad Prism 
5. Statistical analysis was carried out using one-way analysis of variance (ANOVA) and 
Bonferroni post-hoc test in GraphPad Prism 5. P-value of < 0.05 was considered as being 
statistically significant. 
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Fig 2.2 Original representative trace demonstrating the effect of GSK and ionomycin in 
HEKTRPV4+Tet cells. Baseline fluorescence was initially measured for 30 s prior to the application 
of GSK (3 nM). Ionomycin (10 µM) was applied at 400 s and fluorescence was measured for an 
additional 200 s to obtain the maximum response. Values for the mean baseline response along 
with the maximum response induced by GSK and ionomycin were obtained as indicated by the 
arrows.   
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Fig 2.3 Original representative trace demonstrating the effect of DHA and ionomycin in 
HEKTRPV4+Tet cells. Baseline fluorescence was initially measured for 30 s prior to the application 
of DHA (30 µM). Ionomycin (10 µM) was applied at 400 s and fluorescence was measured for 
an additional 200 s. Values for the mean baseline response along with the maximum response 
induced by DHA and ionomycin were obtained as indicated by the arrows.   
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2.8 Patch clamp electrophysiology 
Table 2.26 Composition of intracellular and extracellular patch clamp buffers. For 
intracellular buffer: KOH was used to adjust the pH to 7.2 and 1 ml of filtered (0.2 µm) aliquots 
were stored at -20 ℃. For extracellular buffer: NaOH was used to adjust the pH to 7.4 and buffer 
was stored at 4 ℃. 
Intracellular buffer Extracellular buffer 
Component Final 
concentration 
(mM) 
Component Final 
concentration 
(mM) 
KCl 110 KCl 4 
MgCl2· 
6H2O 
1 MgCl2· 
6H2O 
1 
EGTA 10 NaCl 130 
HEPES 10 HEPES 10 
MgATP 3 D-Glucose 10 
NaADP 1 CaCl2 1.8 
 
The activation of KATP channels by n-3 PUFAs was further investigated using whole cell 
patch clamp. Depending upon the experimental plan, HEKVC and/or HEKKATP cells were 
seeded at 2.5 x 105 cells/well in a 6 well plate with coverslips and incubated overnight.  
2.8.1 Intracellular and extracellular buffers 
The intracellular buffer was prepared using the recipe shown in table 2.26. The buffer 
was then filtered (0.2 µm) and 1 ml aliquots were stored at -20 ℃. The intracellular buffer 
was thawed in ice prior to use for experiments. 500 ml of the extracellular buffer was 
prepared using the recipe from table 2.26 and stored at 4 ℃.  
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2.8.2 Patch pipettes 
Glass capillaries (BF150-86-10, Sutter) were vertically pulled using a Narishige PP-830 
puller (Narishige Group) to make patch pipettes with a resistance of ~3 MΩ. The double 
pull setting was incorporated where the first and the second pull were conducted at 62 ℃ 
and 49 ℃ respectively. Multiple patch pipettes were prepared before starting any 
experiments. 
2.8.3 Acquiring giga seal 
Cells were initially transferred into the recording chamber and a single isolated cell was 
positioned at the centre of the microscope. A patch pipette was filled with the intracellular 
buffer and was attached to the pipette holder. A light positive pressure was applied by 
gently attaching a 1ml syringe to the tube connected to the pipette holder. Using the 
coarse setting, the micromanipulator was used to lower the pipette into the bath until it 
was just above the cell. A rectangular current response was observed due to the test pulse 
(10 mV, 100 Hz) along with the resistance of the pipette (~3 MΩ) in pClamp 10.6 
software (Molecular devices). The value for the pipette resistance was recorded and the 
offset was electronically set to zero using the MultiClamp 700B commander software 
(Molecular devices). The pipette was then lowered using the fine setting of the 
micromanipulator until the tip touched the cell, which was indicated by a reduction in 
current and an increase in pipette resistance of not more than 1 MΩ. The syringe was 
immediately removed to release the positive pressure, facilitating the formation of a giga 
Ω seal (characterised by increase in resistance to >1 GΩ) and the voltage was held at -40 
mV. In some cases, additional application of suction was required to enhance seal 
formation. This resulted in the cell-attached patch clamp configuration which led to the 
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production of fast capacitive transients due to the pipette’s capacitance. These transients 
were then electronically cancelled using the MultiClamp 700B commander software. 
2.8.4 Whole-cell patch clamp 
To achieve the whole cell configuration, a negative pressure was applied to the pipette to 
break through the membrane, with mouth pipetting using the tube connected to the pipette 
holder. This resulted in the production of slow capacitive transients due to the formation 
of a series circuit consisting of the cell capacitance and the series resistance (Rs, pipette 
resistance + access resistance), also known as the RC circuit. To avoid any detrimental 
effects of the RC circuit when clamping the voltage, the capacitance and Rs were 
compensated electronically using MultiClamp 700B commander software. The series 
resistance was compensated to 70% to avoid any oscillation in the positive feedback 
(ringing) mediated by a higher Rs compensation (Walz et al. 2002). The values for series 
resistance and the membrane capacitance were recorded. Whole-cell patch–clamp 
recordings were performed using MultiClamp 700B amplifier (Molecular devices). 
Current signals were filtered at 2 kHz and sampled at 10 kHz using Axon Digidata 1550B 
(Molecular devices). Currents were recorded using a ramp protocol (-150 to +50 mV over 
1 s with a holding potential of -80 mV) with pClamp 10.6. Briefly, the ramp protocol was 
used to initially measure the baseline currents for 10 s. Changes in the current signals 
were recorded following the initial application of the vehicle followed by the 
pharmacological agents until the responses plateaued. Finally, an inhibitor in 
combination with the same agonist was used until maximum reduction in the agonist 
response was achieved. 
 
 
 
  
122 
 
2.8.5 Data analysis 
Peak current values at +40 mV were obtained from pClamp 10.6 and the mean current-
density (pA/pF) was calculated in Microsoft Excel. Graphs were plotted using GraphPad 
Prism 5. Results were expressed as mean±SEM of n experiments, where n refers to a 
single individual cell from a separate cover slip. Statistical analysis was carried out using 
one-way analysis of variance (ANOVA) and Bonferroni post-hoc test in GraphPad Prism 
5. P-value of < 0.05 was considered as being statistically significant. 
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Chapter 3 
 
The role of endothelium in n-3 PUFA-
mediated vasodilation 
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3.1 Introduction 
The inner endothelium layer of blood vessels has an important role in the production of 
various vasodilators including NO, PGI2 and EDHFs such as EETs (Bunting et al. 1976; 
Dusting et al. 1977; Chen et al. 1988; Shimokawa et al. 1996; Forstermann and Münzel 
2006; Edwards et al. 2010). Stimulation of M3 receptors can result in subsequent 
activation of eNOS which can facilitate the production of NO (Marlettaz 1993). NO can 
then diffuse into the underlying SMCs and enhance PKG activity, leading to the 
activation of MLCP which subsequently inhibits vasoconstriction (Wu et al. 1996; Lee 
et al. 1997). The metabolites of AA, such as PGI2 and EETs, have also been reported to 
induce vasodilation following enzymatic metabolism by COX and CYP respectively 
(Silva et al. 2016; Fleming 2016). PGI2 can activate IP receptors present in SMCs which 
augments PKA activity resulting in vascular relaxation (Majed and Khalil 2012). CYP-
derived EETs are also involved in eliciting relaxation of vascular SMCs through 
mechanisms that activate potassium channels such as BKCa channels (Li et al. 2002; 
Archer et al. 2003; Campbell et al. 2006; Dimitropoulou et al. 2007). n-3 PUFAs can 
compete with these enzymes to produce metabolites that are also involved in vasodilation, 
these include the COX-derived series-3 PGs along with CYP-derived EpETEs and EDPs 
(Arnold, Konkel, et al. 2010; Thomson et al. 2012; Engler et al. 2000; Ye et al. 2002; 
Hercule et al. 2007).  
n-3 PUFAs have been reported to improve the ability of endothelium to induce 
vasodilation through mechanisms that enhance production of NO and COX metabolites 
(Tagawa et al. 1999; Engler et al. 2000). Both DHA and EPA have been reported to 
augment NO production in rat aorta and bovine coronary arteries respectively (Hirafuji 
et al. 2002; Omura et al. 2001). In aging spontaneously hypertensive and ApoE KO mice, 
supplementation of n-3 PUFAs also led to enhanced NO production (Raimondi et al. 
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2005; Casós et al. 2010). These findings were consistent with clinical studies; for 
example, with patients suffering from coronary artery disease, treatment with EPA led to 
improvements in NO-dependent vasodilation response (Tagawa et al. 1999). There is also 
evidence indicating that both DHA- and EPA-mediated relaxations of rat aorta were 
sensitive to the blockade of COX (Engler et al. 2000; Sato et al. 2014). Furthermore, n-3 
PUFA supplementation was reported to attenuate constriction of human forearm 
resistance arteries via COX-dependent pathway (Chin et al. 1993).   
EETs, CYP metabolites of AA, were also reported to induce vasodilation in canine 
coronary arteries through activation of KCa channels (Oltman et al. 1998) and it was later 
confirmed that BKCa was the subtype involved (Fukao et al. 2001). Similarly, CYP 
epoxygenase metabolites of DHA, EDPs, were also reported to activate BKCa channels 
resulting in hyperpolarization of vascular SMCs derived from porcine coronary arteries 
(Ye, Zhang et al. 2002). Acute application of DHA was reported to elicit concentration-
dependent increase in BKCa currents in rat coronary vascular SMCs (Lai, Wang et al. 
2009). In addition, in isolated rat coronary arterial tissues the blockade of BKCa channels 
completely abolished DHA-induced vasodilation (Wang, Chai et al. 2011). The 
underlying mechanism was reported to involve the release of calcium from sarcoplasmic 
reticulum mediated by EDPs in rat coronary arteries, resulting in subsequent activation 
of BKCa channels. Furthermore, a reduction in the blood pressure was observed following 
intravenous administration of DHA in wild type mice but not in BKCa KO mice 
(Toshinori Hoshi, Wissuwa, et al. 2013). 
EDH pathway is another major vasodilation pathway predominantly associated with 
maintaining resistance arterial tone and involves the KCa channels, especially SKCa and 
IKCa (Ozkor and Quyyumi 2011; Edwards et al. 2010; Shimokawa et al. 1996). Most of 
the research demonstrates that DHA and CYP-derived metabolites of both DHA and EPA 
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are involved in the activation of BKCa channels (Patterson et al. 2002; Lai et al. 2009; Ye 
et al. 2002; Hercule et al. 2007), however, currently there is no evidence indicating the 
involvement of SKCa and IKCa channels in n-3 PUFA-mediated relaxation. At present 
there is only one study that demonstrated DHA-mediated inhibition of IKCa channels 
expressed in HEK cells (Kacik et al. 2014).  
As indicated by table 1.1 (chapter 1), mechanisms associated with n-3 PUFA-mediated 
relaxation can differ depending upon factors such as the size of the artery, the type of n-
3 PUFAs and its metabolites. However, most of these studies are limited to one type of 
n-3 PUFA and a specific vascular bed. Therefore, the main aim of this study was to 
investigate the vasodilation pathways of both n-3 PUFAs, DHA and EPA, using a conduit 
artery (aorta) and a resistance artery (mesenteric artery), allowing a detailed 
characterisation and comparison of any heterogeneity involved with the vasodilation 
mechanisms of each n-3 PUFA. 
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3.2 Results 
3.2.1 Effect of endothelium removal in n-3 PUFA mediated vascular 
relaxation 
The endothelial layer is involved in the regulation of various vasodilation pathways 
including NO, COX, CYP and EDH (Forstermann and Münzel 2006; Bunting et al. 1976; 
Dusting et al. 1977; Chen et al. 1988; Shimokawa et al. 1996; Ozkor and Quyyumi 2011; 
Edwards et al. 2010), therefore I investigated the role of endothelium in n-3 PUFA 
mediated vascular relaxation. Using wire myograph (chapter 2, section 2.2), the relaxant 
effect of n-3 PUFAs were recorded before and after the removal of endothelium from the 
arteries. Arteries demonstrating <10% relaxation to ACh were considered to have 
functional removal of endothelium. Cumulative administration of DHA and EPA 
individually led to potent relaxation of both mesenteric artery and aorta. Relaxation was 
expressed as percentage reduction of U46619-induced stable tone and statistical analysis 
of the curves was carried out using two-way ANOVA and Bonferroni post-hoc test.  
Representative traces demonstrating the effect of endothelium removal in DHA-induced 
relaxation of rat mesenteric artery and aorta are shown in Fig 3.1 and Fig 3.2 respectively. 
In rat mesenteric artery, endothelium removal led to partial inhibition of DHA-induced 
vascular relaxation [Log EC50; -5.79±0.04 (Control) and -5.56±0.05 (Endothelium 
removed)] (Figs 3.3A) (n=5, P<0.05) whereas relaxation mediated by EPA remained 
unaffected (Figs 3.3B) (n=6). In contrast, endothelium removal attenuated EPA-induced 
relaxation of rat aorta [Log EC50; -5.25±0.03 (Control) and -5.11±0.05 (Endothelium 
removed)] (Fig 3.4B) (n=6, P<0.05). However, the relaxation elicited by DHA was not 
modified following removal of the endothelium in rat aorta (Fig 3.4A) (n=7).  
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Fig 3.1 Original representative traces demonstrating the effect of endothelium removal in 
DHA-induced relaxation of rat mesenteric artery. After initially obtaining the control response 
curve, changes in vascular tone were recorded following removal of the endothelium from the 
same arterial segment. DHA was cumulatively added (0.01 – 30 µM) to induce vascular 
relaxation as indicated by the arrows.  
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Fig 3.2 Original representative traces demonstrating the effect of endothelium removal in 
DHA-induced relaxation of rat aorta. After initially obtaining the control response curve, 
changes in vascular tone were recorded following removal of the endothelium from the same 
arterial segment. DHA was cumulatively added (0.1 – 30 µM) to induce vascular relaxation as 
indicated by the arrows.  
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Fig 3.3 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=6) in rat mesenteric artery before and after the removal of 
endothelium. Using wire myograph, changes in n-3 PUFA (10 nM – 30 µM) mediated relaxation 
were recorded by initially obtaining a control response curve followed by endothelium removal 
from the same arterial segment.  Data are expressed as mean±SEM. *P<0.05 indicates significant 
difference from the control curve as determined using two-way ANOVA with Bonferroni post-
test. 
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Fig 3.4 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=7) and (B) EPA (n=6) in rat aorta before and after the removal of endothelium. Using 
wire myograph, changes in n-3 PUFA (100 nM – 30 µM) mediated relaxation were recorded by 
initially obtaining a control response curve followed by endothelium removal from the same 
arterial segment. Data are expressed as mean±SEM. *P<0.05 indicates significant difference from 
the control curve as determined using two-way ANOVA with Bonferroni post-test. 
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3.2.2 Effect of NO and COX inhibition in n-3 PUFA mediated 
vascular relaxation 
In the earlier section 3.2.1, I demonstrated that there was a small endothelium-dependent 
component involved in DHA- and EPA-induced relaxation of rat mesenteric artery along 
with EPA-induced relaxation of rat aorta. Therefore, the next experiments were designed 
to characterise these endothelium-dependent pathways that were involved with n-3 PUFA 
mediated relaxation. The role of NO and COX was initially investigated through the pre-
treatment (20 min) of the arteries with L-NAME (300 µM) and indometacin (10 µM). 
Fig 3.5 and 3.6 shows the representative traces demonstrating the effect of NO and COX 
inhibition in DHA-induced relaxation of rat mesenteric artery and aorta respectively. The 
arterial incubation with L-NAME led to inhibition of basal NO production resulting in 
potentiation of constriction, as a result, U46619 had to be applied at 10x lower 
concentration to match the tone of the previous control response curve. Additionally, 
these effects were mostly observed in rat mesenteric arteries as demonstrated by Fig 3.5B. 
Pre-treatment with L-NAME followed by the additional inhibition of COX using 
indometacin failed to modify both DHA- and EPA-mediated relaxation in rat mesenteric 
artery (Figs 3.7A and 3.7B) (n=5). Consistently, pre-treatment of rat aorta with L-NAME 
and indometacin also failed to modify both DHA- and EPA-induced relaxation (Figs 3.8A 
and 3.8B) (n=5).  
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Fig 3.5 Original representative traces demonstrating the effect of L-NAME (300 µM) and 
indometacin (10 µM) in DHA-induced relaxation of rat mesenteric artery. After initially 
obtaining the control response curve, changes in vascular tone were recorded following 
successive incremental treatments of the same arterial segment with L-NAME to inhibit eNOS 
and additional treatment with indometacin to inhibit COX. DHA was cumulatively added (0.01 
– 30 µM) to induce vascular relaxation as indicated by the arrows.  
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Fig 3.6 Original representative traces demonstrating the effect of L-NAME (300 µM) and 
indometacin (10 µM) in DHA-induced relaxation of rat aorta. After initially obtaining the 
control response curve, changes in vascular tone were recorded following successive incremental 
treatments of the same arterial segment with L-NAME to inhibit eNOS and additional treatment 
with indometacin to inhibit COX. DHA was cumulatively added (0.1 – 30 µM) to induce vascular 
relaxation as indicated by the arrows.  
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Fig 3.7 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat mesenteric artery following inhibition of eNOS with L-
NAME (300 µM) and indometacin (10 µM). Using wire myograph, changes in n-3 PUFA (10 
nM – 30 µM) mediated relaxation were recorded by initially obtaining a control response curve 
followed by pre-treatment of the same arterial segment with the inhibitors (20 min). Data are 
expressed as mean±SEM. *P<0.05 indicates significant difference from the control curve as 
determined using two-way ANOVA with Bonferroni post-test. 
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Fig 3.8 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat aorta following inhibition of eNOS with L-NAME (300 µM) 
and indometacin (10 µM). Using wire myograph, changes in n-3 PUFA (100 nM – 30 µM) 
mediated relaxation were recorded by initially obtaining a control response curve followed by 
pre-treatment of the same arterial segment with the inhibitors (20 min). Data are expressed as 
mean±SEM. *P<0.05 indicates significant difference from the control curve as determined using 
two-way ANOVA with Bonferroni post-test. 
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3.2.3 Effect of n-3 PUFAs on ACh- and NONOate-mediated 
vasodilation in n-3 PUFA-mediated vascular relaxation 
As demonstrated in the previous sections 3.2.1 and 3.2.4, endothelium removal only 
partially attenuated relaxation elicited by acute application of n-3 PUFAs. Most of the 
research demonstrating the role of NO in the n-3 PUFA-induced vasodilation involves 
chronic supplementation with n-3 PUFAs. Therefore, the next objective was to 
investigate the effects of the pre-treatment of rat mesenteric artery with DHA in ACh-
induced vasodilation. NONOate, which is a NO donor that can cause endothelium-
independent relaxation, was also used to investigate the effect of DHA at the level of 
SMCs. The protocol (chapter 2, section 2.2.5.iii) involved preincubation of rat mesenteric 
artery with a low concentration of DHA (300 nM) for 1 h, followed by pre-constriction 
with U46619 and subsequent vasodilation using either ACh (endothelium dependent) or 
NONOate (endothelium independent). Fig 3.9 and 3.10 shows the representative traces 
demonstrating the effect of DHA in ACh- and NONOate-induced relaxation of rat 
mesenteric artery respectively. Pre-treatment of mesenteric artery with DHA did not 
modify the ACh-induced vascular relaxation (1 nM–3 µM) (Fig 3.11A) (n=6). However, 
significant potentiation in NONOate-induced relaxation (1 nM – 3 µM) of mesenteric 
artery was observed following arterial incubation with DHA [Log EC50; -6.96±0.09 
(Control) and -7.46±0.10 (300 nM DHA)] (Fig 3.11B) (n=7, P<0.05).  
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Fig 3.9 Original representative traces demonstrating the effect of DHA in ACh-induced 
relaxation of rat mesenteric artery. After initially obtaining the control response curve, changes 
in vascular tone were recorded following treatment of the same arterial segment with DHA (300 
nM) for 1 h. ACh was cumulatively added (0.001 – 30 µM) to induce vascular relaxation as 
indicated by the arrows.  
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Fig 3.10 Original representative traces demonstrating the effect of DHA in NONOate-
induced relaxation of rat mesenteric artery. After initially obtaining the control response 
curve, changes in vascular tone were recorded following treatment of the same arterial segment 
with DHA (300 nM) for 1 h. NONOate was cumulatively added (0.001 – 30 µM) to induce 
vascular relaxation as indicated by the arrows.  
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Fig 3.11 Concentration response curves demonstrating relaxation mediated by (A) ACh 
(n=6) and (B) NONOate (n=7) in rat mesenteric artery following treatment of the arteries 
with DHA (300 nM) for 1 h. Using wire myograph, changes in either ACh or NONOate (10 nM 
– 30 µM) mediated relaxation were recorded by initially obtaining a control response curve 
followed by pre-treatment of the same arterial segment with DHA. Data are expressed as 
mean±SEM. *Indicates P<0.05, significant difference from control curve assessed by two-way 
ANOVA followed by Bonferroni post-test. 
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3.2.4 Effect of CYP epoxygenase inhibition in n-3 PUFA mediated 
vascular relaxation 
The endothelium-dependent component observed with n-3 PUFA-induced vasodilation 
was not associated with the NO and COX pathway in both rat mesenteric artery and aorta, 
therefore I investigated CYP epoxygenase which is also found in the endothelium. 
Multiple electrophysiological studies have reported that acute application of CYP-
derived metabolites of n-3 PUFAs can directly activate BKCa channels present in vascular 
SMCs (Patterson et al. 2002; Hercule et al. 2007; Ye et al. 2002; Qian et al. 2018). 
Therefore, n-3 PUFA mediated relaxation of U46619 constricted arteries were recorded 
before and after the treatment of the arteries with clotrimazole (1 µM, 20 min) for the 
non-selective inhibition of CYP. Representative traces demonstrating the effect of 
inhibiting CYP in DHA-induced relaxation of rat mesenteric artery and aorta are shown 
in Fig 3.12 and Fig 3.13 respectively. DHA-induced relaxation was unaffected following 
inhibition of CYP epoxygenase in both rat mesenteric artery and aorta (Figs 3.14A and 
3.15A) (n=6 and 5, respectively). However, EPA-mediated relaxation was partially 
attenuated in both rat mesenteric artery [Log EC50; -6.20±0.03 (Control) and -5.56±0.06 
(Clotrimazole)] and aorta [Log EC50; -5.00±0.06 (Control) and -4.93±0.44 
(Clotrimazole)] following inhibition of CYP (Figs 3.14B and 3.15B) (n=5, P<0.05). 
Although the responses to EPA in rat aorta did not plateau, there was a rightward shift of 
the response curve following clotrimazole pre-treatment (Fig 3.15B) which was 
consistent with the mesenteric data (Fig 3.14B), further indicating the role of CYP40 in 
EPA-induced relaxation. Log EC50 and maximal relaxation (Emax) values for each 
experimental group are summarized in table 3.1.          
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Fig 3.12 Original representative traces demonstrating the effect of clotrimazole in DHA-
induced relaxation of rat mesenteric artery. After initially obtaining the control response 
curve, changes in vascular tone were recorded following treatment of the same arterial segment 
with clotrimazole (1 µM) to inhibit CYP epoxygenase. DHA was cumulatively added (0.1 – 30 
µM) to induce vascular relaxation as indicated by the arrows.  
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Fig 3.13 Original representative traces demonstrating the effect of clotrimazole in DHA-
induced relaxation of rat aorta. After initially obtaining the control response curve, changes in 
vascular tone were recorded following treatment of the same arterial segment with clotrimazole 
(1 µM) to inhibit CYP epoxygenase. DHA was cumulatively added (0.1 – 30 µM) to induce 
vascular relaxation as indicated by the arrows.  
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Fig 3.14 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=6) in rat mesenteric artery before and after the treatment of the 
arteries with clotrimazole (1 µM). Using wire myograph, changes in n-3 PUFA (10 nM – 30 
µM) mediated relaxation were recorded by initially obtaining a control response curve followed 
by pre-treatment of the same arterial segment with clotrimazole (20 min). Data are expressed as 
mean±SEM. *P<0.05 indicates significant difference from the control curve as determined using 
two-way ANOVA with Bonferroni post-test. 
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Fig 3.15 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat aorta before and after the treatment of the arteries with 
clotrimazole (1 µM). Data are expressed as mean±SEM. Using wire myograph, changes in n-
3 PUFA (100 nM – 30 µM) mediated relaxation were recorded by initially obtaining a control 
response curve followed by pre-treatment of the same arterial segment with clotrimazole (20 
min). *P<0.05 indicates significant difference from the control curve as determined using two-
way ANOVA with Bonferroni post-test. 
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3.2.5 Effect of SKCa, IKCa and BKCa inhibition in n-3 PUFA mediated 
vascular relaxation  
In the previous section 3.2.3, I demonstrated that the endothelium-dependent component 
of EPA-induced vasodilation involved the CYP epoxygenase. BKCa has been reported to 
be activated both directly by DHA and indirectly through CYP-derived metabolites of 
both n-3 PUFAs (Patterson et al. 2002; Lai et al. 2009; Ye et al. 2002; Hercule et al. 
2007). Therefore, to investigate whether the n-3 PUFA-mediated vasodilation involved 
activation of KCa channels, arteries were pre-treated in successive increments with L-
NAME (300 µM), apamin (50 nM, SKCa inhibitor), TRAM-34 (1 µM, IKCa inhibitor) and 
paxilline (1 µM, BKCa inhibitor) for 20 min. The relaxant effects of n-3 PUFAs were then 
assessed following constriction with U46619. 
3.2.5.i. Rat mesenteric artery 
Fig 3.16 shows the representative traces demonstrating the effect of KCa inhibition in 
DHA-induced relaxation of rat mesenteric artery. DHA-induced relaxation was 
unaffected following incubation of L-NAME (300 µM) and apamin (50 nM). However, 
partial attenuation in relaxation was observed with the additional inhibition of IKCa with 
TRAM-34 (1 µM) (Fig 3.17A) (n=5, P<0.05) and further reduction in relaxation was 
observed following subsequent addition of paxilline (1 µM) [Log EC50; -5.87±0.04 
(Control) and -5.37±0.06 (L-NAME+Apamin+TRAM-34+Paxilline)] (Fig 3.17A) (n=5, 
P<0.05). EPA-induced relaxation was also assessed in rat mesenteric artery, however, 
attenuation in relaxation was only observed via the inhibition of BKCa channels by 
paxilline [Log EC50; -5.41±0.02 (Control) and -5.11±0.07 (L-NAME+Apamin+TRAM-
34+Paxilline)] (Fig 3.17B, n=5, P<0.05). Since these experiments involved five 
consecutive concentration response curves that were acquired using the same piece of 
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tissue, additional experiments were conducted to confirm that these effects were real and 
exclusive to the action of n-3 PUFAs. Time control groups were ran in parallel with the 
test group using segments from the same piece of mesenteric artery to assess changes in 
the contractile tone. Although the concentration of U46619 had to be increased to match 
the original tone of the control curve, especially for the last concentration response curve 
(Fig 3.16B); there was no difference between the first and the fourth time control curve 
(Fig 3.18A and 3.18C respectively), demonstrating that a similar stable contractile tone 
could be achieved. Furthermore, randomizing the pre-treatments by individually 
inhibiting the BKCa channels with L-NAME and paxilline immediately after obtaining 
the first control response curve, also led to significant attenuation of DHA-induced 
relaxation [Log EC50; -6.34±0.05 (Control) and -5.89±0.06 (L-NAME+Paxilline)]. This 
is consistent  with my previous findings and further confirms the role of BKCa channels 
in DHA-induced vasodilation. Another experiment was also conducted with the 
additional blockade of SKCa and IKCa channels using a single pre-treatment (consisting 
of L-NAME, apamin, TRAM-34 and Paxilline) immediately after the first control curve. 
The findings from this experiment demonstrated further enhancement in the inhibition of 
DHA-induced relaxation [Log EC50; -6.25±0.07 (Control) and -5.57±0.07 (L-
NAME+Apamin+TRAM-34+Paxilline)] (Fig 3.19B), confirming the additional role of 
IKCa channels as indicated before (Fig 3.17A). Moreover, multiple incremental pre-
treatments with the KCa inhibitors did not modify EPA-induced relaxation of rat aorta 
(Fig 3.21B), further validating that the reported effects were elicited entirely due to the 
action of n-3 PUFAs rather than due to changes in the tissue’s responsiveness to n-3 
PUFAs.  
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3.2.5.ii. Aorta 
Studies indicate that the role of EDH as the predominant vasodilation mechanism 
increases as the arterial size decreases (Shimokawa et al. 1996). Consistent with these 
studies, my findings also demonstrate that IKCa and BKCa are involved in both DHA- and 
EPA-induced relaxation of rat mesenteric artery. Therefore, the next experiments 
focussed on investigating whether there was heterogeneity in the EDH component of n-
3 PUFAs between the conduit and resistance arteries. Rat aorta was examined using the 
same protocol as described earlier (see section 3.2.5). Representative traces 
demonstrating the effect of KCa inhibition in DHA-induced relaxation of rat aorta are 
shown in Fig 3.20. DHA-induced relaxation was unaffected following inhibition of eNOS 
with L-NAME (300 µM) and SKCa with apamin (50 nM) (Fig 3.21A). Similar to rat 
mesenteric artery, additional inhibition of IKCa with TRAM-34 (1 µM) partially 
attenuated DHA-induced relaxation (n=5, P<0.05) and subsequent inhibition of BKCa 
with paxilline (1 µM) led to further attenuation of relaxation [Log EC50; -5.25±0.04 
(Control) and -5.07±0.08 (L-NAME+Apamin+TRAM-34+Paxilline)] (n=5, P<0.05). In 
contrast to DHA, EPA-induced relaxation of rat aorta was unaffected following the 
blockade of eNOS and KCa channels (Fig 3.21B) (n=5). A summary of log EC50 and 
maximal relaxation (Emax) values for each experimental group can be found in table 3.1.          
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Fig 3.16 Original representative traces demonstrating the effect of inhibiting KCa in DHA-
induced relaxation of rat mesenteric artery. After initially obtaining the control response 
curve, changes in vascular tone were recorded following treatment (20 min) of the same arterial 
segment with L-NAME (300 µM) to inhibit eNOS, apamin (50 nM) to inhibit SKCa, TRAM-34 
(1 µM) to inhibit IKCa and paxilline (1 µM) to inhibit BKCa. DHA was cumulatively added (0.01 
– 30 µM) to induce vascular relaxation as indicated by the arrows. TRAM = TRAM-34 and Pax 
= paxilline. 
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Fig 3.17 Concentration response curves demonstrating relaxation mediated by (A) DHA 
and (B) EPA in rat mesenteric artery following inhibition of eNOS with L-NAME (300 µM), 
SKCa with apamin (50 µM), IKCa with TRAM-34 (1 µM) and BKCa with paxilline (Pax, 1 µM) 
(n=5). Using wire myograph, changes in n-3 PUFA (10 nM – 30 µM) mediated relaxation were 
recorded by initially obtaining a control response curve followed by pre-treatment of the same 
arterial segment with KCa inhibitors (20 min). Data are expressed as mean±SEM. *Indicates 
P<0.05, significant difference from control curve assessed by two-way ANOVA followed by 
Bonferroni post-test. Pax = paxilline. 
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Fig 3.18 Original representative traces demonstrating time control and DHA response 
curves. Two segments derived from the same rat mesenteric artery were used in parallel to 
initially obtain (A) time- and (B) DHA-control response curves. (C) Stable constriction with 
U46619 was observed in the fourth concentration response experiment as demonstrated by the 
time control group whereas (D) inhibition in relaxation was observed with the other tissue 
following pre-treatment (20 min) with L-NAME (300 µM), apamin (50 nM), TRAM-34 (1 µM) 
and paxilline (1 µM). DHA was cumulatively added (0.01 – 30 µM) to induce vascular relaxation 
as indicated by the arrows. TRAM = TRAM-34 and Pax = paxilline. 
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Fig 3.19 Concentration response curves demonstrating relaxation mediated by DHA in rat 
mesenteric arteries following pre-treatment with (A) L-NAME (300 µM) + paxilline (Pax, 1 
µM) and (B) L-NAME + apamin (50 µM) + TRAM-34 (1 µM) + paxilline (n=4). Using wire 
myograph, changes in DHA (100 nM – 30 µM) mediated relaxation were recorded by initially 
obtaining a control response curve followed by the subsequent pre-treatment of the same arterial 
segment with L-NAME+KCa inhibitor(s) (20 min). Data are expressed as mean±SEM. *Indicates 
P<0.05, significant difference from control curve assessed by two-way ANOVA followed by 
Bonferroni post-test. Pax = paxilline. 
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Fig 3.20 Original representative traces demonstrating the effect of inhibiting KCa in DHA-
induced relaxation of rat aorta. After initially obtaining the control response curve, changes in 
vascular tone were recorded following treatment (20 min) of the same arterial segment with L-
NAME (300 µM) to inhibit eNOS, apamin (50 nM) to inhibit SKCa, TRAM-34 (1 µM) to inhibit 
IKCa and paxilline (1 µM) to inhibit BKCa. DHA was cumulatively added (0.1 – 30 µM) to induce 
vascular relaxation as indicated by the arrows. TRAM = TRAM-34 and Pax = paxilline. 
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Fig 3.21 Concentration response curves demonstrating relaxation mediated by (A) DHA 
and (B) EPA in rat aorta following inhibition of eNOS with L-NAME (300 µM), SKCa with 
apamin (50 µM), IKCa with TRAM-34 (1 µM) and BKCa with paxilline (Pax, 1 µM) (n=5). 
Using wire myograph, changes in n-3 PUFA (100 nM – 30 µM) mediated relaxation were 
recorded by initially obtaining a control response curve followed by pre-treatment of the same 
arterial segment with KCa inhibitors (20 min). Data are expressed as mean±SEM. *Indicates 
P<0.05, significant difference from control curve assessed by two-way ANOVA followed by 
Bonferroni post-test. Pax = paxilline. 
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Table 3.1 Summary of log EC50 and maximal relaxation (Emax) values for each experimental 
group. Values were obtained using standard variable slope least squares fit based on the hill 
equation in GraphPad Prism 5. N.D. indicates not determined as GraphPad could not produce an 
optimal curve fit due to nature of the data points, resulting in ambiguity for the values obtained. 
L-N = L-NAME, TRAM = TRAM-34 and Pax = paxilline. 
Experiment Type of 
artery 
n-3 
PUFA 
Experimental 
Condition 
Log EC50 Emax (%) 
Log EC50 SEM (±) Emax (%) SEM (±) 
 
 
 
 
 
 
 
Endothelium 
removed 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=5 
Control -5.79 0.04 92.71 2.77 
Endothelium 
removed 
-5.56 0.05 95.80 4.56 
 
EPA 
n=6 
Control -5.43 0.02 100.60 2.11 
Endothelium 
removed 
-5.37 0.03 100.30 2.31 
 
 
 
Aorta 
 
 
DHA 
n=7 
Control -5.37 0.06 89.52 5.28 
Endothelium 
removed 
-5.30 0.07 91.33 7.03 
 
EPA 
n=6 
Control -5.25 0.03 94.19 2.13 
Endothelium 
removed 
-5.11 0.05 94.72 5.18 
 
 
 
 
 
 
 
 
 
 
L-NAME, 
Indometacin 
 
 
 
 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=5 
Control -5.80 0.03 95.89 1.93 
L-N -5.79 0.04 98.59 2.79 
L-N+ 
Indometacin 
-5.80 0.06 98.36 4.11 
 
EPA 
n=5 
Control -5.56 0.06 101.10 5.43 
L-N -5.68 0.06 99.46 4.99 
L-N+ 
Indometacin 
-5.58 0.08 102.40 7.35 
 
 
 
 
 
Aorta 
 
 
DHA 
n=5 
Control -5.30 0.05 90.08 4.29 
L-N -5.22 0.07 89.00 5.98 
L-N+ 
Indometacin 
-5.20 0.07 87.54 5.74 
 
EPA 
n=5 
Control -5.31 0.05 93.34 3.03 
L-N -5.27 0.04 92.13 2.12 
L-N+ 
Indometacin 
-5.25 0.03 92.41 1.32 
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Acetylcholine Mesenteric 
artery 
 
 
n=6 
Control -7.46 0.07 94.25 3.33 
300 nM DHA -7.72 0.17 92.11 5.53 
NONOate Mesenteric 
artery 
 
 
n=7 
Control -6.96 0.09 95.32 5.60 
300 nM DHA -7.46 0.10 100.2 4.50 
 
 
 
 
 
 
 
Clotrimazole 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=5 
Control -6.34 0.06 98.90 2.81 
Clotrimazole -6.16 0.06 96.84 2.76 
 
EPA 
n=5 
Control -6.20 0.03 94.80 1.94 
Clotrimazole -5.56 0.06 106.70 5.41 
 
 
 
Aorta 
 
 
DHA 
n =5 
Control -5.41 0.08 86.80 4.73 
Clotrimazole N.D. N.D. 77.76 2.07 
 
EPA 
n=5 
Control -5.00 0.06 97.05 9.89 
Clotrimazole -4.93 0.44 77.89 24.04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-NAME, 
Apamin, 
TRAM-34, 
Paxilline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
 
 
 
DHA 
n=5 
Control -5.87 0.04 96.66 2.72 
L-N -5.88 0.04 97.65 3.36 
L-N+ 
Apamin 
-5.82 0.04 96.34 3.10 
L-N+Apamin 
+TRAM 
-5.68 0.04 96.19 3.04 
L-N+Apamin 
+TRAM+Pax 
-5.37 0.06 91.20 5.31 
 
 
 
 
EPA 
n=5 
Control -5.41 0.02 99.13 1.72 
L-N -5.44 0.04 100.2 4.77 
L-N+ 
Apamin 
-5.43 0.03 98.31 3.38 
L-N+Apamin 
+TRAM 
-5.34 0.06 99.94 6.06 
L-N+Apamin 
+TRAM+Pax 
-5.11 0.07 96.29 8.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
DHA 
n=5 
Control -5.25 0.04 87.82 3.60 
L-N N.D. N.D. 77.73 2.10 
L-N+ 
Apamin 
N.D. N.D. 78.76 2.72 
L-N+Apamin 
+TRAM 
-5.28 0.06 71.98 4.28 
L-N+Apamin 
+TRAM+Pax 
-5.07 0.08 62.20 6.75 
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Aorta 
 
 
 
 
 
EPA 
n=5 
Control -5.19 0.06 91.54 5.08 
L-N -5.25 0.03 90.74 1.29 
L-N+ 
Apamin 
-5.24 0.03 89.89 1.56 
L-N+Apamin 
+TRAM 
-5.19 0.03 93.41 3.12 
L-N+Apamin 
+TRAM+Pax 
-5.10 0.05 91.16 4.72 
 
3.3 Summary 
There is evidence indicating that the endothelium-dependent vasodilation pathways are 
involved in the n-3 PFUA-mediated relaxation (Table 1.1). Consistent with these 
findings, my myograph experiments revealed that there was minor but a significant role 
of the endothelium in DHA mediated relaxation of rat mesenteric artery (Fig 3.3A-B) and 
EPA mediated relaxation in rat aorta (Fig 3.4B), demonstrating heterogeneity in the 
vasodilation mechanisms of n-3 PUFAs. Relaxation mediated by the acute application of 
both n-3 PUFAs did not involve NO and COX pathways (Fig 3.7-3.8). A postprandial 
study reported that enhancement in the vascular reactivity of healthy men was observed 
within few hours of consuming a fish oil rich meal (Jackson et al. 2009). Therefore, I 
investigated the effects of the pre-treatment of rat mesenteric arteries with DHA for 1 h. 
My findings indicated that the pre-treatment was associated with potentiation of 
NONOate-induced relaxation (Fig 3.11A). In contrast to NONOate, ACh-induced 
relaxation (Fig 3.11B) was unaffected by DHA, indicating that improvements in NO-
mediated relaxation perhaps occurs at the level of SMCs. In agreement with my findings, 
the in vivo human study involving n-3 PUFA supplementation also demonstrated that 
sodium nitroprusside (NO donor) was more potent in enhancing vascular reactivity 
compared to ACh (Jackson et al. 2009). It is possible that these effects are only observed 
during chronic exposure to n-3 PUFAs. In fact most of the studies that demonstrated the 
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role of NO in n-3 PUFA-induced relaxation, investigated the effects of n-3 PUFA 
supplementation lasting more than a week (Omura et al. 2001; Hirafuji et al. 2002; López 
et al. 2004; Raimondi et al. 2005). Indeed acute studies conducted using rat arterial tissue 
indicated an absence of NO component in relaxation elicited by both DHA and EPA, 
consistent with my findings (Fig 3.7 and 3.8) (Engler et al. 2000). Due to the current 
evidence, it is logical to suggest that the acute vascular relaxation observed with n-3 
PUFAs does not involve the endothelial production of NO, and any improvements in this 
component possibly requires chronic exposure to n-3 PUFAs.     
CYP epoxygenase is expressed in vascular ECs and can produce metabolites of DHA and 
EPA (EDPs and EPETEs respectively) that have been reported to elicit vasodilation, in 
various vascular beds such as mouse cerebral artery (Hercule et al. 2007), mouse 
mesenteric artery (Hercule et al. 2007), rat cerebral (Hercule et al. 2007) and rat coronary 
arteries (Wang et al. 2011) (Table 1.1). As a result, to further characterise the 
endothelium-dependent vasodilation pathways of n-3 PUFAs, I investigated the role of 
CYP epoxygenase. My findings demonstrate that CYP epoxygenase was only associated 
with EPA-induced relaxation of both arteries (Fig 3.14-3.15), indicating heterogeneity in 
vasodilation mechanism that can depend upon the type of n-3 PUFA. This also suggests 
that CYP-derived metabolites of EPA may be involved in activation of KCa channels as 
indicated by a previous study (Hercule et al. 2007). As a result, my next objective was to 
investigate the EDH pathway.  
Based on my findings, SKCa channels were not involved in n-3 PUFA-induced relaxation. 
Some studies have reported TP receptor-mediated inhibition SKCa channels in rat cerebral 
(McNeish and Garland 2007) and mesenteric arteries (Crane and Garland 2004). 
Therefore, it is possible that any potential SKCa component of n-3 PUFA-mediated 
vasodilation was lost due to the TP receptor-mediated pre-constriction of the arteries with 
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U46619. My findings demonstrated a novel role of the endothelial IKCa channels which 
was only observed with DHA-induced relaxation of both arteries (Fig 3.17A and 3.21A). 
Similarly, BKCa was also involved in DHA mediated vasodilation of both vascular beds 
(Fig 3.17A and 3.21A) and EPA mediated relaxation of the mesenteric artery (Fig 3.17B), 
further indicating heterogeneity in the mechanisms depending upon both the type of n-3 
PUFA and vascular bed. A summary of log EC50 and maximal relaxation (Emax) values 
for each experimental group can be found in table 3.1 for comparison. An interesting 
finding from the above experiments is the large residual relaxation that remained 
following blockade of the KCa channels, indicating the presence of other endothelium-
independent mechanisms. Therefore, my next objective was to characterise these 
unidentified pathways in rat mesenteric artery and aorta.  
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Chapter 4 
 
The role of TRPV4 in n-3 PUFA 
mediated vasodilation 
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4.1 Introduction 
TRPV4 is a non-selective cation channel with six transmembrane domains that is 
expressed in  vascular ECs and SMCs (Everaerts and Owsianik 2010). It is involved in 
different physiological processes throughout the body including osmoregulation, 
thermoregulation and vasodilation (Everaerts and Owsianik 2010). An increased influx 
of Ca2+ into the endothelium is one of the main mechanisms involved in initiating a 
cascade of vasodilation pathways including EDH which involves KCa channels (Edwards 
et al. 2010). Therefore, different mechanisms have been reported to be involved with 
TRPV4 mediated vasodilation including EDH and NO pathways following local Ca2+ 
influx via TRPV4 (Filosa et al. 2013; Sukumaran et al. 2013; Cabral and Garvin 2014).  
PUFAs such as AA have been reported to directly activate TRPV4 in human coronary 
arteries, resulting in vasodilation through activation of endothelial SKCa and IKCa 
channels (Zheng et al. 2013). EETs were also reported to activate TRPV4 present in mice 
mesenteric arteries through a similar mechanism involving the SKCa and IKCa, resulting 
in hyperpolarization and relaxation of adjacent vascular SMCs (Sonkusare et al. 2012). 
Furthermore, in rat cerebral (Earley et al. 2005) and mouse mesenteric arteries (Earley, 
Pauyo, et al. 2009), EETs were found to activate TRPV4 present in vascular SMCs 
resulting in the intracellular release of Ca2+ from SR and subsequent activation of BKCa. 
n-3 PUFAs have also been reported to activate other TRP channels such as transient 
receptor potential cation channel subfamily V member 1 (TRPV1) (Matta et al. 2007) 
and transient receptor potential cation channel, subfamily A, member 1 (TRPA1) (Motter 
and Ahern 2012). Futhermore, PUFAs with the greater amount of unsaturation and an n-
3 double bond were indicated to be more potent in activating PKC-phosphorylated 
TRPV1 channels (Matta et al. 2007). Both DHA and EPA were also reported to directly 
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activate TRPA1 channels expressed in HEK cells, using patch-clamp electrophysiology 
(Motter and Ahern 2012).  
My findings reported in chapter 3 demonstrated the role of IKCa and BKCa in DHA-
induced relaxation of both rat aorta and mesenteric artery along with EPA-induced 
relaxation of the rat mesenteric artery. Although there is evidence indicating TRPA1 
mediated vasodilation via KCa activation (Earley, Gonzales, et al. 2009; Sinha et al. 2015), 
current studies indicate that the expression of TRPA1 in the vasculature is limited to ECs 
present in cerebral arteries (Earley 2012). In contrast to TRPA1, TRPV4 channels have 
been reported to be expressed in both ECs and SMCs found in various arteries (Filosa et 
al. 2013). Furthermore, numerous studies indicate that TRPV4 can activate both BKCa 
and IKCa present in the vasculature and as a result, it is possible that TRPV4 channels 
may be the initial target of n-3 PUFAs resulting in subsequent activation of the 
downstream vasodilation signalling cascade involving the KCa. Based on these findings, 
the next experiments focused on investigating whether n-3 PUFAs could directly 
stimulate TRPV4 to activate KCa resulting in vasodilation. I initially used wire myograph 
(chapter 2, section 2.2) to investigate whether vascular relaxation mediated by both n-3 
PUFAs were modified following inhibition of TRPV4. I then created a stable cell line 
with inducible expression of TRPV4 (chapter 2, section 2.3) and used Fluo-4 AM based 
calcium imaging (chapter 2, section 2.7) to investigate whether the n-3 PUFAs directly 
modulated TRPV4 activity. Results obtained from each experiment are described in the 
following sections.  
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4.2 Results 
4.2.1 Effect of TRPV4 inhibition in n-3 PUFA mediated vascular 
relaxation 
As indicated earlier, TRPV4 is expressed in the vasculature and regulates vasodilation 
through different mechanisms including modulation of KCa. As my findings from chapter 
3 (section 3.2.5) demonstrated a component of EDH is involved with n-3 PUFA mediated 
vasodilation, I initially investigated whether n-3 PUFAs were indirectly modulating KCa 
through TRPV4 using wire myograph. Experimental protocol for wire myograph has 
been described in detail in chapter 2 (section 2.2). Briefly, the relaxant effect of n-3 
PUFAs were recorded before and after the incubation of arteries with a TRPV4 
antagonist, either RN-1734 (10 – 30 µM) or HC-067047 (1 µM), for 20 min. Results were 
expressed as mean±SEM of n experiments and statistical analysis was carried out using 
two-way ANOVA and Bonferroni post-hoc test. 
Representative traces from Fig 4.1 and Fig 4.2 demonstrate the effect of RN-1734 in 
DHA-induced relaxation of rat mesenteric artery and aorta respectively. In rat mesenteric 
artery, RN-1734 (30 µM) led to partial inhibition of DHA-induced vascular relaxation 
[Log EC50; -6.39±0.04 (Control) and -6.09±0.08 (RN-1734)] (Fig 4.3A) (n=6, P<0.05). 
Both DHA- and EPA-induced relaxation were unaffected following treatment of rat aorta 
with RN-1734 (Figs 4.3B-C, n=4-5, P<0.05). Additional experiments were not conducted 
using a higher cocentraiton of RN-1734 as it disrupted the maintenance of the contractile 
tone. This is possibly due to problems with the selectivity of blocker since it has been 
reported to inhibit other ion channels such as TRPV1 (IC50 > 100 µM) (Vincent et al. 
2009). 
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Experiments with HC-067047 (1 µM) were only conducted in rat aorta as it affected the 
stability of U46619-constricted tone in rat mesenteric artery. Representative traces from 
Fig 4.4 demonstrates the effect of HC-067047 in DHA-induced relaxation of rat aorta. 
Both DHA- and EPA-induced relaxation were unaffected by HC-067047 in rat aorta (Figs 
4.5A-B, n=5, P<0.05). A summary of log EC50 and maximal relaxation (Emax) values for 
each experimental group can be found in table 4.1 for comparison. 
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Fig 4.1 Original representative traces demonstrating the effect of RN-1734 (10 µM – 30 µM) 
in DHA-induced relaxation of rat mesenteric artery. After initially obtaining the control 
response curve using wire myograph, changes in the vascular tone were recorded following 
treatment of the same arterial segment with RN-1734 (20 min) to inhibit TRPV4. DHA was 
cumulatively added (0.01 – 30 µM) to induce vascular relaxation as indicated by the arrows.  
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Fig 4.2 Original representative traces demonstrating the effect of RN-1734 (10 µM) in DHA-
induced relaxation of rat aorta. After initially obtaining the control response curve using wire 
myograph, changes in the vascular tone were recorded following treatment of the same arterial 
segment with RN-1734 (20 min) to inhibit TRPV4. DHA was cumulatively added (0.1 – 30 µM) 
to induce vascular relaxation as indicated by the arrows.  
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Fig 4.3 Concentration response curves demonstrating the effect of RN-1734 (10 – 30 µM), a 
TRPV4 inhibitor, in relaxation mediated by (A) DHA in rat mesenteric artery (n=6), (B) 
DHA in rat aorta (n=5) and (C) EPA in rat aorta (n=4). Using wire myograph, changes in n-
3 PUFA (10 nM – 30 µM) mediated relaxation were recorded by initially obtaining a control 
response curve followed by consecutive pre-treatments of the same arterial segment with RN-
1734 (20 min).  Data are expressed as mean±SEM. *P<0.05 indicates significant difference from 
the control curve as determined using two-way ANOVA with Bonferroni post-test. 
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Fig 4.4 Original representative traces demonstrating the effect of HC-067047 (1 µM) in 
DHA-induced relaxation of rat aorta. After initially obtaining the control response curve using 
wire myograph, changes in the vascular tone were recorded following treatment of the same 
arterial segment with HC-067047 (20 min) to inhibit TRPV4. DHA was cumulatively added (0.1 
– 30 µM) to induce vascular relaxation as indicated by the arrows.  
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Fig 4.5 Concentration response curves demonstrating relaxation mediated by (A) DHA- and 
(B) EPA-induced relaxation of rat aorta (n=5) following inhibition of TRPV4 with HC-
067047 (1 µM). Using wire myograph, changes in n-3 PUFA (100 nM – 30 µM) mediated 
relaxation were recorded by initially obtaining a control response curve followed by pre-treatment 
of the same arterial segment with HC-067047 (20 min). Data are expressed as mean±SEM. 
*P<0.05 indicates significant difference from the control curve as determined using two-way 
ANOVA with Bonferroni post-test. 
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Table 4.1 Summary of log EC50 and maximal relaxation (Emax) values from each myograph 
experiments that were conducted to investigate the effects of TRPV4 inhibition. Values were 
obtained using standard variable slope least squares fit based on the hill equation in GraphPad 
Prism 5.  
 
Experiment Type of 
artery 
n-3 
PUFA 
Experimental 
Condition 
Log EC50 Emax (%) 
Log EC50 SEM (±) Emax (%) SEM (±) 
 
 
 
 
 
 
RN-1734 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=6 
Control -6.39 0.04 98.24 2.43 
RN-1734  
(10 µM) 
-6.27 0.06 97.11 3.28 
RN-1734  
(30 µM) 
-6.09 0.08 95.54 4.73 
 
 
 
Aorta 
 
 
DHA 
n=5 
Control -5.82 0.15 87.26 9.24 
RN-1734  
(10 µM) 
-5.84 0.19 78.55 9.69 
 
EPA 
n=4 
Control -5.31 0.06 87.08 2.28 
RN-1734  
(10 µM) 
-5.28 0.12 83.82 4.13 
 
 
 
HC-067047 
 
 
 
Aorta 
 
 
DHA 
n=5 
Control -5.70 0.42 92.38 34.54 
HC-067047 -5.64 0.13 86.27 9.28 
 
EPA 
n=5 
Control -5.18 0.08 87.82 7.08 
HC-067047 -5.11 0.06 89.30 5.93 
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4.2.2 Generation of HEK Flp-In T-REx-293 pcDNA5/FRT/TO and 
pcDNA5/FRT/TO+TRPV4-HA cell lines 
My myograph results indicated that TRPV4 was involved with DHA-induced relaxation 
in rat mesenteric artery. Therefore, the next step was to investigate whether n-3 PUFAs 
could directly activate TRPV4 channels. To this aim, I began by generating a stable cell 
line expressing the ion channel and using Fluo-4 AM based calcium imaging assay to 
examine channel activity. Methods used for creating the stable cell line has been 
described in detail in chapter 2, section 2.3. 
4.2.2.i Construction of recombinant plasmids: pcDNA5/FRT+TRPV4-HA 
PCR (chapter 2, section 2.3.1.i) was used to generate a 3’ end DNA segment of the 
TRPV4 gene without the stop codon to enable fusion of TRPV4 to the HA epitope tag 
present in the plasmid. The amplified DNA fragment was then analysed using sanger 
sequencing (chapter 2, section 2.3.1.ii). Restriction digests (chapter 2, section 2.3.1.iii) 
were then performed to generate the DNA fragments required for the construction of 
pcDNA5/FRT+TRPV4-HA plasmid (Fig 4.6). The following REs and plasmids were 
used to obtain the necessary fragments (chapter 2, table 2.4): 
a) pcDNA5/FRT/TO+TRPV4 (required fragment expected at 2663 bp) = Bam 
HI and Kpn I 
b) 3’ end DNA segment of TRPV4 (required fragment expected at 138 bp) = 
Kpn I  
c) pcDNA5/FRT+HA (required fragment expected at 4876 bp) = Eco RV and 
Bam HI 
The digested DNA was then loaded on an agarose gel and the fragments were separated 
using gel electrophoresis (chapter 2, section 2.3.1.iv). The required DNA fragments were 
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then excised from the gel and purified using QIAquick gel extraction kit (chapter 2, 
section 2.3.1.v) and subsequently ligated (chapter 2, section 3.1.vi). The ligated DNA 
was then used to transform Mach1 competent cells (chapter 2, section 2.3.1.vii) and the 
cells were spread onto agar plates. Single bacterial colonies were then screened by colony 
PCR (chapter 2, section 2.3.1.viii) using the primers, TRPV4 forward primer and BGH 
reverse. PCR samples were then analysed using gel electrophoresis and positive clones 
were identified in lanes 8 and 14 as shown in Fig 4.7A, indicated by single bands 
representing the PCR amplified DNA (604 bp). The clones were then inoculated 
overnight in 5 ml of sterile SOB with MgCl2 and ampicillin. After preparing a glycerol 
stock (chapter 2, section 2.3.1.ix) from the overnight culture, plasmid DNA was purified 
using QIAprep Spin Miniprep Kit (chapter 2, section 2.3.1.x). The purified plasmid DNA 
was then screened by restriction digest using Bam HI and Xho I followed by gel 
electrophoresis. Bands for the TRPV4+3’ end DNA segment-HA (predicted size, 2663 
bp) fragment and the remaining of the pcDNA5/FRT vector (predicted size, 5014 bp) 
were observed as shown in Fig 4.7B. The glycerol stock obtained from one of the positive 
clones was then used to inoculate a 250 ml culture and the DNA was purified using 
EndoFree Plasmid Maxi Kit (chapter 2, section 2.3.1.xi). DNA was screened again using 
sanger sequencing and restriction digest followed by gel electrophoresis. Bands for 
TRPV4+3’ end DNA segment-HA (predicted size, 2663 bp) fragment and the remaining 
of the pcDNA5/FRT vector (predicted size, 5014 bp) were observed (Fig 4.7C). 
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Fig 4.6 Vector map of the recombinant plasmid pcDNA5/FRT+TRPV4-HA. Primers 
(TRPV4 forward, TRPV4 reverse and BGH reverse), restriction enzyme sites (Bam HI, Kpn I and 
Xho I) and the different fragments (TRPV4, 3’ end with no stop codon and pcDNA5/FRT-HA) 
involved in the construction and analysis of the plasmid have been indicated. Figure was created 
using SnapGene 4.1.9. 
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Fig 4.7 Analysis of the recombinant plasmid pcDNA5/FRT+TRPV4-HA using agarose gel 
electrophoresis. (A) Colony PCR was used to identify single colonies of transformed Mach1 
cells with DNA containing the correct inserts. Positive clones were identified in lane 8 and 14 
indicated by single bands representing the PCR-amplified DNA (604 bp). Restriction digest with 
Bam HI and Xho I was used to analyse the plasmid following (B) small scale and (C) large scale 
plasmid preparation. Bands for the pcDNA5/FRT vector (expected at 5014 bp) and TRPV4+3’ 
end DNA segment-HA (expected at 2663 bp) fragment were observed. 
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4.2.2.ii Construction of recombinant plasmids: pcDNA5/FRT/TO+TRPV4-HA 
My aim was to create a stable cell line that allowed inducible expression of the TRPV4 
channels following tetracycline administration. Therefore, this required re-insertion of 
the HA tagged TRPV4 sequence without the stop codon into the pcDNA5/FRT/TO vector 
containing the tet operator 2 regions that allowed tetracycline-induced protein expression. 
The following REs and plasmids were used to obtain the necessary fragments (Fig 4.8) 
(chapter 2, table 2.4): 
a) pcDNA5/FRT+TRPV4-HA (required fragment expected at 2663 bp) = Bam 
HI and Xho I 
b) pcDNA5/FRT/TO (required fragment expected at 5081 bp) = Xho I and Bam 
HI 
The DNA fragments were initially separated using gel electrophoresis (chapter 2, section 
2.3.1.iv), extracted with QIAquick gel extraction kit (chapter 2, section 2.3.1.v) and 
subsequently ligated (chapter 2, section 2.3.1.vi). The ligated DNA was then used to 
transform Mach1 competent cells (chapter 2, section 2.3.1.vii) and the cells were spread 
onto agar plates. Colony PCR (chapter 2, section 2.3.1.viii) was then used to screen single 
bacterial colonies. DNA samples from each colony were analysed using gel 
electrophoresis. Positive clones were identified in lane 1 and 3 as shown by the single 
bands for the PCR-amplified DNA (predicted size, 604 bp) in Fig 4.9A. A 5 ml bacterial 
culture was then inoculated overnight for each clone and 1 ml of the inoculated culture 
was used for glycerol stocks (chapter 2, section 2.3.1.ix). The remaining culture was then 
used to purify the DNA using QIAprep Spin Miniprep Kit (chapter 2, section 2.3.1.x). 
The purified DNA was then screened through restriction digest followed by gel 
electrophoresis. The correct bands were observed for TRPV4+3’ end DNA segment-HA 
fragment (predicted size, 2663 bp) and the remaining of the pcDNA5/FRT/TO vector 
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(predicted size, 5081 bp) as shown in Fig 4.9B. The glycerol stock was then used to 
inoculate a 250 ml culture and the DNA was purified using EndoFree Plasmid Maxi Kit 
(chapter 2, section 2.3.1.xi). Single and double RE digest along with a control (undigested 
plasmid) was then used to assess the size and quality of the purified plasmid followed by 
gel electrophoresis (Fig 4.9C). Double RE digest with Bam HI and Xho I produced bands 
with the correct predicted sizes as described earlier. Single digest of the plasmid with 
either of the RE produced a single band confirming the presence of a single restriction 
site for each RE. The uncut plasmid produced three different bands each representing 
nicked circular, linear and supercoiled (highest intensity) plasmid from top to bottom (Fig 
4.9C). 
4.2.2.iii Detection of the expression of TRPV4-HA following PEI mediated stable 
transfection of the plasmids 
Using the techniques described in chapter 2 (section 2.3.2 and 2.3.3), PEI was used to 
stably transfect HEK Flp-In T-REx-293 cells with the recombinant plasmids generated 
in the earlier section. The Flp-In T-REx system allowed inducible expression of the gene 
of interest following exposure to tetracycline. Briefly, cells were plated in antibiotic-free 
DMEM medium (10% FBS, v/v) and divided into two groups which included a control 
group (HEKVO) that was transfected with just the plasmid vector, pcDNA5/FRT/TO, and 
another group transfected with the vector containing the gene of interest (HEKTRPV4), 
pcDNA5/FRT/TO+TRPV4-HA. The following day, the transfection mix was prepared at 
3:1 ratio of polyethylenimine (PEI) (9 µg/well) and pOG44+DNA (3 µg/well). The 
pOG44/DNA was prepared in 9:1 ratio (2.7 µg of pOG44:0.3 µg of either 
pcDNA5/FRT/TO or pcDNA5/FRT/TO+TRPV4-HA). The transfection mix was then 
added to each well and cells were incubated for 2-3 days. Cells were then selected using 
medium containing the appropriate antibiotics (chapter 2, table 2.1) which was replaced 
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every 2-3 days for 2-3 weeks. Single colonies of the cell line were then isolated (chapter 
2, section 2.3.4) and transferred into a 12 well plate. The clones were transferred to larger 
culture plates and flasks once they were confluent. Immunocytochemistry (chapter 2, 
section 2.5) and western blotting (chapter 2, section 2.6) were then used to detect the 
expression of TRPV4-HA following treatment of HEKVO and HEKTRPV4 with (+) and 
without tetracycline (0.1 µg/ml, 16 h). Using epifluorescent microscopy, TRPV4-HA 
immunoreactivity was undetectable in most of the uninduced HEKTRPV4 cells; however, 
few of these cells demonstrated some TRPV4-HA expression, indicating a possible 
leakage in the tetracycline-inducible expression system (Figure 4.10A). Other studies 
have also reported a similar leakage with the T-REx system (Liu et al. 2011; Cachat et 
al. 2014). Significant expression of TRPV4-HA was detected in HEKTRPV4+Tet cells (Fig 
4.10A) indicating that the expression system was functional. In addition, results from the 
western blot also revealed an immunoreactive band at approximately 98 kDa, the 
predicted molecular weight of TRPV4-HA, for HEKTRPV4+Tet cells only (Fig 4.10B). 
TRPV4-HA expression was undetectable in HEKVO+Tet and uninduced HEKTRPV4, further 
confirming the specificity of detection and a functional tetracycline inducible system in 
the HEKTRPV4 cells. Although expression of TRPV4 was not detected in the uninduced 
HEKTRPV4 cells using western blot, images obtained with immunocytochemistry revealed 
a possible leakage with the T-REx system, resulting in lower levels of TRPV4 expression. 
Immunocytochemistry is a technique that allows the visual detection of the target protein 
expression in a single cell and as a result is more sensitive compared to western blot. 
Therefore, it is possible that due to the lower levels of TRPV4 expression in the 
uninduced HEKTRPV4, western blot was not sensitive enough to detect any expression of 
these channels. In addition, some antibodies can only bind to the target proteins that are 
either in their denatured structure or in their native tertiary structure (Willingham 1999). 
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The conditions used for western blot results in denaturation of the protein molecules 
whereas proteins are fixed and are closer to their native structure with 
immunocytochemistry, therefore it is possible that this might have affected the antigen 
binding affinity of the primary antibody. However, tetracycline induction of 
HEKTRPV4+Tet cells clearly demonstrated TRPV4 expression with western blot and 
therefore the observed discrepancy was most likely due to the reduced protein levels of 
TRPV4 in the uninduced HEKTRPV4 cells. 
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Fig 4.8 Vector map of the recombinant plasmid pcDNA5/FRT/TO+TRPV4-HA. Primers 
(TRPV4 forward and BGH reverse), restriction enzyme sites (Bam HI and Xho I) and the different 
fragments (TRPV4+3’ end with no stop codon-HA and pcDNA5/FRT/TO) involved in 
construction of the plasmid have been indicated. Figure was created using SnapGene 4.1.9. 
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Fig 4.9 Analysis of the recombinant plasmid pcDNA5/FRT/TO+TRPV4-HA using agarose 
gel electrophoresis. (A) Using colony PCR, positive clones of transformed Mach1 cells were 
identified in lane 1 and 3 indicated by single bands representing the PCR-amplified DNA (604 
bp). Restriction digest was used to analyse the plasmid following (B) small scale and (C) large 
scale plasmid preparation. Bands for the pcDNA5/FRT/TO vector (expected at 5081 bp) and 
TRPV4+3’ end DNA segment-HA (expected at 2663 bp) fragment were observed following 
double restriction digest with Bam HI and Xho I. Single bands were observed following digestion 
with either of the enzymes. The undigested plasmid was separated into three fragments that 
represent nicked circular, linear and supercoiled DNA.  
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Fig 4.10 The effect of tetracycline on TRPV4-HA expression. Immunofluorescence and 
epifluorescent microscopy (20x objectives) of HEKTRPV4 cells using anti-HA antibody (green) 
and nuclear stain DAPI (blue), (A) TRPV4 signals were mostly absent in HEKTRPV4 cells 
(although TRPV4 signals were detected in a few cells, arrows). Significant expression of TRPV4 
(arrows) was detected in tetracycline (0.1 µg/ml) induced HEKTRPV4+Tet cells. Scale bar, 50 µm. 
(B) Western blot analysis for TRPV4-HA expression in HEKTRPV4 and HEKVO cells with (+) and 
without tetracycline. The immunoreactive band at ~98 kDa indicates expression of TRPV4 in 
induced HEKTRPV4+Tet cells. Bands were absent in HEKVO or HEKTRPV4 cells.  
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4.2.3 TRPV4 is not directly modulated by n-3 PUFAs 
PUFAs such as AA and EETs have been reported to directly activate TRPV4, resulting 
in subsequent activation of KCa that can lead to vasodilation (Zheng et al. 2013; Sonkusare 
et al. 2012; Earley et al. 2005; Earley, Pauyo, et al. 2009). My myograph results indicate 
the role of IKCa and BKCa along with TRPV4 in n-3 PUFAs, notably DHA mediated 
vascular relaxation. Therefore, I investigated whether the TRPV4 channels were directly 
modulated by n-3 PUFAs using the fluorescent calcium indicator, Fluo-4 AM. As 
described in chapter 2 (section 2.7), HEKVO and HEKTRPV4 cells were initially seeded 
onto a 6 well plate with poly-D-lysine and the following day tetracycline (0.1 µg/ml, 16 
h) was added to each well containing HEKTRPV4 cells. Cells were then washed and loaded 
in the dark with Fluo-4 AM (4 μM, 20 min, 37 °C). For some experiments HC-067047 
(1 µM), an inhibitor of TRPV4, was also added together with the Fluo-4 AM whereas 
some experiments involved the initial pre-treatment of the cells with either DHA or EPA 
(30 μM, 1 h). Cells were then washed and the coverslips were transferred into a 24 well 
plate to enable visualisation under the microscope. Baseline fluorescence was initially 
measured for 30 s prior to the administration of the drug [either n-3 PUFA (30 µM) or 
GSK (3 nM)] and the subsequent responses were measured for an additional 370 s 
followed by the application of ionomycin (10 µM, responses were measured for another 
200 s). GSK failed to elicit any significant changes in [Ca2+]i  with HEKVO cells (Fig 
4.11A and 4.12A-B), prior to the application of ionomycin. In uninduced HEKTRPV4 cells, 
GSK led to a significant increase in [Ca2+]i which was about half of the response 
generated by ionomycin (Fig 4.11B and 4.12A-B), confirming the presence of some 
leakage in the tetracycline-inducible expression system as mentioned earlier (Fig 4.10A). 
In tetracycline induced HEKTRPV4+Tet cells, GSK elicited significant increase in [Ca
2+]i 
that was comparable to the ionomycin response (Fig 4.11C, 4.12A-B). However, these 
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responses were completely abolished following treatment of HEKTRPV4+Tet cells with the 
HC-067047 (Fig 4.11D and 4.12A-B), indicating the presence of functional of TRPV4 
channels. The presence of n-3 PUFA-mediated activation of TRPV4 was then 
investigated with HEKTRPV4+Tet cells. Application of the vehicle (ethanol) used for the 
dilution of n-3 PUFAs along with DHA and EPA failed to elicit any significant increase 
in [Ca2+]i, as indicated by Fig 4.13 and Fig 4.14. Pre-treatment of the HEKTRPV4+Tet cells 
with either of the n-3 PUFA for 1h, also did not induce any significant changes in GSK-
induced calcium influx, as demonstrated by Fig 4.15 and 4.16.  
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Fig 4.11 Representative images of HEKVO and HEKTRPV4 cells loaded with Fluo-4 AM 
demonstrating the changes in [Ca2+]i at different time points, following acute application of 
GSK. Images indicate baseline fluorescence (1 sec), maximum fluorescence induced by GSK 
(GSK1016790A) (3 nM, 400 sec) and maximum fluorescence induced by ionomycin (10 µM, 
600 sec) in; (A) HEKVO, (B) HEKTRPV4, (C) HEKTRPV4+Tet and (D) HEKTRPV4+Tet pre-treated with 
HC-067047 (HC) (1 µM, 20 min). HEKTRPV4+Tet cells were pre-incubated with tetracycline (0.1 
µg/ml, 16 h) to induce TRPV4 expression. Fluorescence was measured with 40x objective lens 
using excitation and emission wavelengths of 488 nm and 506 nm respectively.  
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Fig 4.12 HEKTRPV4+Tet cells express functional TRPV4 channels. (A) Original traces and (B) 
bar graph demonstrating the changes in [Ca2+]i following the acute application of GSK 
(GSK1016790A) (3 nM) in HEKVO, HEKTRPV4 and HEKTRPV4+Tet cells pre-treated with or without 
HC-067047 (HC) (1 µM, 20 min). GSK and ionomycin (10 µM) were applied at 30 and 400 s 
respectively, as indicated by the arrows. Tetracycline (0.1 µg/ml, 16 h) was used to induce TRPV4 
expression in HEKTRPV4+Tet cells. *P<0.05 indicates significant difference from the GSK response 
in HEKVO cells as determined using one-way ANOVA with Bonferroni post-test (n=3). 
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Fig 4.13 Representative images demonstrating changes in [Ca2+]i at different time points. 
Images indicate baseline fluorescence (1 sec) and maximum fluorescence (400 sec) induced by 
(A) GSK (GSK1016790A) (3 nM) in HEKVO cells (control) and by (B) vehicle (ethanol), (C) 
DHA (30 µM), (D) EPA (30 µM) and (E) GSK in HEKTRPV4+Tet cells. The third column of images 
represents maximum fluorescence elicited by ionomycin (10 µM, 600 sec). HEKTRPV4+Tet cells 
were pre-incubated with tetracycline (0.1 µg/ml, 16 h) to induce TRPV4 expression. Fluorescence 
was measured with 40x objective lens using excitation and emission wavelengths of 488 nm and 
506 nm respectively. 
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Fig 4.14 Acute application of n-3 PUFAs did not elicit any significant changes in [Ca2+]i. (A) 
Original traces and (B) bar graph demonstrating the changes in [Ca2+]i following the acute 
application of GSK (GSK1016790A) (3 nM) in HEKVO cells along with vehicle (ethanol), DHA 
(30 µM), EPA (30 µM) and GSK in HEKTRPV4+Tet cells. Compounds and ionomycin (10 µM) were 
applied at 30 and 400 s respectively, as indicated by the arrows. Tetracycline (0.1 µg/ml, 16 h) 
was used to induce TRPV4 expression in HEKTRPV4+Tet cells. *P<0.05 indicates significant 
difference from the GSK response in HEKVO cells as determined using one-way ANOVA with 
Bonferroni post-test (n=3). 
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Fig 4.15 Representative images of HEKTRPV4+Tet cells pre-treated with or without n-3 PUFAs 
demonstrating the changes in [Ca2+]i at different time points. Images indicate baseline 
fluorescence (1 sec), maximum fluorescence (400 sec) induced by GSK (GSK1016790A) (3 nM); 
in HEKTRPV4+Tet cells (A) without any pre-treatments (control) and with the pre-treatment of (B) 
DHA (30 µM, 1 h) and (C) EPA (30 µM, 1 h), followed by maximum fluorescence induced by 
ionomycin (10 µM, 600 sec). HEKTRPV4+Tet cells were pre-incubated with tetracycline (0.1 µg/ml, 
16 h) to induce TRPV4 expression. Fluorescence was measured with 40x objective lens using 
excitation and emission wavelengths of 488 nm and 506 nm respectively. 
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Fig 4.16 Pre-treatment of HEKTRPV4+Tet cells with n-3 PUFAs did not alter GSK-mediated 
response. (A) Original traces and (B) bar graph demonstrating changes in [Ca2+]i following the 
acute application of GSK (GSK1016790A) (3 nM) in HEKTRPV4+Tet cells pre-treated with or 
without n-3 PUFA (30 µM, 1 h). GSK and ionomycin (10 µM) were applied at 30 and 400 s 
respectively, as indicated by the arrows. Tetracycline (0.1 µg/ml, 16 h) was used to induce TRPV4 
expression in HEKTRPV4+Tet cells. *P<0.05 indicates significant difference from the GSK response 
in HEKVO cells as determined using one-way ANOVA with Bonferroni post-test (n=3). 
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4.3 Summary 
Multiple studies have reported that PUFAs such as AA and EETs can stimulate TRPV4 
to subsequently activate KCa channels resulting in hyperpolarization and relaxation of 
vascular SMCs (Earley et al. 2005; Earley, Pauyo, et al. 2009; Zheng et al. 2013; 
Sonkusare et al. 2012). In chapter 3 (section 3.2.5), the role of IKCa and BKCa channels 
were demonstrated in DHA-mediated relaxation of both rat aorta and mesenteric artery 
along with EPA-mediated relaxation of the rat mesenteric artery. Therefore, the next 
experiments focussed on investigating whether TRPV4 was initially stimulated by n-3 
PUFAs which subsequently led to the activation of KCa channels resulting in relaxation 
of rat arteries. My myograph findings demonstrate that DHA-induced vascular relaxation 
was partially attenuated through the inhibition of TRPV4 with RN-1734 in rat mesenteric 
artery (Fig 4.3A), and the magnitude of inhibition appeared to be similar to the IKCa 
component observed previously (Fig 3.17A). However, RN-1734 did not affect both 
DHA- and EPA-induced relaxation of rat aorta (Figs 4.3B and 4.3C), indicating 
heterogeneity in the vasodilation mechanisms depending upon the vascular bed. 
Similarly, another TRPV4 blocker, HC-067047, also did not affect both DHA- and EPA-
induced relaxation of rat aorta (Figs 4.5A-B).  
To assess whether n-3 PUFAs were involved in the modulation of TRPV4, a stable cell 
line that allowed inducible expression of TRPV4 was generated using molecular cloning 
and PEI-mediated transfection of the recombinant plasmids (Fig 4.6-4.9). Epifluorescent 
microscopy and western blot was then used to confirm the expression of TRPV4-HA in 
HEKTRPV4+Tet cells (Fig 4.10). Using the calcium indicator, Fluo-4 AM, I then 
investigated whether the TRPV4 channels were functional and if the n-3 PUFAs could 
influence channel activity. In my negative control, HEKVO cells, GSK failed to evoke any 
changes in [Ca2+]i as shown in Fig 4.11A and 4.12. In uninduced HEKTRPV4 cells, 
  
191 
 
application of GSK led to some increase in [Ca2+]i  as demonstrated by Fig 4.11B and 
4.12, indicating the presence of some leakage in the tetracycline-inducible expression 
system. In tetracycline-induced HEKTRPV4+Tet cells, application of GSK led to significant 
calcium influx compared to HEKVO cells and this effect was completely abolished 
following additional treatment with HC067047 (Fig 4.11C-D and 4.12A). This 
demonstrated that the TRPV4 channels expressed in the stable cell line were functional. 
The effects of n-3 PUFAs were then investigated via acute application of both DHA and 
EPA. Both n-3 PUFAs failed to activate TRPV4 channels in HEKTRPV4+Tet cells (Fig 
4.13C-D and 4.14B). Pre-treatment of these cells with either of the n-3 PUFA for 1 h also 
did not elicit any significant changes in GSK-induced calcium influx (Fig 4.15 and 4.16).  
My myograph finding demonstrated that the blockade of TRPV4 can result in partial 
inhibition of DHA-induced relaxation in rat mesenteric artery. However, in HEKTRPV4+Tet 
cells, n-3 PUFAs failed to elicit any increase in [Ca2+]i. There is a possibility that TRPV4 
maybe indirectly modulated by metabolites of n-3 PUFA, similar to AA-derived EETs. 
Furthermore, the microdomains such as the localization of IKCa and TRPV4 in 
myoendothelial projections reported in native vascular ECs are not present in the stable 
HEK cells. There is also evidence indicating that n-3 PUFAs can only activate TRPV1 
channels following initial phosphorylation by PKC (Matta et al. 2007). Studies indicate 
that the opening of TRPV1 to certain stimuli such as heat, capsaicin and anandamide can 
be potentiated by PKC-mediated channel phosphorylation (Vellani et al. 2001). As a 
result, it can be speculated that the stable cells may lack these necessary microdomains 
and intracellular machinery required to observe any changes in [Ca2+]i, with the acute 
application of n-3 PUFAs. Consistent with my findings, a recent electrophysiological 
study also demonstrated that the acute application of EPA does not activate TRPV4 
channels expressed in HEK cells (Caires et al. 2017). However, an indirect interaction 
  
192 
 
between TRPV4 and n-3 PUFA was indicated, as overnight supplementation of vascular 
ECs with EPA was reported to enhance TRPV4 currents, due to an increase in cell 
membrane fluidity (discussed in chapter 6, section 6.3). To summarize, my findings along 
with other studies indicate that DHA does not directly affect the activity of TRPV4 
channels and the TRPV4 component of DHA-mediated relaxation, observed in rat 
mesenteric artery (Fig 4.3A), possibly involves an indirect activation of these channels. 
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Chapter 5 
 
The role of KATP in n-3 PUFA 
mediated vasodilation 
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5.1 Introduction 
Omega-6 PUFAs such as AA have been reported to induce vasodilation through different 
molecular mechanisms including activation of potassium channels. Studies using patch 
clamp electrophysiology have demonstrated that AA can directly activate BKCa channels 
present in SMCs derived from rabbit pulmonary artery (Kirber et al. 1992; Clarke et al. 
2002). Furthermore, numerous studies have indicated that CYP metabolites of AA 
(EETs) can also directly activate BKCa expressed in various mammalian arteries such as 
rabbit carotid artery (Dong et al. 1997), rat mesenteric artery (Adeagbo 1997), rat renal 
arteries (Zou et al. 1996), guinea pig coronary artery (Eckman et al. 1998), bronchial 
SMCs (Dumoulin et al. 1998) and bovine coronary arteries (Harder et al. 1984).  
There is also evidence indicating that EETs can activate other types of potassium 
channels including KATP (Ye et al. 2005; Ye et al. 2006). These channels are hetero-
octameric complexes composed of Kir6 and SUR subunits (Inagaki et al. 1995; Inagaki 
et al. 1996; Seino 1999). Expression of these channels has been reported in different types 
of cells including pancreatic, skeletal muscle, vascular endothelial and SMCs (Ashcroft 
et al. 1984; Spruce et al. 1985; Janigro et al. 1993; Dart and Standen 1993). KATP is 
involved in various physiological processes such as insulin secretion, cardiac arrhythmia 
(Ye et al. 2005; Ye et al. 2006; Lu et al. 2006) and vasodilation (Ashcroft and Rorsman 
1990; Tinker et al. 2014; Blanco-Rivero et al. 2008; Standen et al. 1989). Most of the 
studies investigating the effect of PUFAs on vascular KATP have been conducted using 
CYP-derived metabolites of AA (EETs). Depending upon the type of tissue, EETs have 
been reported to activate KATP through two different mechanisms; for example in cardiac 
myocytes, EETs can directly bind to the Kir6 subunit present in cardiac KATP resulting in 
reduction of channel sensitivity to ATP (Lu, Hoshi, et al. 2001; Lu et al. 2005), whereas 
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in rat mesenteric artery, EETs indirectly activate vascular KATP through PKA-dependent 
pathway (Ye et al. 2005; Ye et al. 2006; Lu et al. 2006).   
Similar to AA and EETs, n-3 PUFAs have also been reported to elicit vasodilation 
through activation of potassium channels. Studies demonstrate a direct activation of BKCa 
present in mouse aortic (Toshinori Hoshi, Wissuwa, et al. 2013) and rat coronary (Lai et 
al. 2009) SMCs by DHA. Furthermore, CYP metabolites of DHA (EDPs) also activate 
BKCa in porcine (Ye et al. 2002) and rat coronary arteries (Wang et al. 2011). Studies also 
indicate that CYP-derived metabolites of EPA (EpETEs) can activate BKCa present in 
SMCs derived from rat cerebral and mouse mesenteric arteries (Hercule et al. 2007). 
There is also some evidence indicating that both DHA (Sato et al. 2014) and EPA (Engler 
et al. 2000) can relax rat arteries through activation of the KATP channels. Myograph data 
from these studies demonstrated an inhibition in n-3 PUFA- and EDP-induced relaxation 
of rat aorta following blockade of KATP (Engler et al. 2000). However, there is currently 
no evidence in the literature indicating a direct modulation of these channels by n-3 
PUFAs. 
Kv7 channels have also been reported to be modulated by fatty acids such as AA and n-3 
PUFAs. These are voltage-gated potassium channels composed of five α subunits, Kv7.1-
7.5, that form homomeric and heteromeric complexes (Greene and Hoshi 2017). They 
are involved in the regulation of vascular tone and current evidence suggests that most of 
the α-subunits, excluding Kv7.2, are expressed in blood vessels (Ng et al. 2011). Studies 
have demonstrated that 12-lipoxygenase metabolites of AA can enhance M currents 
(Villarroel 1994; Yu 1995), which mainly involve Kv7.2 and Kv7.3 heteromers (Brown 
and Passmore 2009). Cardiac IKs channel which is composed of Kv7.1 and KCNE1 
subunits was also reported to be modulated by n-3 PUFAs (Osteen et al. 2010). DHA was 
found to enhance IKs currents in Xenopus oocytes which was dependent upon the presence 
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of KCNE1 subunit (Doolan et al. 2002). Another study also reported that dietary inclusion 
of n-3 PUFAs enhanced IKs currents in porcine ventricular myocytes (Verkerk et al. 
2006). In-depth studies revealed that acute administration of both n-3 PUFAs was 
involved in facilitating activation of IKs in guinea pig cardiomyocytes (Moreno et al. 
2015). Negatively charged n-3 PUFAs were also reported to enhance M currents in 
Xenopus oocytes by promoting channel opening (Liin et al. 2016). On the contrary, 
chronic administration of n-3 PUFAs could not enhance IKs currents and also attenuated 
the expression of  Kv7.1 in COS7 cells (Moreno et al. 2015).  
My myograph data from the earlier experiments (chapter 3, section 3.2.1 and 3.2.5) 
revealed that a significant amount of residual relaxation remained, following removal of 
endothelium and inhibition of KCa, indicating the presence of other endothelium-
independent vasodilation mechanism(s) that still allowed full relaxation of the arteries. 
Hyperpolarization of SMCs through opening of the potassium channels is one of the most 
important vasodilation mechanisms especially in resistance arteries, therefore the next set 
of experiments focussed on investigating this pathway. I initially used wire myograph 
(chapter 2, section 2.2) to investigate the effect of non-selective inhibition of potassium 
channels-induced hyperpolarization in n-3 PUFA mediated relaxation of both rat aorta 
and mesenteric artery. To characterise the potassium channels involved, I then 
investigated the role of KATP channels in n-3 PUFA mediated relaxation with wire 
myograph, using a KATP selective inhibitor (PNU37883A). To further investigate whether 
n-3 PUFAs could directly modulate KATP, I initially created a stable cell line expressing 
the Kir6.1 and SUR2B subunits (chapter 2, section 2.4). These stable cells were then used 
for whole cell patch clamp (chapter 2, section 2.8) to examine KATP channel activity. 
Finally, I also examined the role of Kv7 channels in n-3 PUFA mediated relaxation with 
wire myograph using a non-selective Kv7 inhibitor (XE991).  
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5.2 Results 
5.2.1 Effect of inhibiting potassium channel-induced 
hyperpolarization in n-3 PUFA mediated vascular relaxation 
Potassium channels have an important role in inducing vasodilation through 
hyperpolarization of vascular smooth muscle cells. Findings from the earlier experiments 
revealed that a significant amount of residual relaxation remained following removal of 
endothelium and inhibition of KCa with n-3 PUFA-induced relaxation (chapter 3, section 
3.2.1 and 3.2.5). Therefore, the next experiments focussed on characterising these 
unknown vasodilation mechanisms. High KCl Krebs (30 mM) can be used to alter the 
reversal potential for potassium ions which can lead to inhibition of intracellular 
potassium efflux, resulting in subsequent inhibition of hyperpolarization at physiological 
membrane potentials. As a result, I initially investigated the effect of high KCl Krebs (30 
mM) in n-3 PUFA mediated vasodilation using wire myograph (protocol described in 
chapter 2, section 2.2.5.ii). The relaxant effect of n-3 PUFAs was recorded before and 
after the incubation of arteries with high KCl Krebs for 20 min. Representative traces 
from Fig 5.1 and Fig 5.2 demonstrate the effects of high KCl Krebs in DHA-induced 
relaxation of rat mesenteric artery and aorta respectively. In rat mesenteric artery, 
incubation of high KCl Krebs led to significant inhibition and reduction of the efficacy 
of DHA to induce vascular relaxation [(30µM DHA; 96±0.9% (Control) and 35±7.6% 
(High KCl Krebs)] (Fig 5.3A) (n=6, P<0.05). Similarly, high KCl Krebs also inhibited 
EPA-induced relaxation of rat mesenteric artery although to a lesser extent [30µM EPA; 
98.2±0.26% (Control) and 69.3±4.4% (High KCl Krebs)] (Fig 5.3B) (n=5, P<0.05). 
DHA-induced relaxation was completely abolished following incubation with high KCl 
Krebs in rat aorta [30µM DHA; 89.4±2.3% (Control) and 2.6±3.2% (High KCl Krebs)] 
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(Figs 5.4A) (n=5, P<0.05). Similarly, EPA-induced relaxation was also abrogated 
following pre-treatment with high KCl Krebs [30µM EPA; 92.9±2.4% (Control) and 
9.4±4.1% (High KCl Krebs)] (Figs 5.4B) (n=5, P<0.05) 
5.2.2 Effect of KATP inhibition on n-3 PUFA mediated vascular 
relaxation 
The robust reduction and abrogation of n-3 PUFA mediated relaxation in rat mesenteric 
artery and aorta respectively, following pre-incubation with high KCl Krebs, strongly 
indicates that potassium channels are involved. As I have already demonstrated the role 
of IKCa and BKCa in n-3 PUFA-induced relaxation, I investigated KATP channels to further 
characterise the potassium channels involved using wire myograph (chapter 2, section 
2.2.5.ii). Experiments were initially conducted with glibenclamide, however, application 
of this inhibitor disrupted the maintenance of arterial tone. This was not surprising as 
previous studies have indicated that glibenclamide can act as a TP receptor antagonist 
(Cocks et al. 1990). Fig 5.5 and Fig 5.6 shows representative traces demonstrating the 
effect of PNU37883A (3 µM) in DHA-induced relaxation of rat mesenteric artery and 
aorta respectively. In rat mesenteric artery, PNU37883A caused significant inhibition of 
n-3 PUFA-induced relaxation that was more potent with DHA [30µM DHA; 91.9±0.9% 
(Control) and 54.3±12.3% (PNU37883A)] in comparison to EPA [30µM EPA; 
92.2±1.7% (Control) and 84.6±2.7% (PNU37883A)] (Fig 5.7A-B) (n=5, P<0.05). 
Similarly in rat aorta, PNU37883A-induced inhibition was also more potent with DHA-
mediated relaxation [30µM DHA; 86.8±1.5% (Control) and 12.2±3.7% (PNU37883A)] 
(Fig 5.8A) (n=5, P<0.05) when compared to the relaxant effects of EPA [30µM EPA; 
89.6±1.8% (Control) and 40±13.8% (PNU37883A)] (Fig 5.8B) (n=5, P<0.05). A detailed 
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summary of log EC50 and maximal relaxation (Emax) values for each experimental group 
can be found in table 5.1. 
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Fig 5.1 Original representative traces demonstrating the effect of high KCl Krebs (30 mM) 
in DHA-induced relaxation of rat mesenteric artery. After initially obtaining the control 
response curve using wire myograph, changes in the vascular tone were recorded following 
treatment of the same arterial segment with high KCl Krebs (20 min) to inhibit hyperpolarization 
induced by potassium channels. DHA was cumulatively added (0.01 – 30 µM) to induce vascular 
relaxation as indicated by the arrows.  
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Fig 5.2 Original representative traces demonstrating the effect of high KCl Krebs (30 mM) 
in DHA-induced relaxation of rat aorta. After initially obtaining the control response curve 
using wire myograph, changes in the vascular tone were recorded following treatment of the same 
arterial segment with high KCl Krebs (20 min) to inhibit hyperpolarization induced by potassium 
channels. DHA was cumulatively added (0.1 – 30 µM) to induce vascular relaxation as indicated 
by the arrows. 
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Fig 5.3 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=6) and (B) EPA (n=5) in rat mesenteric artery following inhibition of hyperpolarization 
mediated by potassium channels with high KCl Krebs (30 mM). Using wire myograph, 
changes in n-3 PUFA (10 nM – 30 µM) mediated relaxation were recorded by initially obtaining 
a control response curve followed by pre-treatment of the same arterial segment with high KCl 
Krebs (20 min). Data are expressed as mean±SEM. *P<0.05 indicates significant difference from 
the control curve as determined using two-way ANOVA with Bonferroni post-test. 
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Fig 5.4 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat aorta following inhibition of hyperpolarization mediated by 
potassium channels with high KCl Krebs (30 mM). Using wire myograph, changes in n-3 
PUFA (100 nM – 30 µM) mediated relaxation were recorded by initially obtaining a control 
response curve followed by pre-treatment of the same arterial segment with high KCl Krebs (20 
min). Data are expressed as mean±SEM. *P<0.05 indicates significant difference from the control 
curve as determined using two-way ANOVA with Bonferroni post-test. 
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Fig 5.5 Original representative traces demonstrating the effect of PNU37883A (3 µM) in 
DHA-induced relaxation of rat mesenteric artery. After initially obtaining the control response 
curve using wire myograph, changes in the vascular tone were recorded following treatment of 
the same arterial segment with PNU37883A (20 min) to inhibit KATP channels. DHA was 
cumulatively added (0.01 – 30 µM) to induce vascular relaxation as indicated by the arrows. 
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Fig 5.6 Original representative traces demonstrating the effect of PNU37883A (3 µM) in 
DHA-induced relaxation of rat aorta. After initially obtaining the control response curve using 
wire myograph, changes in the vascular tone were recorded following treatment of the same 
arterial segment with PNU37883A (20 min) to inhibit KATP channels. DHA was cumulatively 
added (0.1 – 30 µM) to induce vascular relaxation as indicated by the arrows. 
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Fig 5.7 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat mesenteric artery following inhibition of KATP channels with 
PNU37883A (3 µM). Using wire myograph, changes in n-3 PUFA (10 nM – 30 µM) mediated 
relaxation were recorded by initially obtaining a control response curve followed by pre-treatment 
of the same arterial segment with PNU37883A (20 min). Data are expressed as mean±SEM. 
*P<0.05 indicates significant difference from the control curve as determined using two-way 
ANOVA with Bonferroni post-test. 
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Fig 5.8 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat aorta following inhibition of KATP channels with PNU37883A 
(3 µM). Using wire myograph, changes in n-3 PUFA (100 nM – 30 µM) mediated relaxation 
were recorded by initially obtaining a control response curve followed by pre-treatment of the 
same arterial segment with PNU37883A. Data are expressed as mean±SEM. *P<0.05 indicates 
significant difference from the control curve as determined using two-way ANOVA with 
Bonferroni post-test. 
 
  
  
208 
 
Table 5.1 Summary of log EC50 and maximal relaxation (Emax) values from each myograph 
experiments that were conducted to investigate the effects of high KCl Krebs and 
PNU37883A. Values were obtained using standard variable slope least squares fit based on the 
hill equation in GraphPad Prism 5. N.D. indicates not determined as GraphPad could not produce 
an optimal curve fit due to nature of the data points, resulting in ambiguity for the values obtained.  
 
Experiment Type of 
artery 
n-3 
PUFA 
Experimental 
Condition 
Log EC50 Emax (%) 
Log EC50 SEM (±) Emax (%) SEM (±) 
 
 
 
 
 
 
 
High KCl 
Krebs 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=6 
Control -5.95 0.04 95.98 3.43 
High KCl 
Krebs 
-5.74 0.16 33.75 4.25 
 
EPA 
n=5 
Control -5.39 0.03 99.02 2.66 
High KCl 
Krebs 
-4.98 0.05 77.45 5.84 
 
 
 
Aorta 
 
 
DHA 
n=5 
Control -5.37 0.05 89.54 2.17 
High KCl 
Krebs 
N.D. N.D. N.D. N.D. 
 
EPA 
n=5 
Control -5.33 0.05 93.11 3.59 
High KCl 
Krebs 
-5.08 0.21 9.48 2.00 
 
 
 
 
 
 
PNU37883A 
 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=5 
Control -6.17 0.05 91.12 2.65 
PNU37883A -5.60 0.18 53.61 8.17 
 
EPA 
n=5 
Control -5.64 0.04 94.10 2.83 
PNU37883A -5.24 0.18 99.30 15.38 
 
 
 
Aorta 
 
 
DHA 
n=5 
Control -5.39 0.05 87.07 2.62 
PNU37883A -5.01 0.11 12.39 3.03 
 
EPA 
n=5 
Control -5.31 0.06 90.11 5.55 
PNU37883A -5.00 0.20 41.90 16.44 
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5.2.3 Generation of HEK Flp-In-293 pcDNA5/FRT and 
pcDNA5/FRT+SUR2B cell lines 
Using wire myograph, I have demonstrated that activation of potassium channels is 
perhaps the main mechanism that determines the vasodilation effect of n-3 PUFAs 
especially in rat aorta (Fig 5.4), likely via a hyperpolarisation mechanism. Further 
investigation of the potassium channels revealed that KATP has a major role in n-3 PUFA-
induced relaxation (Figs 5.7-5.8). Therefore, the next step was to investigate whether n-
3 PUFAs could directly modulate KATP. The KATP channel is a complex composed of four 
sulfonylurea receptor (SUR) subunits and four Kir6 subunits (Fig 1.10) (Shi et al. 2012). 
Most studies indicate that the vascular KATP channels, present in both ECs and SMCs, are 
mainly composed of Kir6.1 and SUR2B (Foster and Coetzee 2016). To this aim, I 
generated a stable cell line in a two-step process where the initial step involved the 
construction and transfection of one of the subunits, SUR2B, followed by construction 
and lentiviral transduction of Kir6.1. Detailed description of the methods used for 
creating the stable cell line can be found in chapter 2, section 2.4. 
5.2.3.i Construction of recombinant plasmids: pcDNA5/FRT and 
pcDNA5/FRT+SUR2B 
Restriction digests (chapter 2, section 2.3.1.iii) were performed to obtain the DNA 
fragments required for the construction of pcDNA5/FRT+SUR2B plasmid (Fig 5.9). The 
following REs and plasmids were used to obtain the necessary fragments (chapter 2, table 
2.4): 
a) pcDNA5/FRT (required fragment expected at 4246 bp) = Mfe I and Xho I 
b) pcDNA3+SUR2B (required fragment expected at 7069 bp) = Mfe I and  
Xho I  
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The digested DNA was then loaded on an agarose gel and the fragments were separated 
using gel electrophoresis (chapter 2, section 2.3.1.iv). The required DNA fragments were 
then excised from the gel and purified using QIAquick gel extraction kit (chapter 2, 
section 2.3.1.v) and subsequently ligated (chapter 2, section 2.3.1.vi). The ligated DNA 
was then used to transform Mach1 competent cells (chapter 2, section 2.3.1.vii). Plasmid 
DNA from five individual bacterial colonies was prepared using QIAprep Spin Miniprep 
Kit (chapter 2, section 2.3.1.x) from overnight cultures. After preparing glycerol stocks 
(chapter 2, section 2.3.1.ix) from the overnight cultures, plasmid DNA was then screened 
by restriction digest using Mfe I and Xho I, followed by gel electrophoresis. All clones 
produced the correct bands for the pcDNA5/FRT vector (predicted size, 4246 bp) 
fragment and the pcDNA3+SUR2B (predicted size, 7069 bp) fragment as shown in Fig 
5.10A. The glycerol stock obtained from one of the clones was then used to inoculate a 
250 ml culture and the plasmid DNA was purified using EndoFree Plasmid Maxi Kit 
(chapter 2, section 2.3.1.xi). Plasmid DNA was screened again using restriction digest 
followed by gel electrophoresis. Bands for the pcDNA5/FRT vector (predicted size, 4246 
bp) fragment and the pcDNA3+SUR2B (predicted size, 7069 bp) fragment were observed 
with Mfe I and Xho I (Fig 5.10B). An additional restriction digest with Afl II also produced 
the correct bands for the two fragments predicted at around 3528 and 7786 bp. 
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Fig 5.9 Vector map of the recombinant plasmid pcDNA5/FRT+SUR2B. Restriction enzyme 
sites (Afl II, Mfe I and Xho I) and the different fragments (pcDNA3+SUR2B and pcDNA5/FRT) 
involved in the construction and analysis of the plasmid have been indicated. Figure was created 
using SnapGene 4.1.9. 
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Fig 5.10 Analysis of the recombinant plasmid pcDNA5/FRT+SUR2B using agarose gel 
electrophoresis. Single restriction digest with Afl II and double digest with Mfe I and Xho I was 
used to analyse the plasmid following (A) small scale and (B) large scale plasmid preparation. 
Mfe I and Xho I produced two bands representing the pcDNA5/FRT vector (expected at 4246 bp) 
and pcDNA3+SUR2B (expected at 7069 bp) fragments. Afl II also produced two fragments that 
were expected at 3528 and 7786 bp. 
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5.2.3.ii Detection of the expression of SUR2B following lipofectamine mediated 
stable transfection of the plasmids 
As described in chapter 2 (section 2.4.3), lipofectamine was used to stably transfect HEK 
Flp-In-293 cells with the recombinant plasmids generated in the earlier section. Briefly, 
cells were plated in antibiotic-free DMEM medium (10% FBS, v/v) and divided into two 
groups which included a control group (HEKVC) that was transfected with the empty 
plasmid vector, pcDNA5/FRT, and another group (HEKSUR2B) transfected with the vector 
containing the gene of interest, pcDNA5/FRT+SUR2B (+POG44), as described in 
chapter 2, section 2.4. Following antibiotic selection, single clones of SUR2B were 
expanded and then analysed for expression by immunocytochemistry (chapter 2, section 
2.5) and western blotting (chapter 2, section 2.6). Using epifluorescent microscopy, 
SUR2B expression was absent in HEKVC cells whereas immunoreactivity was detected 
in HEKSUR2B cells (Fig 5.11A). Furthermore, western blot also confirmed the expression 
of SUR2B in HEKSUR2B cells (Fig 5.11B) whereas immunoreactive signals were absent 
in HEKVC cells. However, the immunoreactive band for SUR2B was observed at a higher 
molecular weight compared to the expected size of 174 kDa, indicating the involvement 
of either a post-translational modification or an SDS-resistant oligomer of SUR2B.   
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Fig 5.11 Expression of SUR2B subunits in HEKSUR2B. (A) Immunofluorescence and 
epifluorescent microscopy (40x objectives) were used to investigate HEKVC and HEKSUR2B cells 
using nuclear stain DAPI (blue) and anti-SUR2B antibody (green). Significant expression of 
SUR2B (arrows) was detected in HEKSUR2B cells whereas these signals were absent in HEKVC 
cells. Scale bar, 20 µm. (B) Western blot analysis for SUR2B expression in HEKVC and HEKSUR2B 
cells. The immunoreactive band indicates expression of SUR2B in HEKSUR2B cells.  
 
 
 
 
  
215 
 
5.2.4 Generation of HEK Flp-In-293 
pcDNA5/FRT+pLenti6.3/FRT/MCS and 
pcDNA5/FRT+SUR2B+pLenti6.3/FRT/MCS+Kir6.1 cell line 
There is evidence indicating that EETs can activate potassium channels such as KATP 
channels present in the vasculature, resulting in vasodilation (Ye et al. 2005; Ye et al. 
2006; Lu et al. 2006). Based on the findings from the myograph experiments, I 
demonstrated that KATP channels have a major role in n-3 PUFA-induced relaxation (Figs 
5.7-5.8). Therefore, the next step was to investigate whether n-3 PUFAs could directly 
modulate KATP. To this aim I generated a stable cell line expressing KATP channels 
(HEKKATP). As the vascular KATP isoform is composed of the SUR2B and Kir6.1 
subunits, this experiment of generating the HEKKATP cell line was divided into a two-step 
process. As demonstrated in the earlier section, the initial step involved the generation of 
a stable cell line expressing the SUR2B subunit. Therefore, my next objective was to 
virally transduce the other subunit, Kir6.1, into HEKSUR2B stable cells to enable the 
formation of the KATP channel complex in these cells. The detailed description of the 
methods can be found in chapter 2, section 2.4. 
5.2.4.i Construction of recombinant plasmids: pLenti6.3/FRT/MCS and 
pLenti6.3/FRT/MCS+Kir6.1 
The DNA fragments required for the construction of pLenti6.3/FRT/MCS+Kir6.1 
plasmid (Fig 5.12) were obtained using restriction digests (chapter 2, section 2.3.1.iii). 
The following REs and plasmids were used to obtain the necessary fragments (chapter 2, 
table 2.4): 
a) pLenti6.3/FRT/MCS (required fragment expected at 7639 bp) = Bam HI and 
Psp OMI 
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b) pcDNA3.1/Zeocin+ Kir6.1 (required fragment expected at 2200 bp) = Bam 
HI and Psp OMI 
The digested DNA was separated using gel electrophoresis (chapter 2, section 
2.3.1.iv) and the necessary DNA fragments were then excised from the gel and 
purified using QIAquick gel extraction kit (chapter 2, section 2.3.1.v) followed by 
ligation (chapter 2, section 2.3.1.vi). Mach1 competent cells were then transformed 
using the ligated DNA (chapter 2, section 2.4.1.ii). Plasmid DNA from four 
individual bacterial colonies was prepared using QIAprep Spin Miniprep Kit 
(chapter 2, section 2.3.1.x). After preparing glycerol stocks (chapter 2, section 
2.3.1.ix) from the overnight cultures, plasmid DNA was then screened by restriction 
digest using Afl II followed by gel electrophoresis. Only one of the clones (Lane 2) 
produced the correct bands representing the fragments of 
pLenti6.3/FRT/MCS+Kir6.1 plasmid with the predicted size of 2315, 3656 and 3936 
bp as shown in Fig 5.13A. The purified DNA from the positive clone was then 
transformed into Stbl3 competent cells (chapter 2, section 2.4.1.ii) and plasmid DNA 
from two individual bacterial clones was purified using QIAprep Spin Miniprep Kit. 
After preparing the glycerol stocks from the overnight cultures, plasmid DNA was 
then analysed using restriction digest (Afl II) and gel electrophoresis that revealed 
the presence of the correct bands as described earlier (Fig 5.13B). The glycerol stock 
obtained from the positive clone was then used to inoculate an initial 5ml culture 
followed by a 250 ml culture at 28 ℃ and the plasmid DNA was purified using 
EndoFree Plasmid Maxi Kit (chapter 2, section 2.3.1.xi). Finally, screening of the 
DNA with restriction digest (Afl II)  and gel electrophoresis revealed the presence of 
the correct bands for both bacterial clones (Fig 5.13C). 
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Fig 5.12 Vector map of the recombinant plasmid pLenti6.3/FRT/MCS+Kir6.1. Restriction 
enzyme sites (Afl II, Bam HI and Psp OMI) and the different fragments (pLenti6.3/FRT/MCS and 
pcDNA3.1/Zeocin+Kir6.1) involved in the construction and analysis of the plasmid have been 
indicated. Figure was created using SnapGene 4.1.9. 
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Fig 5.13 Analysis of the recombinant plasmid pLenti6.3/FRT/MCS+Kir6.1 using agarose 
gel electrophoresis. Restriction digest with Afl II was used to analyse the plasmid following (A) 
small scale (Mach1 culture), (B) small scale (Stbl3 culture) and (C) large scale (Stbl3 culture) 
plasmid preparation. Bands for the pLenti6.3/FRT/MCS+Kir6.1 vector were expected at 2315, 
3656 and 3936 bp. 
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5.2.4.ii Detection of the expression of Kir6.1 following lentiviral transduction 
of the plasmids 
The detailed protocol for lentiviral production and transduction of HEKSURB cells with 
Kir6.1 has been described in chapter 2 (section 2.4.4-2.4.5). Briefly, the Lenti-X 293T 
cells were initially seeded in 10 cm dishes coated with poly-D-lysine using antibiotic-
free DMEM medium (10% FBS, v/v). The cells were then divided into two groups to 
perform transfection with the recombinant plasmids, pLenti6.3/FRT/MCS (control) and 
pLenti6.3/FRT/MCS+Kir6.1 respectively. Based on the 3:1 ratio of PEI:plasmid DNA, 
the transfection mix was prepared in optimem and gently pipetted onto the cells followed 
by overnight incubation. The medium was then replaced with antibiotic free medium 
containing HEPES and FBS (10% v/v). Lentivirus was then purified using ViraBind 
lentivirus purification kit (Cell Biolabs) according to the manufacturer’s guidelines.  
HEKVC and HEKSUR2B cells were seeded in a 6 well plate and lentivirally transduced with 
the plasmid vector, pLenti6.3/FRT/MCS (HEKVC1) and pLenti6.3/FRT/MCS+Kir6.1 
(HEKKATP) respectively. Cells were then incubated in antibiotic-free medium for 72 h 
and transferred to 2x 10 cm dishes/well containing medium with the appropriate 
antibiotic (chapter 2, table 2.1) for selection. Dilution cloning (chapter 2, section 2.4.6) 
which involved serial dilution of the cells, resulting in the presence of 50-100 cells per 
10 cm dish, was used to obtain single colonies of the cell line. The clones were transferred 
to larger culture plates and flasks once they were confluent. Immunocytochemistry 
(chapter 2, section 2.5) and western blotting (chapter 2, section 2.6) were then used to 
detect the expression of Kir6.1. Confocal microscopy (chapter 2, section 2.5.4) revealed 
the presence of both Kir6.1 and SUR2B immunoreactivity in HEKKATP (Fig 5.14A). 
However, the expression of both KATP subunits were completely absent in HEKVC1 as 
shown in Fig 5.14A. Western blot also affirmed the expression of Kir6.1 in HEKKATP (Fig 
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5.14B) which was completely absent in HEKVC1 cells further confirming that the viral 
transduction was successful. However, the smeared immunoreactive band for Kir6.1 was 
observed at a considerably higher molecular weight compared to the expected size of 48 
kDa, indicating the involvement of either a post-translational modification or an SDS-
resistant oligomer of the subunit(s). As HEKKATP cells were transfected and transduced 
with both KATP subunits, it is possible that these oligomers could be made up of either 
Kir6.1 or SUR2B+Kir6.1 subunits.    
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Fig 5.14 Expression of KATP channels in HEKKATP. (A) Immunofluorescence and confocal 
microscopy (100x objectives) of HEKVC1 and HEKKATP cells using nuclear stain DAPI (blue), 
anti-SUR2B antibody (green) and anti-Kir6.1 antibody (red). Significant expression of SUR2B 
(arrows) and Kir6.1 (arrow heads) was detected in HEKKATP cells whereas these signals were 
absent in HEKVC1 cells. Scale bar, 10 µm. (B) Western blot analysis for Kir6.1 expression in 
HEKVC1 and HEKKATP cells. The immunoreactive band indicates expression of Kir6.1 in 
HEKSUR2B cells.  
 
  
  
222 
 
5.2.5 KATP is not directly modulated by n-3 PUFAs  
My myograph experiments indicated a significant role of KATP channels in the relaxation 
mediated by both DHA and EPA in rat aorta and mesenteric artery (Fig 5.7-5.8). 
However, a direct modulation of KATP channels by n-3 PUFAs is yet to be reported. 
Therefore, I investigated whether the KATP channels could be directly activated by n-3 
PUFAs. This study involved the use of patch clamp electrophysiology with the stable cell 
line expressing KATP channels (HEKKATP).  
The protocol used for the patch clamp technique has been described in chapter 2, section 
2.8. Briefly, HEKKATP cells were seeded in 6 well plates and incubated overnight. Using 
the microscope and the micromanipulator, pipette was lowered until it was just above a 
single cell. After recording the pipette resistance, giga Ω seal was formed and negative 
pressure was applied using mouth pipetting to achieve the whole cell configuration. The 
currents were recorded using a ramp protocol (-150 to +50 mV over 1 s with a holding 
potential of -80 mV). Following initial recording of the baseline currents for 10 s, 
pharmacological agents or n-3 PUFAs were applied until responses plateaued.     
Although ethanol was used for diluting n-3 PUFAs in the myograph experiments, 
perfusion of this solvent generated a biphasic response characterised by an increase and 
subsequent irreversible reduction in whole cell currents (data not shown). As a result, 
DMSO was the vehicle used for dissolving the pharmacological agents along with n-3 
PUFAs and therefore, it was essential to initially investigate the effects of DMSO on KATP 
channel activity. Application of DMSO (0.3 %) failed to elicit any changes in current 
density as indicated by the representative current density-voltage traces (Fig 5.15A) and 
time course traces (Fig 5.15B). KATP openers such as levcromakalim (10 µM) and 
pinacidil (10 µM), were then used to investigate whether the KATP channels expressed by 
the stable cell line were functional. Levcromakalim evoked significant increase in current 
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density compared to DMSO and this effect was inhibited following additional application 
of PNU37783A (3 µM) (Fig 5.15A-B). Similarly, pinacidil also activated KATP channels 
as indicated by the enhanced current density whereas additional administration of 
PNU377883A significantly reduced this effect (Fig 5.15C-D). Following confirmation of 
the presence of functional KATP channels in the stable cells, direct modulation of KATP 
activity by DHA (30 µM) was then investigated. DHA failed to directly activate KATP 
channels (n=4, P<0.05) (Fig 15 E-F) and significant increase in KATP currents were only 
achieved following additional application of either levcromakalim (n=2, P<0.05) or 
pinacidil (n=4, P<0.05) (Fig 5.15G).    
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Fig 5.15 DHA is not involved in the direct modulation of KATP channels. Whole cell current 
density-voltage traces and current density time course traces at +40 mV, indicating the effects of 
the acute application of (A) (B) DMSO (0.3%), Lev (10 µM), Lev+PNU (3 µM), (C) (D) Pin (10 
µM), Pin+PNU and (E) (F) DHA (30 µM), Lev, Lev+PNU. Currents were recorded using a ramp 
protocol (-150 to +50 mV) over 1 s with a holding potential of -80 mV. After recording the 
baseline currents for 10 s, the effects of n-3 PUFA/pharmacological agonist were then recorded 
until the responses plateaued. An inhibitor in combination with the agonist was then used until 
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maximum inhibition was achieved. (G) Bar graph indicating the mean current densities of 
HEKKATP at +40 mV. Values were taken from the peak current obtained following application of 
DMSO (0.3 %) (n=4), Lev (10 µM) (n=2), Lev+PNU (3 µM) (n=2), Pin (10 µM) (n=4), Pin+PNU 
(n=4) and DHA (30 µM) (n=4). Current density values were obtained by dividing the peak current 
(mV) at +40 mV by cell capacitance (pF). Data are expressed as mean±SEM. *P<0.05 indicates 
significant difference from DMSO-induced response as determined using one-way ANOVA with 
Bonferroni post-test. 
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5.2.6 Effect of Kv7 inhibition in n-3 PUFA mediated vascular 
relaxation  
Previous myograph experiments demonstrated that high KCl Krebs was marginally more 
effective compared to PNU37883A in inhibiting n-3 PUFA-induced relaxation, 
especially with EPA (Fig 5.1-5.8). This indicated that the other potassium were also 
involved besides KATP. Studies have demonstrated that n-3 PUFAs can directly activate 
Kv7 channels present in cardiac and neuronal cells (Doolan et al. 2002; Verkerk et al. 
2006; Moreno et al. 2015; Liin et al. 2016). Therefore, I investigated the role of these 
channels in n-3 PUFA-induced relaxation of rat aorta and mesenteric artery using wire 
myograph (protocol described in chapter 2, section 2.2). 
Concentration dependent relaxation produced by n-3 PUFAs were significantly inhibited 
following pre-treatment with the Kv7 channel blocker, XE991 (1 µM). Representative 
traces demonstrating the effect of XE991 in DHA-induced relaxation of rat mesenteric 
artery and aorta can be found in Fig 5.16 and Fig 5.17. In rat mesenteric artery, XE991 
partially attenuated DHA-induced relaxation (Fig 5.18A) (n=5, P<0.05). Similarly, EPA-
induced relaxation was also partially inhibited following pre-treatment with XE991 (Fig 
5.18B) (n=5, P<0.05). In rat aorta, pre-treatment with XE991 elicited significant 
inhibition of relaxation that was more potent with DHA [30µM DHA; 80.2±6.1% 
(Control) and 24.2±8.8% (XE991)] (Fig 5.19A) (n=6, P<0.05) in comparison to EPA 
[30µM EPA; 87.4±2.2% (Control) and 55.2±17.7% (XE991)]  (Fig 5.19B) (n=5, P<0.05). 
A detailed summary of log EC50 and maximal relaxation (Emax) values for each 
experimental group can be found in table 5.2. 
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Fig 5.16 Original representative traces demonstrating the effect of XE991 (1 µM) in DHA-
induced relaxation of rat mesenteric artery. After initially obtaining the control response curve 
using wire myograph, changes in the vascular tone were recorded following treatment of the same 
arterial segment with XE991 (20 min) to non-selectively inhibit Kv7 channels. DHA was 
cumulatively added (0.01 – 30 µM) to induce vascular relaxation as indicated by the arrows.  
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Fig 5.17 Original representative traces demonstrating the effect of XE991 (1 µM) in DHA-
induced relaxation of rat aorta. After initially obtaining the control response curve using wire 
myograph, changes in the vascular tone were recorded following treatment of the same arterial 
segment with XE991 (20 min) to inhibit non-selectively Kv7 channels. DHA was cumulatively 
added (0.1 – 30 µM) to induce vascular relaxation as indicated by the arrows.  
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Fig 5.18 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=5) and (B) EPA (n=5) in rat mesenteric artery following non-selective inhibition of Kv7 
channels with XE991 (1 µM). Using wire myograph, changes in n-3 PUFA (10 nM – 30 µM) 
mediated relaxation were recorded by initially obtaining a control response curve followed by 
pre-treatment of the same arterial segment with XE991 (20 min). Data are expressed as 
mean±SEM. *P<0.05 indicates significant difference from the control curve as determined using 
two-way ANOVA with Bonferroni post-test. 
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Fig 5.19 Concentration response curves demonstrating relaxation mediated by (A) DHA 
(n=6) and (B) EPA (n=5) in rat aorta following non-selective inhibition of Kv7 channels with 
XE991 (1 µM). Using wire myograph, changes in n-3 PUFA (100 nM – 30 µM) mediated 
relaxation were recorded by initially obtaining a control response curve followed by pre-treatment 
of the same arterial segment with XE991 (20 min). Data are expressed as mean±SEM. *P<0.05 
indicates significant difference from the control curve as determined using two-way ANOVA 
with Bonferroni post-test. 
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Table 5.2 Summary of log EC50 and maximal relaxation (Emax) values from each myograph 
experiments that were conducted to investigate the effects of Kv7 inhibition. Values were 
obtained using standard variable slope least squares fit based on the hill equation in GraphPad 
Prism 5. N.D. indicates not determined as GraphPad could not produce an optimal curve fit due 
to nature of the data points, resulting in ambiguity for the values obtained.  
 
Experiment Type of 
artery 
n-3 
PUFA 
Experimental 
Condition 
Log EC50 Emax (%) 
Log EC50 SEM (±) Emax (%) SEM (±) 
 
 
 
 
 
 
 
XE991 
 
 
 
 
 
 
 
Mesenteric 
artery 
 
 
DHA 
n=5 
Control -5.94 0.04 96.88 2.91 
XE991 -5.68 0.05 96.22 4.07 
 
EPA 
n=5 
Control -5.63 0.03 98.35 2.50 
XE991 -5.43 0.06 98.60 5.40 
 
 
 
Aorta 
 
 
DHA 
n=6 
Control -5.44 0.07 80.03 6.46 
XE991 -4.98 1.41 32.30 47.45 
 
EPA 
n=5 
Control -5.37 0.08 89.16 6.34 
XE991 N.D. N.D. 26.51 10.53 
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5.3 Summary 
My initial myograph findings demonstrated that the endothelial component of n-3 PUFA 
mediated relaxation involved CYP and IKCa channels. Subsequent characterization of the 
endothelium independent mechanisms revealed that BKCa channels were associated with 
n-3 PUFA mediated relaxation, consistent with previous studies (Ye et al. 2002; Hercule 
et al. 2007; Toshinori Hoshi, Wissuwa, et al. 2013). The residual relaxation that remained 
indicated the presence of other compensatory mechanisms that led to full relaxation of 
rat arteries by n-3 PUFAs.  
Numerous studies have indicated that PUFAs can modulate potassium channels such as 
BKCa, KATP and Kv7 (Ye et al. 2005; Ye et al. 2006; Liin et al. 2014; Moreno et al. 2015; 
Liin et al. 2016), therefore, the next objective was to investigate the role of 
hyperpolarization mediated by potassium channels in n-3 PUFA-induced relaxation using 
high KCl Krebs. The high KCl Krebs changes the reversal potential of potassium ions 
resulting in inhibition of potassium efflux and hyperpolarization at physiological 
membrane potentials. High KCl Krebs completely abolished n-3 PUFA-mediated 
relaxation in rat aorta (Fig 5.4) and in rat mesenteric artery, it led to significant attenuation 
in the vasodilation effect of n-3 PUFAs, especially with DHA, resulting in the reduction 
of the maximum relaxation response (Fig 5.3). My findings from previous myograph 
experiments demonstrated the role of BKCa and IKCa channels (Fig 3.17A-B and 3.21A) 
in the vasodilation effects of n-3 PUFAs, however in contrast to high KCl Krebs a large 
residual relaxation remained following blockade of these channels indicating the 
involvement of other potassium channels. Therefore, I investigated whether vascular 
KATP channels were also involved as there is some evidence indicating the role of these 
channels in n-3 PUFA-induced relaxation (Engler et al. 2000; Sato et al. 2014). Similar 
to high KCl Krebs, inhibition of KATP by PNU37883A also resulted in almost complete 
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abolishment and significant reduction of n-3 PUFA-mediated relaxation in rat aorta (Fig 
5.7A-B) and mesenteric artery (Fig 5.8A-B) respectively. Furthermore, the inhibitory 
effect of PNU37883A was more profound with relaxation mediated by DHA compared 
to EPA, indicating heterogeneity in vasodilation mechanisms of n-3 PUFAs.  
Due to evidence from the myograph experiments, my next objective was to investigate 
whether KATP channels were directly activated by n-3 PUFAs. Therefore, a stable cell 
line expressing KATP channels was generated by initially transfecting with SUR2B and 
subsequently transducing with Kir6.1 subunit. Using whole cell patch clamp, my findings 
demonstrated that both levcromakalim (Fig 5.15A-B) and pinacidil (Fig 5.15C-D) 
elicited significant increase in current density that was inhibited following additional 
administration of PNU37883A. This verified the presence of functional KATP channels in 
the stable cell line and therefore, the acute effects of DHA on KATP channel activity was 
then investigated. DHA failed to evoke any changes in KATP currents (Fig 5.15E-F), 
indicating an indirect modulation of KATP in n-3 PUFA-mediated relaxation. There is 
evidence demonstrating that activation of KATP by EETs initially involves the stimulation 
of Gαs protein and PKA dependent signalling in rat mesenteric SMCs (Ye et al. 2006). 
Therefore, it is possible that the HEKKATP stable cells lack these intracellular machineries 
required for KATP activation by n-3 PUFAs and as a result, future electrophysiological 
studies should involve the use of native vascular cells, to fully confirm whether n-3 
PUFAs indirectly modulate KATP channel activity.    
The findings from the myograph experiments (Fig 5.1-5.8) indicate that high KCl Krebs 
was marginally more effective compared to PNU37883A, in inhibiting the n-3 PUFA-
mediated relaxation, especially involving EPA. Furthermore, inhibition of KATP channels 
led to significant attenuation of EPA-induced relaxation, however there was still some 
residual relaxation that remained. Recent studies have indicated that Kv7 channels can be 
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directly activated by n-3 PUFAs (Liin et al. 2014; Moreno et al. 2015; Liin et al. 2016), 
however, there are no studies at the moment that have investigated whether these 
channels are involved in the relaxation effects of n-3 PUFAs. Therefore, I investigated 
the role of Kv7 channels in n-3 PUFA-mediated relaxation of rat aorta and mesenteric 
artery. Similar to the earlier myograph experiments, inhibition of Kv7 by XE991 led to 
significant attenuation of n-3 PUFA-induced relaxation that was more profound in rat 
aorta compared to the mesenteric artery (Fig 5.18-5.19). Furthermore, consistent with 
high KCl Krebs and PNU37883A data, XE991-mediated inhibition of relaxation was 
more profound with DHA compared to EPA. A detailed discussion regarding these 
findings can be found in chapter 6, section 6.5.   
Findings from my myograph experiments demonstrate the important role of potassium 
channels in vasodilation mediated by n-3 PUFAs. One of the most interesting findings 
from these experiments is the heterogeneity in the vasodilation mechanisms, as potassium 
channels seem to completely regulate n-3 PUFA-induced relaxation only in the rat aorta 
but not in the mesenteric artery. This is the first study to comprehensively investigate the 
role of KATP channels in conduit and resistance rat arteries using both DHA and EPA. 
Furthermore, my findings indicate that the vasodilation effect of n-3 PUFAs probably 
involves an indirect activation of KATP channels. This is also the first study to demonstrate 
the role of Kv7 channels in the n-3 PUFA-mediated relaxation of rat arteries. To 
summarize, potassium channels have an important role in the vasodilation effect of n-3 
PUFAs especially in the conduit rat aorta and my findings indicate that it mainly involves 
the KATP and Kv7 channels.  
  
  
235 
 
Chapter 6 
 
Discussion 
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6.1 Overview 
In 2015, CVDs were the cause of 31% of total deaths around the world which accounts 
for 17.7 million people, making it the leading cause of mortality (WHO 2017). There are 
many risk factors that are associated with CVDs such as hypertension, dyslipidaemia, 
obesity and endothelial dysfunction (Stewart et al. 2017). Endothelial dysfunction 
involves the impairment of endothelial vasodilation mechanisms resulting in an enhanced 
contractile state of the blood vessels. Both DHA and EPA have been reported to improve 
endothelial function and cardiovascular health especially in people suffering from CVDs 
(Mori 2014); and one of the mechanisms associated with these protective effects is the 
vasodilation of blood vessels. However, currently there is a gap in the literature as most 
studies only investigate one type of vascular bed and n-3 PUFA (see Table 1.1 for 
summary of these studies). In addition, there is extensive evidence indicating that 
vasodilation mechanisms can vary depending upon the size of blood vessels. For 
example, EDH has been reported to be more predominant in the smaller resistance 
arteries whereas NO is the main pathway involved in conduit arteries (Shimokawa et al. 
1996; Sandow and Hill 2000; Hilgers et al. 2006).  
Endothelial dysfunction can occur in both conduit and resistance arteries due to 
cardiovascular risk factors such as aging (Blackwell et al. 2004; Csiszar et al. 2007; 
Lesniewski et al. 2009). As previously mentioned, resistance arteries are mainly involved 
in the regulation of mean blood pressure as these vessels provide the greatest vascular 
resistance in systemic circulation (Pocock et al. 2013). In clinical practice, peripheral 
blood pressure is commonly measured by assessing the brachial artery and it has been 
extensively used as a predictor of CVDs. Although large conduit arteries, such as aorta, 
do not elicit moment to moment control of the overall mean arterial pressure, there is 
evidence indicating that the central aortic pressure might be the better indicator of 
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cardiovascular risk compared to peripheral pressure (McEniery et al. 2014). This is 
perhaps justified by the predominance of aortic over brachial pressure in major organs 
such as heart, kidney and brain (McEniery et al. 2014). Furthermore, central rather than 
peripheral pressure was reported to have a higher correlation with CVD surrogate 
markers such as left ventricular mass by various studies (Covic et al. 2000; Wang et al. 
2009; Roman et al. 2010). Central pressure can be elevated via inhibition of NO 
production resulting in the subsequent enhancement of arterial stiffness in conduit arteries 
such as aorta (Wilkinson et al. 2002; Wilkinson et al. 2004). The largest dampening of 
pulsatile ventricular pressure in the circulatory system is observed in the aorta (Marchais 
et al. 1993) and therefore, aortic stiffness has been reported to be the most reliable 
predictor (blood pressure-independent) of CVDs compared to other conduit arteries 
(Laurent et al. 2007). This is not surprising as stiffening of the aorta results in the 
reduction of vascular compliance and enhances the propagation speed of forward and 
reflected pulse pressure in arteries; this subsequently increases systolic central blood 
pressure, pulse pressure and cardiac afterload (Chen et al. 2017). These effects can be 
detrimental as it can promote ventricular hypertrophy (Yucel et al. 2015) and can damage 
the smaller peripheral arteries (Van Sloten et al. 2015). Multiple studies have 
demonstrated that aortic stiffening rather than elevated peripheral resistance is involved 
in isolated systolic hypertension (Wallace et al. 2007; McEniery et al. 2009). In addition, 
both structural and functional changes, such as aortic calcification and endothelial 
dysfunction respectively, were reported to enhance vascular stiffness (Wallace et al. 
2007; McEniery et al. 2009). Multiple studies have indicated the role of vasodilation in 
the reduction of arterial stiffness in major arteries. Nebivolol, a β-blocker that induces 
vasodilation, was reported to reduce arterial stiffness of large conduit arteries and this 
effect was inhibited following the blockade of eNOS (McEniery et al. 2004). 
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Furthermore, studies were conducted to compare the therapeutic efficacy of nebivolol 
against other non-vasodilating β-blockers. Nebivolol was found to be more effective in 
reducing aortic pulse pressure, central blood pressure and left ventricular wall thickness 
in patients with isolated systolic and untreated hypertension (Dhakam et al. 2006; 
Kampus et al. 2011). These studies reported that the improved effectiveness of nebivolol 
was due to its additional ability of eliciting NO-dependent vasodilation. Similarly, a 
nonselective α/β-blocker, arotinolol, was also reported to induce eNOS phosphorylation 
and NO-dependent vasodilation in aorta, resulting in the subsequent reduction of central 
blood pressure and aortic stiffness in spontaneously hypertensive rats (SHR) (Zhou et al. 
2014). Although resistance arteries are predominantly involved in the regulation of 
peripheral resistance and the overall mean blood pressure, these findings clearly 
demonstrate the therapeutic potential of reducing central aortic pressure and aortic 
stiffness via activation of vasodilation pathways. Therefore, my PhD project involved the 
use of both conduit (rat aorta) and resistance arteries (rat mesenteric artery) for the 
characterization of the mechanisms underlying DHA- and EPA-mediated vasodilation. 
To make the study physiologically relevant, relaxation to n-3 PUFA was elicited at 
concentrations of free fatty acid (100nM - 30 µM) that are attainable in human plasma 
following n-3 PUFA rich meal (~70 µM) (Conquer and Holub 1998; Newens et al. 2011).  
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6.2 The role of endothelium in n-3 PUFA-mediated vasodilation 
The endothelium is an important inner layer of the blood vessels and are involved in the 
release of various vasoactive factors that regulate the vascular tone. As described in 
chapter 1, section 1.2, different vasodilation mechanisms involving NO, PGI2, EETs and 
EDH are dependent upon the presence of endothelial layer. As a result, my initial 
experiments aimed at investigating the role of endothelium in n-3 PUFA-induced 
relaxation of rat aorta and mesenteric arteries using wire myograph (chapter 2, section 
2.2). In rat mesenteric artery, endothelium removal led to partial attenuation of DHA- 
mediated relaxation (Fig 3.3A). EPA-induced relaxation was also partially attenuated in 
the rat aorta (Fig 3.4B). These findings are consistent with multiple studies that have 
indicated the role of endothelium-dependent mechanisms in the vasodilation effect of n-
3 PUFAs (Omura et al. 2001; López et al. 2004; Raimondi et al. 2005). Results from my 
experiments demonstrate two interesting characteristics of n-3 PUFA-mediated 
relaxation which are; 1) endothelium removal could only partially attenuate relaxation 
mediated by n-3 PUFAs and therefore, a substantial amount of remaining residual 
relaxation indicates that the mechanisms are primarily endothelium-independent and 2) 
endothelial removal did not affect vasodilation mediated by EPA in rat mesenteric artery 
and DHA in rat aorta, indicating heterogeneity in the pathways involved that depended 
upon the type of artery and n-3 PUFA.    
As my experiments indicated that endothelium is involved in n-3 PUFA-mediated 
relaxation, I then characterized these mechanisms by initially investigating the NO 
pathway. Both animal and human studies have demonstrated that n-3 PUFAs can improve 
NO-mediated relaxation (Geleijnse et al. 2002; López et al. 2004; Raimondi et al. 2005). 
Different mechanisms have been reported such as upregulation of eNOS expression and 
reduction of ADMA (endogenous eNOS inhibitor), especially in rat aorta (López et al. 
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2004; Raimondi et al. 2005). However, my findings demonstrate that both DHA- and 
EPA-induced relaxation remained unaffected following eNOS inhibition in rat 
mesenteric artery and aorta (Fig 3.7-3.8). There is extensive evidence indicating the role 
of NO in the vasodilation effects of n-3 PUFAs, however, most of these murine studies 
have investigated the long-term effects of n-3 PUFA supplementation (Omura et al. 2001; 
Hirafuji et al. 2002; López et al. 2004; Raimondi et al. 2005). The shortest n-3 PUFA 
treatment that was used in these studies was 24 h, whilst most of them lasted for more 
than a week (Hirafuji et al. 2002). Furthermore, these chronic murine studies were 
conducted using vascular cells rather than arterial tissue and therefore lacked functional 
evidence. My project focused on investigating the acute vasodilation effects of n-3 
PUFAs in rat arteries and therefore, the duration of n-3 PUFA exposure could possibly 
explain the discrepancy. Similar to my findings, Engler et al (2000) also reported that 
NO was not involved in relaxation of rat aorta mediated by both DHA and EPA when 
acutely applied.  
 A postprandial study conducted in the University of Reading demonstrated that vascular 
reactivity (examined via the use of sodium nitroprusside and ACh) of healthy men was 
immediately improved within few hours of consuming a fish oil rich meal (Jackson et al. 
2009). Furthermore, these effects were reported to be more potent with sodium 
nitroprusside (a NO donor) compared to ACh (Jackson et al. 2009). Based on the findings 
from this study, I investigated the endothelium dependent and independent vasodilation 
effects of ACh and NONOate (a NO donor) respectively, following pre-treatment of rat 
mesenteric artery with DHA for 1 h. Similar to the postprandial study, my findings also 
demonstrated that the relaxation mediated by NONOate was significantly potentiated 
following pre-treatment with DHA for 1 h (Fig 3.11B). However, ACh-induced 
relaxation was not affected with the same pre-treatment protocol (Fig 3.11B). These 
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findings suggest that the acute effects of n-3 PUFAs mostly involve the activation of 
endothelium independent vasodilation pathways. Therefore, it is plausible to suggest that 
any significant improvements in NO-mediated vasodilation requires chronic 
administration of n-3 PUFAs. Based on the supplementation studies, the shortest n-3 
PUFA treatment that led to enhancement of NO production was 24 h (Hirafuji et al. 
2002). Therefore, it would be interesting to examine the effects of a 24 hr treatment of 
rat arteries with n-3 PUFAs. However, preliminary data from our lab demonstrated 
significant changes in the vascular tone and relaxation of rat aorta from the original 
response, following 24 hr culture of the arterial segments in normal medium (DMEM) 
(Personal communication, Dr Alister McNeish). As a result, experiments involving 
longer pre-treatments were not conducted. These findings indicate that perhaps an in vivo 
approach involving dietary supplementation with n-3 PUFAs, which was beyond the 
scope of my PhD, would be more suitable for investigating the chronic effects of these 
fatty acids in rat arteries. 
There is also evidence indicating that an increase in NO production following DHA 
supplementation can only be observed in conditions where the bioavailability of NO is 
compromised (Villalpando et al. 2015). For example, an elevated NO production with 
DHA was reported in orchidectomized rats, with significantly lower levels of NO, 
however, this was not observed with normal healthy rats (Villalpando et al. 2015). 
Furthermore, a meta-analysis also reported that the reduction of blood pressure due to n-
3 PUFAs was only observed in hypertensive patients and not in the healthy volunteers 
(Morris et al. 1993). Therefore, the findings from my experiments indicate that relaxation 
mediated by the acute application of n-3 PUFAs does not involve endothelial NO and 
different factors such as the type of animal models and duration of the treatment can 
influence the effects of n-3 PUFAs. It is possible that any significant improvements in 
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the NO pathway by these fatty acids can only be observed in patients with compromised 
NO-mediated vasodilation but not in healthy individuals.  
The endothelium is involved in the production of other vasoactive factors including COX 
metabolites of AA (PGI2) that can elicit vasodilation (chapter 2, section 2.2). n-3 PUFAs 
can compete with AA for endothelial enzymes such as COX and there is evidence 
indicating that supplementation with n-3 PUFAs can alter prostanoid production resulting 
in inhibition of noradrenaline- and angiotensin II-induced constriction of human forearm 
vasculature (Chin et al. 1993). Engler et al (2000) demonstrated that both DHA- and 
EPA-induced relaxations of rat aorta were sensitive to COX inhibition. However, my 
findings demonstrate that COX-derived metabolites are not involved in the relaxation 
mediated by both n-3 PUFAs in rat mesenteric artery and aorta (Fig 3.7-3.8). This 
disparity could be explained by the methodological differences between our studies, these 
include; the use of a different vasoconstrictor (noradrenaline) along with considerably 
larger and older WKY rats used by the Engler group (16–17 weeks, 355±11 g). Aging is 
a risk factor for CVDs and has been reported to promote endothelial dysfunction through 
different mechanisms such as impairment of NO production and PGI2-mediated 
relaxation  (Nicholson et al. 2009; Seals et al. 2011). Similar to the discussion regarding 
the NO pathway, it is possible that any significant improvements in the production of 
COX-derived metabolites of n-3 PUFAs can only be observed, following an impairment 
of this pathway. Another interesting difference between our studies was the potency of 
EPA-induced relaxation. The Engler et al (2000) study demonstrated that 30 µM of EPA 
could only elicit 30±4% relaxation of the contractile tone induced by noradrenaline, 
whereas in my experiments EPA normally mediated >80% relaxation in rat aorta [Emax; 
92.60±1.08 (Control) (n=30] (Table 6.1). Surprisingly, their findings also demonstrated 
that EPA could evoke concentration dependent contractile effects following pre-
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treatment of the aorta with indometacin whereas none of the treatments in my 
experiments led to n-3 PUFA-induced constriction. It is possible that this discrepancy in 
the potency of EPA is perhaps due to the difference in the vasoconstrictors that were 
used. However, our preliminary experiments with phenylephrine-constricted arteries 
demonstrated near maximal relaxation with DHA [30 µM; 89.53±4.32], similar to what 
we observed with U46619-induced constriction (Fig 6.1). Although we had problems 
with the stability of the phenylephrine mediated contractile tone as mentioned previously, 
in some experiments we were able to achieve sustained contraction and therefore data 
from Fig 6.1 were taken from these experiments. Furthermore, there is evidence 
indicating that n-3 PUFAs are involved in the inhibition of PGI2 production and COX-2 
expression in human ECs (Dudley et al. 1995; Lee et al. 2009), suggesting that perhaps 
COX-2 metabolites of n-3 PUFAs are probably not involved in vasodilation. In 
agreement with my findings, a study conducted with rats of the same age and weight as 
used in my experiments, demonstrated that DHA-induced relaxation of U46619-
constricted rat aorta was insensitive to the combined inhibition of COX with indometacin 
and eNOS via endothelium removal (Sato et al. 2014). As a result, it is important to 
consider that the type of vasoconstrictor and the age of the animal used in any 
investigation may significantly influence the mechanisms underlying n-3 PUFA 
mediated relaxation.  
In the endothelium, n-3 PUFAs compete with AA as substrates for another enzyme, the 
CYP epoxygenase(s), resulting in the production of DHA-derived EDPs and EPA-
derived EPETEs (22, 25, 60). Both EDPs and EPETEs have been reported to mediate 
vasodilation through activation of BKCa channels in various vascular beds such as mouse 
cerebral artery (Hercule et al. 2007), mouse mesenteric artery (Hercule et al. 2007), 
porcine coronary arteries (Ye et al. 2002), rat cerebral (Hercule et al. 2007) and rat 
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coronary arteries (Wang et al. 2011) (Table 1.1). Therefore, to characterize endothelium-
dependent mechanisms involved with n-3 PUFA-induced relaxation, I investigated the 
role of CYP epoxygenase in rat mesenteric artery and aorta. DHA-induced relaxation was 
not affected following inhibition of CYP in both arteries (Fig 3.14A and 3.15A 
respectively). However, EPA-induced relaxation was partially attenuated by CYP 
inhibition in rat aorta and mesenteric artery (Figs 3.14B and 3.15B). There is evidence 
indicating that the production of EETs can occur within 30 min of AA preincubation in 
cultured bovine coronary arterial ECs and canine coronary arteries (Rosolowsky et al. 
1990; Rosolowsky and Campbell 1996). Furthermore, studies report that the CYP 
enzymes have similar or even higher catalytic activities for n-3 PUFAs compared to AA 
(Arnold, Markovic, et al. 2010). Therefore, it is highly likely that CYP was involved in 
the production of EPETEs in our myograph experiments, since the tissues were exposed 
to n-3 PUFAs for more than 30 min. Furthermore, these findings also demonstrate the 
heterogeneity in the vasodilation mechanisms depending upon the type of n-3 PUFA, 
since clotrimazole-mediated inhibition was only observed with the relaxation elicited by 
EPA (Fig 6.2). The large residual relaxation with EPA following inhibition of CYP, 
indicates that other mechanisms are also involved. Therefore, results from these 
experiments demonstrate that the presence of CYP epoxygenase is not necessary to 
induce full vascular relaxation by n-3 PUFAs and is consistent with the previous 
myograph data (Fig 3.3-3.4) demonstrating minimal contribution of endothelium. As a 
result, my next objective was to investigate endothelium-independent pathways, I started 
by examining the role of BKCa channels in n-3 PUFA-mediated relaxation of rat aorta 
and mesenteric artery. 
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Table 6.1 Summary of log EC50 and maximal relaxation (Emax) values obtained from pooled 
control data for DHA and EPA in aorta and mesenteric arteries. These values were acquired 
using standard variable slope least squares fit based on the hill equation in GraphPad Prism 5. 
Data were analysed using two-tailed t-test. *P<0.05 indicates a significant difference from DHA 
in the artery studied. 
 
Type of 
artery 
n-3 
PUFA 
Log EC50 Emax (%) 
Log EC50 SEM (±) Emax (%) SEM (±) 
 
 
Mesenteric 
artery 
 
DHA 
n=40 
-6.03 0.04 96.54 0.49 
EPA 
n=35 
-5.61* 0.05 97.90 0.59 
 
 
Aorta 
DHA 
n=35 
-5.42 0.04 90.14 1.00 
EPA 
n=30 
-5.30* 0.03 92.60 1.08 
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Fig 6.1 (A) Original representative trace and (B) concentration response curves 
demonstrating relaxation mediated by DHA (n=5) in rat mesenteric artery preconstricted 
with phenylephrine. DHA was cumulatively added (0.1 – 30 µM) to induce vascular relaxation 
as indicated by the arrows. Data are expressed as mean±SEM and were taken from experiments 
with stable contractile tone. 
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Fig 6.2 Summary of the potential vasodilation mechanisms involved in n-3 PUFA-mediated 
relaxation of rat mesenteric artery and aorta preconstricted with U46619. Pathways that 
have been previously reported are indicated by the solid arrows whereas dotted arrows represent 
hypothetical pathways based on my findings. n-3 PUFAs can enter the cytosol of the endothelium 
either through diffusion from the plasma or from the phospholipid bilayer via the activity of 
phospholipase A2 (PLA2); (1) CYP epoxygenase can convert EPA into EpETEs, activating BKCa. 
IKCa may be potentially activated by (2) EpETEs, (3) EPA and (4) DHA. (5) Similar to EpETEs, 
EPA might also directly activate BKCa channels. (6) DHA is involved in the direct activation of 
BKCa (Toshinori Hoshi, Wissuwa, et al. 2013). (7) Both n-3 PUFAs may enter the cytosol of 
vascular SMCs via diffusion or release from the phospholipid bilayer due to the activity of PLA2 
and directly activate BKCa. (8) EpETEs may elicit arterial relaxation through KCa-independent 
mechanisms which could involve other potassium channels such as KATP and Kv7. BKCa = large 
conductance calcium activated potassium channels, DHA = docosahexaenoic acid, EPA = 
eicosapentaenoic acid, EpETEs = epoxyeicosatetraenoic acids and IKCa = intermediate 
conductance calcium activated potassium channels. (Limbu et al. 2018) 
 
  
248 
 
Various endothelial factors such as EETs and NO can activate BKCa channels expressed 
in SMCs resulting in subsequent hyperpolarization and vasodilation (Dimitropoulou et 
al. 2007; Félétou and Vanhoutte 2009) (chapter 1, section 2.5). As mentioned earlier, 
there is extensive evidence indicating that CYP-derived metabolites of n-3 PUFAs are 
involved in activation of BKCa channels present in SMCs. Furthermore, EDPs were 
reported to be 1000 times more potent in activating BKCa channels compared to AA-
derived EETs (Ye et al. 2002). Both DHA and EPA (to a lesser extent) were reported to 
directly activate BKCa channels in cell-free patches, using path clamp electrophysiology 
(Toshinori Hoshi, Wissuwa, et al. 2013). Therefore, I investigated the role of BKCa 
channels in DHA- and EPA-mediated relaxation of rat aorta and mesenteric artery. 
Consistent with previous studies, inhibition of BKCa led to significant attenuation in the 
relaxation effect of DHA in both rat mesenteric artery and aorta (Figs 3.17A and 3.21A 
respectively). Furthermore, DHA might be directly activating these channels as CYP 
metabolites were not involved (Fig 3.14A and 3.15A). However, there is also a possibility 
that lipoxygenase metabolites of DHA such as 17S-HDHA could be involved in the 
activation of BKCa channels (Li et al. 2011). The vasodilation effect of EPA was also 
investigated, and my findings demonstrate that the relaxation was sensitive to the 
blockade of BKCa channels in rat mesenteric artery (Fig 3.17B), whereas relaxation in rat 
aorta was unaffected. As CYP was associated with the vasodilation effect of EPA in rat 
mesenteric artery (Fig 3.14B), it is possible that EPETEs are involved in the activation of 
BKCa channels. Therefore, my findings indicate that BKCa is associated with DHA-
induced relaxation in both arteries. However, with EPA-induced relaxation it was only 
involved in the mesenteric artery, indicating heterogeneity in the vasodilation pathway 
that can depend upon the type of artery and n-3 PUFA (Fig 6.2). Studies indicate that n-
3 PUFAs can activate BKCa channels by binding to the S5 and S6 pore forming segments 
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of the α subunits (Toshinori Hoshi, Xu, et al. 2013). Additionally, the first transmembrane 
segment and the N-terminus present in the β subunits of the BKCa channel complex are 
also involved in n-3 PUFA binding (T. Hoshi et al. 2013). Using PUFAs with various 
acyl chain lengths and double bonds, a study demonstrated that DHA elicited the largest 
enhancement of BKCa currents (Toshinori Hoshi, Xu, et al. 2013). EPA and AA were less 
effective compared to DHA, however both PUFAs evoked similar levels of amplification 
of the BKCa currents (Toshinori Hoshi, Xu, et al. 2013). Although EPA (C20:5) is 
composed of an additional double bond compared to AA (C20:4), both PUFAs are made 
up of 20-carbon chains; suggesting that the increased effectiveness of DHA (C22:6) was 
due to its longer acyl length and not due to the additional double bond. This is consistent 
with our data since the blockade of BKCa with paxilline was more effective in inhibiting 
relaxation induced by DHA compared to EPA in both arteries (Fig 3.17 and 3.21). 
Depending upon the cardiovascular disorder and the type of artery, alteration of BKCa 
expression has been reported by various studies. For example, a decrease in the 
expression of BKCa α subunit was reported in pulmonary artery derived from rats with 
pulmonary hypertension (Bonnet et al. 2003). However, in mesenteric arteries, which is 
involved in regulation of blood pressure, an enhancement of β1 subunit expression of the 
BKCa channels was reported in SHR (Chang et al. 2006). Furthermore, this study also 
demonstrated that an increase in expression was only observed once the animals were 
hypertensive and the reduction of blood pressure with captopril (an angiotensin-
converting enzyme inhibitor) was able to reverse this effect. These findings suggest that 
the BKCa channels may have an important role as a compensatory vasodilation 
mechanism in hypertension and therefore the blood pressure lowering effects reported 
with n-3 PUFAs in hypertensive patients, possibly involves n-3 PUFA mediated 
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activation of these channels (Geleijnse et al. 2002; Campbell et al. 2013; Miller et al. 
2014). 
The EDH response can be initiated by an increase in [Ca2+]i that activates SKCa and IKCa 
channels, resulting in hyperpolarization of ECs which can electrically spread to SMCs, 
via myoendothelial gap junctions, eventually causing vasodilation (Chapter 1, section 
1.2.3). Currently, there are no studies demonstrating the role of SKCa and IKCa channels 
in n-3 PUFA-mediated relaxations. My findings demonstrate that SKCa channels are not 
involved in the relaxation effect of both DHA and EPA in rat aorta and mesenteric artery 
(Fig 3.17 and 3.21). There is evidence indicating that TP receptors can inhibit SKCa 
channels in rat cerebral (McNeish and Garland 2007) and mesenteric arteries (Crane and 
Garland 2004). This was further confirmed by subsequent studies demonstrating that the 
inhibitory mechanism involved activation of Rho/ROCK signalling by TP receptors 
(McNeish et al. 2012; Gauthier et al. 2014). As my myograph experiments involved 
initial preconstriction of rat arteries with a TP receptor agonist (U46619), it can be 
speculated that any potential SKCa component of n-3 PUFA-induced relaxation was 
disguised due to the agonist. I also investigated IKCa channels using both n-3 PUFAs in 
rat arteries. My findings demonstrate an IKCa component in DHA-induced relaxation of 
both rat mesenteric artery and aorta (Figs 3.17A and 3.21A respectively). This is a novel 
finding that not only demonstrates the role of IKCa in the vasodilation effect of DHA, but 
also heterogeneity in the vasodilation mechanisms, as IKCa was not involved in EPA-
mediated relaxation (Fig 6.2). In contrast to my findings which investigated arterial 
tissues, DHA has been reported to inhibit IKCa channel activity in human embryonic 
kidney (HEK) cells (Kacik et al. 2014). This discrepancy might have occurred due to the 
restriction of arterial IKCa channels to signalling microdomains in the endothelium, where 
activation of associated channels such as TRPV4 regulates IKCa-mediated 
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hyperpolarization (Sonkusare et al. 2012); it is possible that HEK cells lack these 
microdomains and the intracellular machinery, therefore the effects observed are perhaps 
due to an indirect stimulation of IKCa channels by DHA in the native tissue.  
Depending upon the type of CVD, there is evidence indicating that some vasodilation 
pathways are significantly impaired whereas other pathways can act as compensatory 
mechanisms; for example, a study with SHRs demonstrated that an increased cholesterol 
intake enhanced the production of EDHF-like factors whereas NO production was 
inhibited (Kagota et al. 1999). Furthermore, EDH-like response was also reported to have 
a compensatory role that prevented the development of hypertension in eNOS/COX KO 
mice (Scotland et al. 2005). Studies indicate that the expression of endothelial KCa 
channels increases with decreasing arterial size in rats (Sandow and Hill 2000; Hilgers et 
al. 2006). This has also been validated by human studies that have demonstrated the 
expression and the functional role of SKCa and IKCa channels in smaller vascular beds 
such as skeletal muscle arterioles (Liu et al. 2008), coronary (Feng et al. 2008; Takai et 
al. 2013) and mesenteric arteries (Chadha et al. 2011) (Table 1.2). Therefore, these 
findings indicate that the KCa channels perhaps have an important role in the regulation 
of resistance arterial tone and blood pressure. Furthermore, in IKCa KO mice, significant 
impairment in endothelial and smooth muscle hyperpolarization was demonstrated, 
resulting in subsequent inhibition of ACh-induced relaxation of carotid and cremaster 
arteries (Si 2006). It was also indicated that the deletion of these channels led to 
significant augmentation of blood pressure and left ventricular hypertrophy (Si 2006). 
Similar to the BKCa channels, the EDH pathway has been reported to act as a 
compensatory vasodilation mechanism in various CVDs such as hypertension. Therefore, 
based on my findings (Fig 3.17 and 3.21) it is possible that the therapeutic effects 
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observed with DHA probably involves activation of both IKCa and BKCa channels 
(Geleijnse et al. 2002; Campbell et al. 2013; Miller et al. 2014). 
6.3 The role of TRPV4 in n-3 PUFA mediated vasodilation 
TRPV4 is a non-selective cation channel expressed in various types of cells including 
vascular ECs and SMCs (chapter 1, section 1.2.3.iii) (Filosa et al. 2013). PUFAs such as 
EETs, CYP-derived metabolites of AA, have been reported to activate TRPV4 channels 
resulting in vascular relaxation of SMCs (Earley et al. 2005). Although it was initially 
thought that EETs were involved in the direct modulation of BKCa channels, subsequent 
electrophysiological studies demonstrated that EETs were unable to enhance BKCa 
currents in isolated membrane patches (Earley et al. 2005). It was later discovered that 
EETs activated TRPV4 channels which subsequently led to the opening of BKCa in rat 
cerebral arteries (Earley et al. 2005). A similar mechanism involving the TRPV4 channels 
was also reported to activate the endothelial SKCa and IKCa channels in murine mesenteric 
arteries (Sonkusare et al. 2012). My findings from chapter 3, section 3.2.5, demonstrated 
that IKCa and BKCa channels are involved in DHA-mediated relaxation of both rat 
mesenteric artery and aorta whereas BKCa was involved with EPA-induced relaxation of 
rat mesenteric artery. Furthermore, TRPV4 has been reported to activate both channels 
in the vasculature; therefore, using wire myograph I investigated the role of these 
channels in n-3 PUFA-induced relaxation. My findings demonstrated that inhibition of 
TRPV4 led to partial attenuation of DHA-mediated relaxation of rat mesenteric artery 
(Fig 4.3), this was similar to the inhibition observed following blockade of the IKCa 
channels (Fig 3.17A). There is evidence demonstrating heterogenous activation of the 
KCa channels by TRPV4 depending upon the type of artery; for example, a study 
conducted in mouse mesenteric artery demonstrated that the relaxation mediated by 
TRPV4 was completely abolished following inhibition of endothelial KCa channels 
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(Sonkusare et al. 2012) and therefore, did not involve the BKCa channels in contrast to rat 
cerebral arteries (Earley et al. 2005). Furthermore, it was also reported that IKCa was 
predominantly activated by TRPV4 (Sonkusare et al. 2012). Therefore, it is possible that 
the IKCa component of DHA-induced relaxation involves the initial activation of TRPV4 
channels in rat mesenteric artery. 
In rat aorta, TRPV4 was not involved in the vasodilation effect of either n-3 PUFAs (Fig 
3B-C and Fig 3A-B). Most studies involving the TRPV4-dependent activation of KCa 
have been reported in resistance arteries such as mesenteric (Sonkusare et al. 2012; Ma 
et al. 2013; Sonkusare et al. 2014; Yap et al. 2014; Ho et al. 2015), cerebral (Earley, 
Pauyo, et al. 2009) and pulmonary artery (Lin et al. 2015) along with cremaster arterioles 
(Bagher et al. 2012). Furthermore, there is also evidence indicating the predominance of 
EDH response in the smaller resistance arteries due to increased expression of KCa and 
myo-endothelial gap junctions in comparison to conduit arteries (Shimokawa et al. 1996; 
Sandow and Hill 2000; Hilgers et al. 2006; Billaud et al. 2014). Therefore, it is possible 
that these myoendothelial microdomains, that allow interaction between TRPV4 and IKCa 
channels, are not present in large conduit arteries like rat aorta. 
Metabolites of PUFAs such as EETs, which are derived from AA, act as endogenous 
agonists of TRPV4 channels that can elicit vasodilation through subsequent activation of 
KCa (Sonkusare et al. 2012). My results demonstrated that both TRPV4 and IKCa were 
involved in DHA-induced relaxation of rat mesenteric artery and therefore, it was logical 
to hypothesize that the IKCa component involves an initial direct activation of TRPV4 by 
DHA, similar to EETs. To assess these effects, I created a stable cell line that allowed the 
inducible expression of TRPV4 following tetracycline administration, as described in 
chapter 4, section 4.2.2. The regulation of TRPV4 channels by DHA and EPA was then 
investigated. Acute application of both n-3 PUFAs failed to elicit any TRPV4-mediated 
  
254 
 
changes in [Ca2+]i levels (Fig 4.13). There is evidence demonstrating that both IKCa and 
TRPV4 channels are localized in the myoendothelial projections and together can elicit 
hyperpolarization in the native vascular cells (Sonkusare et al. 2012; Sonkusare et al. 
2014). Furthermore, it was also reported that indirect modulation of TRPV4 by 
muscarinic receptors was dependent upon the subsequent activation of PKC-anchoring 
protein, AKAP150, which was also localized in the myoendothelial projections. Using 
whole cell patch clamp, a recent study also reported that EPA is not involved in the direct 
activation of TRPV4 channels expressed in HEK cells (Caires et al. 2017). This is 
consistent with my findings and further indicates that perhaps HEK cells lack the 
necessary microdomains that are required for the activation of TRPV4 channels with 
acute application of n-3 PUFAs. Moreover, in human microvascular ECs, overnight 
supplementation with EPA was reported to enhance TRPV4 currents. This study also 
indicated the presence of silent TRPV4 channels in ECs that were insensitive to agonist 
application (Caires et al. 2017). EPA supplementation of these ECs were reported to 
activate the silent channels. Mechanistic investigation into membrane remodelling 
demonstrated that the EPA treatment led to an increase in membrane fluidity and 
reduction in bending stiffness, resulting in the subsequent activation of the silent channels 
(Caires et al. 2017). My findings from Fig 4.16 demonstrated that TRPV4 activity was 
not modified following an acute treatment (1 h) of the stable cells with n-3 PUFAs, 
indicating that perhaps optimum incorporation of these fatty acids into the plasma 
membrane requires a longer treatment (Fig 4.16). However, it should also be noted that 
native ECs were used for the overnight supplementation study and therefore, additional 
experiments are required to fully confirm that these effects are also observed in the stable 
HEK cells.  
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6.4 The role of KATP in n-3 PUFA mediated vasodilation 
Based on the findings from my previous myograph experiments, the most potent 
attenuation of n-3 PUFA-induced relaxation was observed following the combined 
blockade of IKCa and BKCa channels, which are both potassium channels involved in 
hyperpolarization of vascular SMCs (Fig 3.17 and 3.21). However, a considerable 
amount of residual relaxation always remained, indicating that the mechanisms of n-3 
PUFA-mediated vasodilation was largely endothelium independent. Given that my 
results indicated the critical role of hyperpolarization, although it was not examined 
directly, I investigated whether additional potassium channels were also involved in the 
vasodilation effect of DHA and EPA. Therefore, the subsequent myograph experiments 
were focussed on investigating the effects of non-selective inhibition of potassium 
channel-induced hyperpolarization, using high KCl Krebs solution. In the rat mesenteric 
artery, exposure to high KCl Krebs led to significant attenuation in relaxation which was 
characterised by reduction in the maximum response, an effect that seemed more 
profound with DHA compared to EPA (Fig 5.3A-B). Furthermore, the relaxation effect 
of both DHA and EPA was completely abrogated with high KCl Krebs in rat aorta (Fig 
5.4A-B). This is consistent with another study that also demonstrated a similar effect with 
DHA-induced relaxation in rat aorta (Sato et al. 2014). I believe this is the most 
compelling evidence indicating the critical role of potassium channels by any vascular 
study to date, since the relaxation response of both DHA and EPA was completely 
dependent upon the activation of potassium channels in rat aorta and significant inhibition 
in n-3 PUFA-induced relaxation was observed with high KCl Krebs in rat mesenteric 
artery as well. Therefore, the next objective was to characterise the potassium channel(s) 
involved.  
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To date most studies have reported the activation of BKCa channels in n-3 PUFA-
mediated relaxation, however there is also some evidence suggesting a possible role for 
KATP channels (Engler et al. 2000; Engler and Engler 2000). A more recent study led by 
Sato et al. (2014) indicated that both DHA- and EDP-mediated vasodilation of rat aorta 
were sensitive to the inhibition of KATP. Therefore, as my findings have already 
demonstrated that BKCa and IKCa channels are involved in the vasodilation effects of n-3 
PUFAs with a large residual relaxation remaining, I investigated the role of KATP channels 
in rat mesenteric artery and aorta using wire myograph. Consistent with the findings 
involving high KCl Krebs (Fig 5.3A-B), inhibition of KATP with PNU37883A also led to 
significant attenuation of n-3 PUFA-induced relaxation in rat mesenteric artery, that was 
more profound with DHA in comparison to EPA. Similarly, in rat aorta, relaxation to 
DHA was almost completely abrogated whereas EPA-induced relaxation was 
significantly inhibited following the blockade of KATP channels. In contrast to the 
complete abrogation of relaxation observed with high KCl Krebs, some residual 
relaxation remained with EPA in rat aorta following KATP inhibition. Furthermore, a more 
profound inhibition was observed with high KCl Krebs compared to PNU37883A in the 
mesenteric artery, suggesting that additional potassium channels besides KATP are also 
involved. This is consistent with my findings demonstrating the role of additional 
potassium channels, which include IKCa, BKCa and Kv7 channels, in n-3 PUFA mediated 
relaxation. As mentioned before, these findings also demonstrate heterogeneity in the 
vasodilation mechanisms depending upon both the type of artery and n-3 PUFA.  
Taking into consideration that PNU37883A selectively blocks vascular KATP channels 
(Kir6.1/SUR2B) (Kovalev et al. 2004), findings from the myograph experiments 
demonstrated a significant role for KATP channels in n-3 PUFA-induced relaxation of both 
rat aorta and mesenteric arteries. Given that the n-3 PUFAs can directly activate BKCa 
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channels (Toshinori Hoshi, Wissuwa, et al. 2013), it is reasonable to assume their direct 
actions on other potassium channels such as KATP. However, currently there are no studies 
that have investigated this possibility. To address this question, I generated a stable cell 
line that expressed the major vascular isoform of KATP, by transfecting SUR2B and 
transducing Kir6.1 subunit into HEK cells (chapter 5, section 5.2.3-5.2.4). The expression 
of vascular KATP subunits were then confirmed using immunocytochemistry and western 
blotting (Fig 5.11 and 5.14). Using whole cell patch clamp with the stable cells, functional 
KATP channels were detected as demonstrated by the significant increase in current 
density following KATP agonist application, and subsequent abrogation of this effect with 
the perfusion of the KATP inhibitor (Fig 5.15). Application of DHA failed to enhance KATP 
currents, indicating that that a direct modulation of channel activity does not occur during 
relaxation mediated by DHA.      
EETs have been reported to mediate vasodilation by indirectly activating KATP channels 
through a PKA-dependent pathway in rat mesenteric arteries (Ye et al. 2005). Further 
investigation into the mechanisms revealed that EETs activated Gαs protein resulting in 
subsequent activation of PKA which phosphorylated and enhanced KATP channel opening 
(Ye et al. 2006). Due to the nature of the pathway the authors suggested the presence of 
an EET surface receptor, which remains to identified. There is evidence indicating that 
EETs can activate free fatty acid receptor 1 (GPR40), which is a GPCR found in vascular 
ECs and SMCs (Park et al. 2018). EETs were found to elevate [Ca2+]i levels via GPR40 
in HEK cells, however, this receptor was not involved in the EET-induced relaxation of 
bovine coronary arteries (Park et al. 2018). A recent study indicated that resolvins, which 
are n-3 PUFA metabolites involved in the resolution of inflammation, can inhibit TP 
receptor-mediated constriction in rat aorta and human pulmonary artery following 
activation of chemerin receptors (a GPCR) (Jannaway et al. 2018). As a result, it can be 
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speculated that the stable cells used for my patch clamp experiments lacked the necessary 
receptors or the cellular environment involved in the indirect modulation of KATP by n-3 
PUFAs. Furthermore, we have preliminary patch clamp data (personal communication, 
professor Andrew Tinker) demonstrating enhancement of PNU37883A-sensitive 
currents in murine aortic SMCs following acute application of DHA.  
Consistent with an indirect effect of n-3 PUFAS on KATP, activation of cardiac KATP 
channels by AA was dependent upon CYP (Lu et al. 2006). EETs were reported to 
directly modulate cardiac KATP channels and this modulatory effect was indicated to be 
stereospecific, since 11(S), 12(R)-EET enhanced KATP currents, whereas 11(R), 12(S)-
EET did not elicit any effects (Lu et al. 2002; Lu et al. 2006). Furthermore, using EET 
analogs, KATP activation was increased when a double bond was introduced at the n-3 
position of EETs, indicating the possibility of channel modulation by n-3 PUFA 
metabolites (Lu et al. 2002). These findings highlight how the correct metabolites of AA 
are required for KATP activation; hence, it is possible that metabolites of DHA and EPA 
are primarily involved in stimulating KATP and therefore, the stable HEK cells may lack 
the necessary enzymes required to produce these metabolites. As my findings indicated 
that CYP is not involved in DHA-induced relaxation, perhaps metabolites such as 17S-
HDHA and resolvins, derived from other vascular enzymes may have a role (Jannaway 
et al. 2018). In contrast to DHA, EPA-mediated relaxation was sensitive to CYP 
inhibition in both rat aorta and mesenteric artery, as a result, EPETEs may be involved in 
KATP modulation. Thus, future electrophysiological experiments should involve: (1) the 
use of native vascular cells and (2) the use of different vasoactive metabolites of DHA 
and EPA, to further examine if an indirect pathway is involved in KATP activation during 
n-3 PUFA-induced vasodilation. 
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Our findings indicate that n-3 PUFAs are possibly involved in the indirect activation of 
KATP channels in rat arteries. There is evidence indicating that the vascular KATP is mostly 
composed of Kir6.1/SUR2B subunits (Foster and Coetzee 2016). Animal studies have 
demonstrated the expression of these channels in various vascular beds such as aorta 
(Blanco-Rivero et al. 2008), coronary (Miyoshi et al. 1992; Morrissey et al. 2005) and 
mesenteric arteries (Tang et al. 2005). The role of each KATP subunit in the cardiovascular 
system has been investigated using KO models. A study demonstrated that the genetic 
loss of Kir6.1 was associated with complete inhibition of KATP-induced hyperpolarization 
and vasodilation of aorta (Miki et al. 2002). Furthermore, these mice had a higher rate of 
developing sudden cardiac death compared to the wild-type controls (Miki et al. 2002). 
Genetic loss of SUR2 was also associated with focal constriction of coronary arteries 
resulting in vasospasms (Chutkow et al. 2002). An increase in resting blood pressure and 
sudden death was also reported in the SUR2 KO mice (Chutkow et al. 2002). In humans, 
expression of KATP channels has been confirmed in coronary (Yoshida et al. 2004), 
meningeal (Ploug et al. 2008) and pulmonary arteries (Cui et al. 2002) (Table 1.2). 
Although these findings indicate the potential role of KATP channels as a therapeutic 
target, there is also evidence indicating that loss of function mutations of the Kir6.1 and 
SUR2B were not associated with hypertension (Ellis et al. 2010; Duan et al. 2011). This 
is perhaps explained by the compensatory role of other vasodilation mechanisms such as 
BKCa channels and EDH response that have been indicated to prevent the development 
of hypertension in various studies (Scotland et al. 2005; Chang et al. 2006). However, a 
selective KATP opener, iptakalim, was reported to elicit potent blood pressure lowering 
effects in hypertensive animals and humans (Pan et al. 2010). Furthermore, these effects 
were completely absent in the normotensive controls. The enhanced effectiveness of 
iptakalim was associated with its increased selectivity towards the vascular 
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Kir6.1/SUR2B subtype and therefore iptakalim was reported to have a better safety and 
tolerability profile compared to the previous KATP openers (Pan et al. 2010). Although 
direct activation of KATP channels by n-3 PUFAs was not observed according to my 
patch-clamp data (Fig 5.15), profound reduction in relaxation was observed in both 
arteries with KATP inhibition, indicating a possible indirect interaction between the 
channel and n-3 PUFAs (Fig 5.7-5.8). Therefore, it is plausible to suggest that the 
therapeutic effects observed with n-3 PUFA supplementation may involve activation of 
KATP channels, however additional studies involving Kir6.1 and/or SUR2B KO animal 
models are required to further confirm whether a similar inhibition in n-3 PUFA-induced 
relaxation is observed as demonstrated following treatment with PNU-37883A. 
6.5 The role of Kv7 in n-3 PUFA mediated vasodilation 
After examining the findings from the myograph experiments (Fig 5.1-5.8), it can be 
argued that high KCl Krebs was marginally more effective compared to PNU37883A 
(KATP channel inhibitor) in inhibiting the n-3 PUFA-mediated relaxation, especially 
involving EPA. Furthermore, my patch clamp data demonstrated that DHA is not 
involved in direct activation of vascular KATP channels expressed in HEK cells and as a 
result, it is possible that PNU37883A is not selective and may inhibit other vascular 
potassium channels. In fact some studies have reported that although PNU37883A (also 
known as U-37883A) is more selective to Kir6.1 containing KATP channels, it can also 
inhibit other potassium channels present in the vasculature (Teramoto 2006). However, a 
considerably higher concentration (100 µM) of PNU37883A was reported to inhibit both 
KV and Kir channels (channel subtypes were not specified) present in SMCs derived from 
rat mesenteric artery (Wellman et al. 1999). Recent studies have reported that acute 
application of both DHA and EPA can activate the cardiac IKS channel, composed of 
Kv7.1/KCNE1 subunits, and neuronal M-channel, composed of Kv7.2/Kv7.3 subunits 
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(Liin et al. 2014; Moreno et al. 2015; Liin et al. 2016). Currently there are no studies that 
have investigated whether n-3 PUFAs also modulate the vascular Kv7 channels (mainly 
Kv7.4 and 7.5) involved in vasodilation and therefore, the final part of my project 
focussed in examining the role of Kv7 channels in n-3 PUFA-induced relaxation of rat 
arteries. 
In rat mesenteric artery, both DHA- and EPA-mediated relaxations were partially 
inhibited following the blockade of Kv7 channels with XE991 (non-selective inhibitor of 
Kv7) (Fig 5.18). This inhibition of relaxation was considerably smaller compared to 
PNU37883A-mediated attenuation in rat mesenteric artery (Fig 5.7). Surprisingly in rat 
aorta, inhibition of n-3 PUFA-mediated relaxation with XE991 appeared to be almost 
identical to the effects observed with the KATP blockade. It is interesting that the 
magnitude of inhibition mediated by XE991 and PNU37883A was different in rat 
mesenteric artery. This is perhaps explained by the non-selectivity of PNU37883A to 
vascular potassium channels, although a lower concentration (3 µM) of this blocker was 
used in my experiments. There is evidence indicating that PNU37883A is  involved in 
inhibition of KV channels at higher concentration (100 µM), however the channel 
isoforms were not identified (Wellman et al. 1999). Studies have demonstrated that the 
role of  EDH in vasodilation and the expression of SKCa increases with decreasing arterial 
size (Hilgers et al. 2006), therefore, it is possible that other potassium channels, such as 
Kv7, could also have differential expression depending upon the vascular bed. In fact, a 
study confirmed that although Kv7.1 and Kv7.4 subunit expressions were observed in 
mouse vascular beds, a higher expression of Kv7.4 was demonstrated in cerebral 
compared to coronary arteries (Lee et al. 2015). Similarly, using wire myograph, 
pharmacological modulation of Kv7 channel activity had a greater effect in the regulation 
of cerebral vascular tone in comparison to coronary arteries (Lee et al. 2015). This 
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heterogeneity in the contribution of Kv7 was also observed in other arteries, since Kv7 
inhibitors such as linopirdine and XE991 were reported to elicit constrictions in rat and 
mouse pulmonary arteries whereas the contractile tone of mesenteric arteries were 
unaffected by these inhibitors (Joshi et al. 2006). Furthermore, regional differences of 
Kv7 contribution in the same artery was also reported; for example, cAMP-mediated 
relaxation was more profound in the left compared to right coronary artery due to the 
higher activity and expression of Kv7.1 and Kv7.5 (Morales-Cano et al. 2015). Although 
extensive evidence indicates that Kv7.1 channels are not associated with regulation of 
resting arterial tone, activation of these channels were associated with relaxation of 
preconstricted arteries (Bett et al. 2006; Lerche et al. 2007; Preet S Chadha et al. 2012). 
Furthermore, Kv7.1 was reported to be expressed in both rat aorta and mesenteric artery; 
however, relaxation induced by the activation of Kv7.1 channels was more potent in the 
mesenteric artery, indicating variability in the contribution of Kv7 channels in the 
regulation of vascular tone (Preet S Chadha et al. 2012). Therefore, the variable 
expression and contribution of potassium channels in the relaxation of blood vessels, may 
provide an explanation for the observed heterogeneity in our findings. For example, in 
rat mesenteric artery, perhaps the expression of KATP channels is higher compared to Kv7 
and hence PNU37883A (Fig 5.7) elicited a more potent inhibition in relaxation compared 
to XE991 (Fig 5.18). In rat aorta on the other hand, it is possible that the basal expression 
of Kv7 is greater than KATP, therefore, both inhibitors had a similar effect as the relaxation 
was mostly dependent upon Kv7 activity. It would be completely ignorant to not consider 
the possibility that perhaps the KATP and Kv7 channels interact with each other to elicit 
vasodilation and therefore, this could explain why my findings indicated that the 
individual blockade of each channel can elicit an inhibition of a similar magnitude, 
especially in n-3 PUFA-induced relaxation of rat aorta. However, currently there is no 
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evidence demonstrating the presence of such interactions between Kv7 and KATP channels 
in vasodilation.    
The residual relaxation that was observed with EPA in rat aorta, following the pre-
treatment with PNU37883A, demonstrates the involvement of other potassium channels, 
since high KCl Krebs completely abolished this relaxation. Findings from my previous 
myograph experiments indicate that KCa channels are not involved in EPA-induced 
relaxation of aorta (Fig 19). Although I have mentioned the non-selectivity of 
PNU37883A, perhaps combined blockade of both KATP and Kv7 would mimic the effects 
observed with high KCl Krebs. In rat mesenteric artery, residual relaxation was observed 
with high KCl Krebs for both n-3 PUFAs indicating the presence of vasodilation 
mechanism(s) that are independent of potassium channels, these pathways may involve 
voltage-gated sodium and calcium channels as there is evidence of their modulation by 
PUFAs (Elinder and Liin 2017). 
As mentioned previously, studies have demonstrated expression and activity of Kv7 
channels in various murine vascular beds such as aorta (Preet S Chadha et al. 2012), 
cerebral (Lee et al. 2015), coronary (Morales-Cano et al. 2015), pulmonary (Joshi et al. 
2006) and mesenteric arteries (Preet S Chadha et al. 2012). The expression and the 
functional role of Kv7 channels were also investigated in human adipose and mesenteric 
arteries (Ng et al. 2011). The findings from this study demonstrated that Kv7.4 was 
consistently expressed in all the arterial samples whereas variable expression of Kv7.1, 
Kv7.3 and Kv7.5 was reported (Ng et al. 2011). Furthermore, Kv7.4 was predominantly 
involved in vasodilation whereas Kv7.1 did not have a functional role in the regulation of 
vascular tone (Ng et al. 2011). Several animal studies have indicated that Kv7 channels 
are associated with CVDs. For example; in SHR compared to normotensive controls, a 
reduction in Kv7.4 expression and agonist-induced relaxation was demonstrated in 
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various vascular beds such as aorta, coronary, mesenteric and renal arteries (Jepps et al. 
2011; P. S. Chadha et al. 2012). In humans, currently there is limited evidence indicating 
the therapeutic effects of Kv7 activation in hypertension. Although flupirtine, a Kv7 
opener, was reported to attenuate right ventricular pressure and hypertrophy in pulmonary 
hypertensive mice (Morecroft et al. 2009), two human studies reported contrasting effects 
on blood pressure depending upon the duration of the treatments with this opener 
(Herrmann et al. 1987; Hummel et al. 1991). Besides the vasculature, Kv7 subunits are 
also expressed in cardiac muscle cells (IKS channel composed of Kv7.1) and neurons (M-
channel composed of Kv7.2, Kv7.3 and Kv7.5), therefore, it is important to consider that 
Kv7 openers could possibly elicit effects in more than one type of tissue. Selective Kv7 
openers that are targeted more towards the Kv7.4 subunits should be investigated to assess 
if these openers provide a better therapeutic efficacy and safety profile when targeting 
CVDs, compared to the less-selective openers. My novel findings indicate that the Kv7 
has a major role in n-3 PUFA-induced relaxation. Although direct activation of IKS and 
M-channels has been previously indicated in cardiac and neuronal cells (Liin et al. 2014; 
Moreno et al. 2015; Liin et al. 2016), additional studies need to be conducted to fully 
confirm that n-3 PUFAs can also regulate the activity of Kv7 subtypes present in the 
vasculature. Findings from these experiments would be indispensable for studies 
investigating the prospect of using novel analogues that can selectively target specific 
pathways, such as Kv7.4 channels, for the treatment of CVDs.         
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6.6 Conclusion and future experiments 
This is the first comprehensive characterisation of the mechanisms underlying DHA- and 
EPA-mediated relaxation of rat conduit and resistance arteries. According to my control 
curve data, DHA was significantly more potent than EPA in both arteries, however, there 
was no difference in the maximal response of n-3 PUFAs in either artery (Log EC50  and 
Emax values can be found in table 6.1). Consistent with my findings, previous studies have 
indicated that DHA is generally more effective than EPA in activating potassium 
channels. DHA was reported to be more potent in enhancing BKCa currents due to its 
longer acyl chain length compared to EPA (Toshinori Hoshi, Xu, et al. 2013). There is 
also evidence indicating that the negative charge of various PUFAs is crucial in the 
activation of Shaker and Kv7.1 channels (Börjesson et al. 2008; Liin et al. 2015). 
Furthermore, acute treatment with DHA was reported to elicit the largest enhancement 
of Shaker channel currents compared to EPA and in contrast to BKCa channels, the charge 
and the presence of two or more methylene-interrupted cis double bonds were the most 
important structural features of PUFAs in channel modulation, as opposed to acyl chain 
length (Börjesson et al. 2008). The findings from my myograph experiments indicated 
that endothelium has a minor role in these relaxations, since NO and COX were not 
involved whereas CYP metabolism only had a small effect in EPA-induced relaxation. 
IKCa and BKCa channels were both involved in DHA-induced relaxation of both arteries 
whereas only BKCa channels were involved in EPA mediated relaxation of rat mesenteric 
artery. This is the first study demonstrating the novel role of IKCa in n-3 PUFA-mediated 
relaxation. These findings are summarised in Fig 6.2 and they clearly demonstrate 
heterogeneity in the vasodilation mechanisms of n-3 PUFAs, depending upon both the 
type of n-3 PUFA and the vascular bed. Another novel finding of this study is the role of 
TRPV4 in the acute relaxation effect of DHA in rat mesenteric artery, which is possibly 
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involved in the regulation of the IKCa component. n-3 PUFA-mediated relaxation in rat 
aorta was completely dependent upon potassium channels and further characterisation 
revealed that KATP channels were involved. This is also the first study that demonstrated 
the role of Kv7 channels in n-3 PUFA-induced relaxation. The general consensus is that 
both KATP and Kv7 channels are predominately expressed in the vascular SMCs (Fosmo 
and Skraastad 2017). This is consistent with my findings as n-3 PUFA-induced relaxation 
was primarily regulated by endothelium-independent mechanisms. This project was 
focussed on completely characterizing the pathways involved with n-3 PUFA-induced 
relaxation using a conduit and a resistance artery, as most of the previous vascular studies 
are limited to a certain type of vascular bed and n-3 PUFA. We have partly met this goal 
as my findings indicate that n-3 PUFA-induced relaxation in rat aorta is completely 
dependent upon potassium channels. However, in rat mesenteric artery, there was still 
some remaining residual relaxation with high KCl Krebs, indicating the presence of 
vasodilation mechanism(s) that are independent of potassium channels. Additional 
myograph experiments should be conducted to fully characterize these pathways which 
may involve voltage-gated sodium and calcium channels as there is some evidence 
indicating modulation of their activity by PUFAs (Elinder and Liin 2017). 
Although my mesenteric data demonstrated a TRPV4 component in DHA-induced 
relaxation, direct activation of these channels by n-3 PUFAs was not observed in our 
stable cells. This was also validated by a recent study using whole cell patch clamp 
(Caires et al. 2017). Acute pre-treatment (1 h) of these stable cells with EPA did not 
evoke any changes in TRPV4 activity. However, an enhancement in TRPV4 currents was 
reported in human microvascular ECs following overnight supplementation with EPA 
(Caires et al. 2017). It is possible that perhaps acute treatment does not result in optimum 
membrane incorporation of n-3 PUFAs, therefore as a possible future experiment it would 
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be interesting to assess if overnight n-3 PUFA supplementation of the stable HEK cells 
could modify TRPV4 currents. It is quite evident from my findings that a heterologous 
expression system might not be ideal, especially if the pathways involve microdomains 
that are unique to the native tissue. n-3 PUFAs were unable to directly activate both KATP 
and TRPV4 channels and therefore, future electrophysiological experiments should 
involve the use of native vascular cells to further investigate the presence of any indirect 
interaction between these channels and n-3 PUFAs. In fact, due to our collaboration with 
professor Andrew Tinker, we have preliminary data (not shown) demonstrating an 
upregulation in KATP currents following acute application of DHA in murine vascular 
cells. This suggests that there is possibly an indirect pathway that leads to KATP activation 
following acute application of n-3 PUFAs. 
One of the highlights of my findings is the crucial role of the hyperpolarization response 
mediated by the potassium channels. Multiple channels including BKCa, IKCa, KATP and 
Kv7 channels were found to be involved indicating that perhaps a unifying upstream 
pathway could be involved in the subsequent activation of these potassium channels, 
although there is also evidence indicating direct activation of BKCa and Kv7.1 by n-3 
PUFAs (Toshinori Hoshi, Wissuwa, et al. 2013; Liin et al. 2015). This upstream pathway 
perhaps involves the activation of PKA as it can activate multiple potassium channels 
including BKCa (Imig et al. 1999; Fukao et al. 2001; Dimitropoulou et al. 2007), KATP (Ye 
et al. 2005; Ye et al. 2006; Yang et al. 2008) and Kv7 (Stott et al. 2015; Mani et al. 2016; 
Stott et al. 2016). Furthermore, several studies have indicated that n-3 PUFAs can activate 
PKA in cardiac myocytes, epithelial and hepatoma cell lines (Mies et al. 2004; 
Szentandrássy et al. 2007; Tai et al. 2009). Similar to EETs (Ye et al. 2006), it is plausible 
to suggest that n-3 PUFAs are possibly involved in the initial activation of PKA resulting 
in subsequent stimulation of the potassium channels involved in vasodilation. Therefore, 
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additional myograph experiments should be conducted to investigate the role of PKA in 
n-3 PUFA-induced relaxation.  
Studies report that the vasculature is mostly composed of Kv7.1, Kv7.4 and Kv7.5 subunits 
(Ng et al. 2011). However, there is evidence indicating that Kv7.4 is the predominant 
subunit involved in vasodilation of both murine and human vascular beds (Ng et al. 2011; 
Lee et al. 2015). My experiments involved the use of XE991 which is a non-selective Kv7 
inhibitor, therefore, the specific channel subtype(s) involved with n-3 PUFAs was not 
identified. Studies that demonstrated direct activation of Kv7 channels by n-3 PUFAs 
were conducted using cardiac IKS and neuronal M-channels, which were composed of 
Kv7.1, Kv7.2 and Kv7.3 subunits (Liin et al. 2014; Moreno et al. 2015; Liin et al. 2016). 
Therefore, additional experiments are required to investigate whether n-3 PUFAs also 
elicit an identical effect with the Kv7.4 channels. Similar to my project, these experiments 
could be carried out by generating stable cell lines expressing Kv7.4 tetramers, followed 
by patch clamp electrophysiology to detect any changes in channel activity with acute 
application of n-3 PUFAs. As our myograph experiments indicated that pathways 
involved in n-3 PUFA-induced vasodilation were primarily endothelium-independent, 
native vascular SMCs could then be used to further confirm if the acute treatments with 
DHA and EPA can enhance Kv7 currents.    
The gene-targeting techniques are significantly more advanced in mice compared to rats, 
as a result mice have been used as the preferred mammalian model for genetic 
modifications over the years (Homberg et al. 2017). However, rats have several 
experimental advantages over mice for cardiovascular research due to their larger size. 
Different types of tissue including blood vessels are significantly smaller in mice 
compared to rats, therefore, performing functional myograph experiments with the 
smaller vascular beds such as cerebral and mesenteric arteries would be impossible. 
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Furthermore, the measurement of physiological parameters is also more challenging in 
mice compared to rats; for example, studies have indicated that the telemetric 
measurement of blood pressure via the insertion of implants into mice arteries can result 
in the obstruction blood flow, whereas in rats this is does not occur due to the larger size 
of the vessels (Homberg et al. 2017). There is also an increased difficulty in performing 
precise surgical manipulations in mice without the risk of damaging the target tissue. 
Therefore, functional cardiovascular studies should ideally involve the use rats due to its 
superiority as an experimental model in comparison to mice. 
To further validate my findings, additional supplementation studies using KO and disease 
animal models are required. My myograph experiments indicated that NO pathway is not 
involved in n-3 PUFA-induced vascular relaxation, however supplementation studies 
have reported an increase in NO production following n-3 PUFA treatment. It is possible 
that this enhancement in the NO pathway is only observed via chronic exposure with n-
3 PUFAs, as the treatments for most of these studies lasted for more than a week (Hirafuji 
et al. 2002). Furthermore, these studies involved the use of vascular cells rather than 
arterial tissues and therefore lacked functional evidence that demonstrated effects of n-3 
PUFA supplementation on vascular relaxation (Omura et al. 2001; Hirafuji et al. 2002; 
López et al. 2004; Raimondi et al. 2005). To address this discrepancy, future experiments 
with animal models should investigate whether variations in the duration of n-3 PUFA 
supplementation alters NO production and arterial tissues derived from these animals 
should be used to asses if any functional changes in n-3 PUFA-induced vasodilation 
involves the NO pathway.  
My myograph experiments demonstrated that KATP channel inhibition with PNU37883A 
elicited significant reduction in n-3 PUFA-induced relaxation of rat arteries. Therefore, 
to further confirm these findings, an immediate future experiment would be to investigate 
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if similar effects are observed with KATP KO mice which will be kindly provided by 
professor Andrew Tinker (William Harvey Heart Centre, Queen Mary University of 
London). Native vascular cells and arterial tissue derived from these mice could then be 
used to assess the acute effects of n-3 PUFAs, using techniques such as wire myograph 
and patch clamp electrophysiology. Inhibition of Kv7 channels also led to significant 
attenuation in vasodilation mediated by n-3 PUFAs. Due to evidence demonstrating the 
predominance of Kv7.4 subunit in the vasodilation of both murine and human vascular 
beds (Ng et al. 2011; Lee et al. 2015), Kv7.4 KO mice can be used to further corroborate 
my findings. 
The incorporation of EPA into the plasma membrane following overnight 
supplementation has been reported to enhance TRPV4 activity in human microvascular 
ECs (Caires et al. 2017). Therefore, an interesting avenue for supplementation studies 
would be to investigate whether the activity of vascular potassium channels is also 
enhanced due to membrane incorporation of n-3 PUFAs. Although multiple animal and 
human studies have confirmed the protective role of n-3 PUFAs in hypertension 
(Vaskonen et al. 1996; Geleijnse et al. 2002; Campbell et al. 2013; Miller et al. 2014), 
these studies usually only employ physiological parameters to demonstrate the 
therapeutic effects and therefore lack the mechanistic investigation of pathways involved. 
The expression profile of potassium channels has been reported to alter in hypertension 
depending upon the type of vascular bed and ion channel; for example, in SHR compared 
to normotensive controls, an enhancement of the BKCa β1 subunit expression was 
reported in the mesenteric artery (Chang et al. 2006) whereas reduction in Kv7.4 
expression was demonstrated in various vascular beds such as aorta, coronary, mesenteric 
and renal arteries (Jepps et al. 2011; P. S. Chadha et al. 2012). Most disease model studies, 
involving n-3 PUFA supplementation, usually only investigate a particular type of 
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potassium channel and artery. Therefore, more comprehensive supplementation studies 
are required to investigate the effects of CVDs and n-3 PUFA treatment in the expression 
and functional activity of more than one type of vascular potassium channels. The 
findings from these studies would be invaluable for differentiating impaired versus 
compensatory vasodilation pathways in various CVDs which can subsequently facilitate 
the use of more targeted approach for cardiovascular treatments depending upon the 
disorder. 
In conclusion, my study provides evidence of the role of IKCa, KATP and Kv7 in n-3 PUFA-
mediated relaxation of rat aorta and mesenteric artery. The heterogeneity in these 
mechanisms were dependent upon both the type of blood vessels and the n-3 PUFA. 
Compared to healthy individuals, the therapeutic benefits of n-3 PUFAs have been 
reported to be more prominent in individuals with disorders such as hypertension (Morris 
et al. 1993). Therefore, the findings from this project will be invaluable for future vascular 
studies that investigate the prospect of using n-3 PUFA and novel analogues as treatments 
that target specific pathways involved in providing therapeutic effects against 
cardiovascular disorders.    
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